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1General Introduction and outline of this thesis
The landscape of peri-operative care in high-risk surgery is diverse, as many departments 
and care-providers have a role in the care for the patient during the peri-operative period. 
The definition of high-risk surgery has been the topic of perceptions, assumptions and many 
discussions for decades(1). High-risk surgery can be defined as a surgical procedure with 
an expected high mortality and high morbidity risk(2). In many patients an admission to an 
Intensive Care Unit (ICU) is needed as part of their treatment in the peri-operative period 
and following high-risk surgical interventions. As a consequence, variability in the quality of 
peri-operative care will have an influence on the clinical outcome of these patients(3, 4). 
This variability in outcome and recent improvements of outcome may be related to several 
factors, including more-up-to-date technology, a closed format intensive care organisation, 
numbers of nursing staff, education level of staff, use of guidelines and multidisciplinary 
team communication (5). As a result, the high-risk patients’ journey through the hospital may 
encounter many hurdles, obstacles and slippery slopes or have smooth transitions between 
medical and nursing professionals and departments.  Audits, ward-visits and in-depth analy-
ses of complications, reveal that both journeys may exist alongside each other in one system. 
Differences between the perceived use of protocolized care, and the care patients actually 
receive during their hospital stay, are often unknown to patients, care givers and clinical 
leaders. For example in the field of sepsis, variability of care and the effect on outcome has 
been investigated in patients in the ICU(6). Better compliance with guidelines translates in 
better outcome of critically ill patients (7), and there is room for improvement (8), also in The 
Netherlands (9). 
As mentioned, Work-as-Imagined (WAI), developed and built into guidelines, will not always 
mirror utilisation of these guidelines: Work-as-Done (WAD) (10). Because these differences 
will be the result of resources, integrated processes, care-providers and patient character-
istics, they can all have an effect on the outcome of the patient(11). Fortunately, systems, 
team members and patients do often show resilience and the positive effect of this resilience 
can be that the clinical impact of variability in treatment may be limited. Nevertheless, these 
data indicate that improvements are clearly possible and likely, may result in better outcome 
for the ICU patient (12). As a consequence, a safe patients’ journey through the hospital 
system needs processes where Work-as-Done will better represent the use of guidelines 
and variances underneath. This journey also has to rely on a certain amount of resilience 
within the system. 
The total quality of care, provided for patients, is the product of many different procedures 
and systems connected together. According to Donabedian, quality of care can be divided 
in three domains: structure, process and outcome (5, 13). Each domain is character-
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ized by its own set of variables which may have an impact on different levels during the 
patients’ journey. These domains are not isolated, but intertwined and they affect each 
other.  In the “process” domain we can identify patients and their families in interaction 
with careproviders in the hospital. The treatment and care process is based on protocols 
and guidelines which are often developed within one discipline. The “structure” domain 
is very much related to the organization and even architecture of a hospital. The patients’ 
journey through the “Structure” domain will be through different departments and often 
starts at the outpatient clinic or the emergency department. If the hospital has a high-tech 
operating theatre for high-risk surgical procedures, staffing levels on the wards should 
be sufficient in relation to the peri-operative care needed for these complex procedures. 
A decision to raise the volume of specific high-risk surgical procedures will also have an 
impact on the use or number of ICU beds needed, as well as on staffing levels. “Outcome” 
is the third domain. Outcome will often focus on disease related or surgical procedure 
related morbidity and mortality, or ICU or hospital length of stay. While these are rela-
tively easy to determine, Patient Reported Outcomes Measures (PROMs) and Value Based 
Health Care (VBHC) are more recently reported outcome measures. PROM focuses on 
quality and efficiency of care(14). VBHC dictates that care has to be organized around 
medical conditions and care cycles and needs to provide additional value to the patient 
and risk-adjusted outcome and cost should be measured(15). All domains have a form 
of resilience within their own compartment and will react if the content changes in one 
of the other compartments, e.g. expansion in the compartment of structure will have an 
impact on process and/or outcome compartments (Figure 1).
Modification of variables in the Donabedian Structure System can be an advantage or dis-
advantage for the individual patient. Structure interventions such as nurse staffing, closed 
format intensive care organisation, high-tech equipped operating theatres or procedure 
volumes are all related to outcome. A structure intervention, reflecting the setting in which 
care is being delivered, is dependent of choices made by the hospital board and staff, 
together with governance-regulation-rules. Structure interventions will have an impact on 
the total patient population and care-providers.
Process measures can be used to analyse provided care. For example, analysis of complica-
tions can be used by clinicians to identify which processes have been followed (or not), and 
how this affected the outcome of the patient. In the ideal organisational system, Prepare-Act 
and Reflect Cycles (P-A-R-cycle) or Plan-Do-Check-Act cycles are used to monitor provided 
care and outcome. As a result, these differences will be analyzed and reflected on in the 
multidisciplinary treatment team and, if necessary, changes will have to be made in treatment 
protocols or team processes and the P-A-R-cycle can start all over again (16). In health care, 
especially in hospitals,  P-A-R-cycles are an instrument used to analyse ward or department 
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1performance and are often part of audits or (near) adverse event analyses.  Apart from these, mainly incident-driven, actions, repetitive P-A-R-cycles, organized by clinical-leaders, 
supplying feedback to care-providers with the intention to improve given care are scarce.
Actual provided care to patients will be influenced by adherence to protocols by individ-
ual care-givers (physician, nurse, physiotherapist, etcetera) and available resources(10). 
Adherence to these protocols and guidelines relating to a specific medical intervention 
or medical condition is often not measured, or part of a P-A-R-cycle on the ward. As a 
result the cause of differences in provided care and outcome remain often unknown to 
care-givers. More feedback is needed, so that it will become clear that actions in these 
three domains will all influence the patients’ journey and outcome (17). 
Figure 1: Structure, process and outcome flowchart for high-risk surgical procedures.
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An example of a process intervention is the “Enhanced Recovery After Surgery (ERAS)” pro-
gram. After thorough analysis of the aspects in peri-operative care, relating to morbidity 
and mortality following colorectal surgery, Kehlet et al (18) developed the ERAS program, 
as a multimodality intervention to reduce post-operative complications and in-hospital 
Length of stay (LOS). Since the 1990s, ERAS has been implemented in many hospitals and 
aspects of the ERAS protocol have been adopted and implemented in the peri-operative 
care of high-risk surgical procedures (19-22). Unfortunately, knowledge of compliance to 
the ERAS protocol is unknown in most hospitals and seldom part of research questions 
(23, 24).
The setting of ICU-related care for high-risk surgical procedures
The adagium: “doing the right things right” is, for most physicians and nurses, an intrinsic 
motivator and essential in a team that provides care for high-risk surgical patients. Devel-
opment and implementation of medical and nursing protocols is often a mono-disciplinary 
intervention or intra-disciplinary effort by physicians or nurses. This hampers the use of 
these different protocols in a multidisciplinary continuous system, such as is the case in 
the high-risk patients’ journey. Because of the simultaneous use of many different clinical 
algorithms, protocols, guidelines and decision (making) rules of different departments and 
teams, the peri-operative process for the high-risk surgical patient becomes a labyrinth for 
care-providers and patients. This complexity increases even more in one hospital system with 
both high volume procedures like cardiac surgery, and low volume complex surgery such 
as pancreatico-duodenectomies and esophagus resections. Clearly, everybody agrees that 
each individual patient must receive safe and well organized care under all circumstances, 
but in a complex environment, this can be a difficult aim.
Clinical Pathways
Clinical Pathways, or Care pathways, are developed to provide optimal care for a specific 
patient group and to overcome differences of provided care between individual patients 
and individual care-providers. Development and implementation of these clinical pathways 
are considered complex process interventions and are usually accomplished in predict-
able non-complex procedures. 
In the 1990s ‘Clinical Pathways’ (CP) or ‘care pathways’ were developed to integrate nursing 
and medical protocols into multidisciplinary care plans for low- and intermediate-risk surgery 
in the hospital. Development and implementation of a CP is a process intervention based 
on best practice rules, guidelines and available evidence based medicine. CP were originally 
designed to balance the quality of care and costs, by focusing on better use of resources, 
a maximum quality of care and minimization of delay in diagnosis and treatment (25). The 
content of a CP does not consist of  multi-disciplinary or intra-disciplinary protocols and 
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1best practices alone, but is also a ‘day-to-day’ care plan describing all care, interventions or activities needed to be achieved within a specific period of time to provide optimal 
patient care. A CP is specific to a medical condition, patient group or medical intervention, 
such as an operation. Evidence based medicine and best practice guidelines, developed 
as Work-as-Imagined, are often the building blocks for a team of caregivers to start the 
development of a CP. Together with these building blocks, available resources in the 
system, team culture and daily processes have to connect with each other to make the 
transfer from protocol or guideline to a CP. Different CPs for various medical conditions 
may coexist in a department or health care facility. 
Many CPs have been developed, especially for predictable trajectories, where clinical inter-
ventions must be provided in a timely manner, and this implies that a CP is often a day-to-day 
care plan for a specific disease or medical procedure (26). So far many CPs have been devel-
oped for high volume, low- and average-risk healthcare procedures to reduce variations in 
care, complications, length of stay (LOS) and costs (27-30). Clinical pathways with the aim 
to standardize care and to reduce variation in care and outcome are also well known 
in, e.g. cardiology and pulmonology. CPs in cardiology, mainly focus on management 
of acute coronary syndromes and reduction of time-to-stent or time-to-surgery. Imple-
mentation of a CP for the treatment of acute coronary syndrome resulted in improved 
protocol adherence and improved outcome (31-33). The European Pathway Association 
performed an international multicenter cluster randomized controlled trial in 22 hospitals 
with the aim to reduce 6-month readmission rates after COPD exacerbation. Although 
30-day readmission was significantly reduced without a reduction of 6-month readmis-
sion,  evidence-based key interventions were better performed after implementation of a 
CP compared to usual care (34). CPs in day-care surgery, hip surgery, hysterectomy and 
colorectal  surgery show reductions of postoperative morbidity and LOS as well (35). The 
evidence is growing that CP implementation has a positive effect on clinical outcome, 
however, reluctance to implementation of CPs still exist. This reluctance is often related 
to fear of loss of autonomy and aversion to over-regulation(36, 37).
A process intervention like the development and implementation of a CP for high-risk sur-
gery could potentially reduce serious complications and LOS. Currently, many complex 
CP’s in high-risk surgery do not include the ICU period in their CP, or only aspects of ICU 
care are implemented such as mechanical ventilation or care bundles like the treatment 
of sepsis and septic shock (38-44). Unfortunately, CP literature describing the total clinical 
patients’ journey of the high-risk surgical patient, including the ICU period, is not available.
The ICU is a very dynamic environment with very unpredictable responses of patients to 
treatment. High-risk surgical patients with a need for the ICU in the direct postoperative 
period could theoretically also benefit from CP guided care during their ICU stay. A CP 
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in the ICU could be a uniform protocol together with an hour-to-hour written schedule 
for a specific group of patients. This schedule should focus on recognition of deviation 
from the pathway by the attending nurses and should enable them to start immediate 
treatment within the boundaries of prescribed variances. The development, implemen-
tation and evaluation of a CP in the ICU should be part of a PAR-cycle and  should be 
dynamic. Structure interventions in the system, together with changes in guidelines or 
resources, could affect WAD relating to the CP. This should result in agile adaptations of 
the content of the CP. We need to be aware that the ICU is not an isolated department. 
A process intervention in the ICU, like implementation of a CP, may affect the outcome in 
other departments that the patients will visit during their journey. Process and structure 
interventions in other departments at the same time, could also have an effect on the 
patient’s journey. This will not be noticed if the intervention is not communicated, or part 
of the same P-A-R cycle.
Aims of this thesis 
The aim of this thesis is to analyse the process intervention of development and imple-
mentation of clinical pathways in different high-risk surgical procedures relating to the ICU. 
This thesis aims to answer the following questions:
• Is it possible to develop and implement a nurse-driven clinical pathway, together with 
a variance report, to start treatment, within legal boundaries, in the ICU for all cardiac 
surgery patients? If so, what will be the effect on  protocol adherence?
• Can this CP in high-volume, high-risk cardiac surgery patients be used as a blue-print 
for the development of low-volume, high-risk surgical procedures such as Pancreati-
co-duodenectomy and esophagectomy that will be used in the ICU, Post Anaesthesia 
Care Unit (PACU) and gastro-intestinal surgical ward?
• Can a CP be sustainable in high-volume cardiac surgery?
• Does preoperative optimization in the ICU effects outcome in low-volume high-risk 
esophageal surgery?
The outline of this Thesis
This thesis consists of two parts. The first part focuses on feasibility of a postoperative 
hour-to hour CP in the ICU, including the analysis of facilitators and barriers within the 
process. We will also focus on trends over time after implementation of a CP in high 
volume high-risk surgery. The second part of this thesis focuses on the development and 
implementation of CPs in low volume high-risk surgical procedures.
The process intervention of the development, implementation and evaluation of a post-op-
erative clinical pathway based on a uniform protocol, together with an hour-to-hour 
written schedule (coined ‘Radboud variance report’), for all cardiac surgery patients in the 
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1intensive care unit is described in Chapter 2. This CP, in this high volume patient group, describes all multidisciplinary activities of the postoperative ICU processes and focuses 
on recognition of deviation from the pathway by nurses and their treatment within the 
boundaries of the prescribed variances. The aim of this study was to develop and imple-
ment a CP for all cardiac surgery patients in the ICU and to achieve a protocol adherence 
above 80%. In addition, we analysed the results of protocol adherence related to outcome 
in the intervention group and a matched historical control group treated according to the 
existing nursing and medical protocols in the year before the implementation of the CP.
Following implementation of a postoperative CP for cardiac surgery patients we studied 
trends and outcome changes over time in the total group of over 7500 cardiac sur-
gery patients treated in the nine years after the implementation of the CP. This study 
is described in Chapter 3. Primary aim of this study was to determine trends over time 
regarding inclusion and exclusion of patients in the CP. Secondary aims included deter-
mination of the trends over time relating to hospital length of stay, re-operations, ICU 
readmissions, hospital mortality and 1-year mortality between patients treated according 
to the CP and patients excluded from the CP. Subgroup analyses were performed between 
groups and for patients with a high Log EuroSCORE > 10, regarding distribution trends 
over time and clinical outcome. 
In the fourth chapter we describe an observational evaluation study in a group of patients 
treated with an open transhiatal esophagectomy for carcinoma or high-grade dysplasia. 
This low volume group of high-risk surgical patients was pre-operatively optimized in the 
ICU according to an optimization matrix. We studied the association between pre-opera-
tive optimization and processes of care, as well as a comprehensive set of complications 
in a selected group of patients and compared this intervention group with a historical 
control group treated without pre-operative optimization in the two years prior to the 
intervention. The primary outcome was length of stay in hospital as an overall outcome 
measure of changes in post-operative morbidity. Our hypothesis was that pre-opera-
tive optimization in a selection of low volume, high-risk surgical patients would result in 
improvements in post-operative morbidity and mortality. This ICU intervention was a first 
step in the development of a CP for esophagectomy patients.
The postoperative ICU related CP and variance report for cardiac surgery was used as a 
blue print for development of a CP in the ICU and in the Post Anaesthesia Care Unit (PACU) 
for pancreatico-duodenectomy procedures. This process of development and implemen-
tation is described in Chapter 5. The pancreas CP had to be a continuum from admission 
to discharge from the hospital. Essential elements included: restrictive intra-operative fluid 
use, strict pain control, early mobilization, early drain and gastric tube removal, and early 
enteral feeding, all according to the ERAS protocol. Post-operatively, early warning scores 
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(EWS) were measured at least once during every 8 hour shift and additionally whenever 
indicated by the nurses, with strict directives for action by nurses according to the var-
iance report. The incidence of post-operative complications was the primary endpoint 
to determine if implementation of the CP was safe and effective. Secondary endpoints 
were postoperative fluid balance, gastroparesis, protocol adherence to mobilization, drain 
removal, radiologic and surgical re-interventions, ICU readmission, in hospital-LOS, hos-
pital readmission and mortality rate. In chapter 6 we present a small overview of the 
literature on CPs in high-volume,  low- and average risk procedures. Together with  a 
reflection on a possible need for sustainable clinical pathways in high-risk surgery and 
the development of personalized care pathways in the near future.
In Chapter 7, we summarize the results of the work described in this thesis. Chapter 8 
comprises the general discussion and future perspectives. We focus on the relation 
between process interventions like the development and implementation of clinical path-
ways and outcome. Well- known facilitators for implementation and protocol adherence, 
such as clinical leadership and feedback cycles for care-providers, were also identified 
in our ICU and wards. Which barriers could we identify and were these overcome or 
bypassed before a CP  implementation could start. Clinical pathways can be a tool in Work-
as-Done in high-risk surgery to increase protocol adherence, together with a variance 
report. Although not the focus of the study, trends in behaviour and trends in protocol 
adherence of care-providers  will be discussed. Future perspectives for process interven-
tions like clinical pathways integrated in hospital processes and system interventions like 
data management could have a positive impact on quality of care and patient safety. Imple-
mentation of shared decision making and person-centered-care, developed in co-creation 
with care-providers and patients in the near future, will lead us to the clinical pathways 3.0.
Figure 2 shows the timing of our CP interventions in relation to the patients’ journey 
together with the actors in the process.
General Introduction and outline of this thesis
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1
Figure 2: Intervention Flowchart High-risk surgery related clinical pathways.
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Development and 
implementation of a clinical 
pathway for cardiac surgery 
in the intensive care unit: 
effects on protocol adherence
Abstract
Rationale, aims and objectives
Cardiac surgery (CS) is facilitated by multiple peri-operative guidelines and protocols. Use 
of a clinical pathway (CP) may facilitate the care in these patients 
Methods
This is a pre-post design study in the ICU of  a tertiary referral centre.  A CP for CS patients 
in the ICU was developed by ICU-nurses and enabled them to execute pro-actively prede-
fined actions in accordance with and within the preset boundaries which were part of  a 
variance report.. A tailored implementation strategy was used. Primary outcome measure 
was protocol adherence above 80% on the domains of blood pressure control, action on 
chest tube blood loss and electrolyte control within the CP. 
Results
In a four month period 84 consecutive CP patients were included and compared with 
162 matched control patients admitted in the year before implementation, three patients 
were excluded. Propensity score was used as matching parameter. CP patients were more 
likely to receive early adequate treatment for derangements in electrolytes (96% vs 47%, 
p<0.001), blood pressure (90% vs 49%, p<0.001) and more timely treatment for chest tube 
blood loss (90% vs 10%, p<0.001).. We found no differences in hospital and ICU length of 
stay, ICU readmission or mortality.
Conclusion
Use of the CP improved postoperative ICU treatment for cardiac surgical patients. Imple-
mentation of a CP and the use of a special variance report could be a bleu print for the 
implementation and use of a CP in low volume high complex surgery.
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Introduction
Cardiac surgery is considered high-risk surgery and is facilitated by multiple peri-operative 
guidelines and protocols (1). In the USA over 350.000 patients are treated annually for 
coronary bypass graft or a cardiac valve procedure with an overall mortality rate of 3-4% 
(2). While multidisciplinary teamwork for these patients is essential, the current protocols 
are mainly mono-disciplinary, limiting their integration and transparency. The actual use of 
these protocols in daily practice is unknown and compliance to these protocols is seldom 
measured (3)(1). We considered that the use of a clinical pathway (CP) facilitates the care 
of this specific group of patients by increasing compliance with existing protocols (4,5). 
Key elements of a CP are evidence based guidelines, clinical protocols and best practice 
rules, together with a coordinated sequence of activities of the multidisciplinary team (6). 
Many CPs have been developed for high volume, low- and average-risk health care proce-
dures to reduce complications (7-9). In cardiac surgery some CP’s for specific operations 
are being used, however, general CP’s applicable to all cardiac surgery patients are not 
available (10-13). In addition, many complex CP’s in high-risk surgery do not include the 
intensive care unit (ICU) period in their CP (14). 
The ICU is a very dynamic environment, one patient can be hemodynamic or respiratory 
unstable and  this can result in a delay in the treatment of less urgent situations for other 
patients in the ICU. To reduce delay, we developed a clinical pathway (CP) with a uniform 
protocol and an hour-to-hour written schedule for all cardiac surgery patients. The CP 
focused on recognition of deviation from the pathway by nurses and their treatment within 
the boundaries of the prescribed variances. The aim of this study was first to develop 
and implement a CP for all cardiac surgery patients in the ICU and to achieve a protocol 
adherence above 80%. Second, to determine the effects of this CP on patient outcome. 
Chapter 2
28
Methods
Setting and patients 
The Radboud University Medical Centre in Nijmegen is a tertiairy referral center and is 
a 960- bed university hospital with a closed format ICU with 32 beds with 14 ICU-beds 
dedicated to approximately 800-1000 admitted cardiac surgery (CS) patients per year. 
ICU-nurses caring for cardiac surgery  patients in the ICU are working in close cooperation 
with the medical staff. 
Development of the Clinical Pathway
For the development of the CP it was important to identify potential barriers and facilita-
tors in this particular setting and tailor the implementation strategy accordingly. Nursing 
and medical protocols for cardiac surgery patients in the ICU were examined and rede-
fined, when available based on Evidence Based Medicine and Evidence Based Practice. The 
variance report was developed in close relationship with the Clinical Pathway Protocol by 
the two senior nurses (MvdB and CtB-S) and in cooperation with the medical and nursing 
staff.  As part of the evidence based implementation strategy a small group of key-nurses 
reflected on the concepts of the CP and variance report and as part of a Prepare-Act-Re-
flect Cycle, they developed together with the senior nurses the variance report and CP. 
The described actions in the variance report were made in close cooperation with the 
medical staff and were synchronized to the medical protocols. ‘
Three features of our CP are distinctive compared to regular CP’s. First, the CP was devel-
oped for all adult CS patients, irrespective of the type of cardiac surgery. Second, instead of 
a “day-to-day-care” plan, an “hour-to-hour” care plan was developed for ICU care. Describ-
ing all multidisciplinary activities needed to be achieved within a specific period of time, in 
a specific group of patients. Third, in the CP, a special variance report (‘Radboud variance 
model’; appendix) was incorporated. This model enables nurses to execute predefined 
actions in accordance and within the preset boundaries of a variance protocol, without the 
need to consult the responsible physician first. (Dutch law and order for health care pro-
fessionals BWBR0006251 chapter IV, article 35). This nurse driven CP not only included the 
recognition of minimal changes in physiology but also prescribed that recognition of these 
changes had to be followed by treatment in accordance to the variance report. The study 
was carried out in accordance with the applicable rules concerning biomedical research 
using patient information. Patient data were collected and analyzed anonymously. 
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Implementation of the Clinical Pathway
Awareness that  implementation of a clinical pathway will introduce an essential change in 
daily practice for ICU-nurses and doctors is essential during development and implemen-
tation. A small group of key-nurses evaluated the concepts of the CP and the ‘key’ nurses 
were trained in the use of the CP. Feasibility of this nurse-driven clinical pathway for CS 
patients was studied during a  period of two months. The project and the development 
status were discussed in team meetings and daily practice  and feedback was welcomed 
by the developers. After two months we concluded that it was feasible and safe to use 
the CP and variance report in this patient group. Training of all ICU-nurses in the use of 
the CP and the variance report together with bedside teaching started on the ward. Phy-
sicians followed a separate training program about what the CP and the variance report 
entailed and the change in daily work process. After the information and training period 
the implementation started. Postoperative CS patients could only be treated according 
the CP when ’key-’ nurses or senior nurses were on the ward for supervision. Monthly 
evaluation of the implementation process was part of the implementation process and 
did focus on barriers and facilitators of the implementation and on protocol adherence 
according to the variance report. Protocol adherence had to be above 80% and actions 
on deviations according to the variance report had to be within 30 minutes. 
Design
After the implementation of the CP a matched cohort study was performed to determine 
protocol adherence in a group of ICU patients treated according to the CP for cardiac 
surgery patients. Covariates were used as predictors in a logistic regression analysis as 
being in the CP cohort or not. The included covariates, were  type of operation, APACHE-II 
score, log EuroSCORE, COPD, diabetes, age and gender. The match was performed on 
three  decimal places for the predicted probability (propensity score) and subsequently 
tested using the student T-test. Our conclusion was that there was no significant (p-value 
of ≥ 0.2) difference between the control group and CP group and therefore considered 
as good match between the two groups. In order to improve the power of this study a 
1:2 matching design was used.
Control Group of Non-Clinical Pathway cardiac surgery patients
Non-CP patients treated on the ward during the implementation period were not used 
as controls because the risk of crossover contamination. The CP patients were matched 
to historical control patients operated one year before implementation. Except for the 
implementation and use of the CP there were no other relevant changes in therapy or 
treatment between both periods. Protocols and target values for e.g. protective mechani-
cal ventilation, prevention of ventilator associated pneumonia, blood pressure regulation, 
strict glucose and electrolyte regulation did not differ between both groups. 
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End-points
To evaluate protocol adherence of the CP and the effects of implementation of the CP 
for CS patients in the ICU, the following predefined end-points were set: Incidence of 
temperature drop >0.3o C after ICU arrival, percentage of patients adequately treated if 
glucose and electrolytes were out of range, percentage of patients adequately treated 
if mean arterial pressure was out of range within 30 minutes, percentage of patients 
adequately treated within 30 minutes for postoperative chest drain blood production. 
We considered that protocol adherence to the CP should be above 80%. Also, other out-
come effects of adherence to a nurse-driven CP including time to extubation, troponin 
and lactate levels, diuresis and time to mobilization were measured. Finally, ICU-length 
of stay (LOS), hospital-LOS, ICU readmission, and mortality rate were determined as 
secondary measures, as this study was not powered to detect a difference between 
groups in these endpoints. 
Data collection:
Data was obtained via patient’s medical records, including all ICU registrations which 
was similar for both groups. The 24-hour physiology registrations consisted of hemody-
namic and respiratory parameters, levels of pain, fluid infusions, diuresis, and thoracic 
tube blood loss. Interventions like start of insulin, potassium infusion, vasopressors 
etc. were registered from the same 24-hour medical records. Although some data of 
the CP group was directly obtained from the CP list, including the variance report and 
were part of patients’ medical record, these were the same data as was collected for 
the control group. 
Exclusion criteria
Patients were excluded if there was no ‘key-nurse’ or senior nurse was available at the 
moment of post operative arrival at the ICU Patients with per-operative hemodynamic 
instability or ongoing hemodynamic instability during the first postoperative hours or with 
high doses of inotropic support or necessary re-operation, were excluded from the CP. 
The attending nurse and intensivist made the decision for exclusion together.
Statistics
Continuous variables were described as median and interquartile range [IQR, first and last 
quartile] and tested with the Mann-Whitney U test. Differences in dichotomous variables 
were analyzed using Chi-square test. Due to the exploratory nature of this study, and to 
increase the sensitivity to detect differences between groups, no correction for multiple 
testing was performed. Since the primary aim of the study was to achieve improvement 
in protocol adherence this was used for sample size calculation. To detect an increase of 
20% in protocol adherence following the implementation of a clinical pathway, calculating 
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from α=0.05 and a power of 90%, the calculated sample size was 81 patients for the CP 
group and 162 patients for the control group. Covariates were used as predictors in a 
logistic regression analysis as being in the CP cohort or not. In order to improve the power 
of this study a 1:2 matching design was used. 
This study was not powered to detect an effect of CP implementation on LOS-ICU, Hospital 
LOS and mortality. All statistical analyses were performed using SPSS version 20.01 for 
windows (IBM, SPSS statistics, Chicago, IL, USA).
Results
Development period.
The wish to develop the clinical pathway was initiated by the ICU-nurses, as they wanted 
to have more clinical responsibilities. Development of this evidence based clinical pathway 
together with a variance report needed a period of six months. After this period education 
and training of nurses and doctors started together with a pilot period to find out if a CP 
for all cardiac surgery patients in the ICU was feasible
Implementation period.
Prior to the implementation of the clinical pathway, a barrier-facilitator analysis was per-
formed. A negative attitude existed against more protocolizing their nursing work. Special 
attention was paid for this issue during the implementation training and during bedside 
training. During the implementation training it was recognized that the CP gave  more guid-
ance. Furthermore, ICU-nurses acknowledged that this CP together with the Radboud model 
variance report, empowered their work. More swift actions on deviations and availability of 
key-nurses  made the implementation of the CP for cardiac surgery a positive experience. 
Concerning the facilitators, several ICU-nurses ,as well as the head of the medical staff 
contributed to the development of  the CP and the variance report. These nurses served as 
key-nurses and the head of the medical staff approved clear and safe borders for making 
treatment decisions by nurses. Clinical decision making was not compulsory. When an inter-
vention was needed as determined in the CP, nurses could always consult a physician in case 
they felt uncomfortable about the action they had to start according to the variance report.
After this intensive training period the CP for all cardiac surgery patients was implemented 
in daily practice accompanied with training on the job performed by the key-nurses and 
the CP developers. The total period of development, training, feasibility testing and imple-
mentation was 18 months ( Figure 1).
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Figure 1: Flowchart implementation
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Patients
During the four month implementation period, 152 patients underwent cardiac surgery. 
84 patients arrived at the ICU after the operation when a senior nurse or ‘key-nurse’ was 
available for supervision. Three patients were excluded by mutual decision of the intensvist 
and the key-nurse because of post-operative instability with high dose of inotropics. The 
remaining 81 CP patients were matched with 162 non-CP patients (Figure 2).
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Figure 2: Flowchart inclusion in Clinical Pathway
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There was no significant difference in gender, age, type of operation, APACHE-II score 
and Log EuroSCORE between the two groups and these demographic characteristics are 
depicted in (Table 1). 
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Table 1 :Demographic and patients’ characteristics
Clinical pathway 
(n=81)
 Control 
(n=162)
Difference
p-value
Male, N (%) 70 (86) 132 (82) 0.59
Age in years, median [IQR]
Mean (SD)
64 [58-68]
60.8 (11.8)
63 [58-67]
61.2 (9.3)
0.85
Operation type, N (%)
- CABG 
- Valve
- CABG and valve
- Miscellaneous
55 (68)
15 (19)
2 (3)
9 (11)
109 (67)
30 (19)
7 (4) 
16 (10)
0.78
0.89
0.77
0.94
APACHE II median [IQR] 13 [12-17] 13 [12-15] 0.42
Euroscore median [IQR] 3.0 [2.0-4.0] 3.0 [2.0-5.0] 0.67
Euroscore grouped:
 - 0 or 1 14 (18) 31 (20) 0.66
 - 2 14 (18) 29 (19) 0.84
 - 3 16 (20) 27 (18) 0.26
 - 4 17 (22) 32 (21) 0.90
 - greater than 5 18 (23) 35 (23) 0.99
Propensity score 0.33 [0.32-0.44] 0.33 [0.29-0.41] 0.20
Protocol adherence and effects on clinical outcome 
The overall protocol adherence improved from mean 44% to 90% (p=0.01) after the imple-
mentation of the CP (Figure 3). 
Figure 3: Percentage adherence to clinical protocol.
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More patients in the CP group received early adequate treatment for derangements in 
glucose, electrolytes, according to the protocol. The incidence of temperature drop after 
arrival on the ICU was lower in the CP group. Protocol adherence for adequate and timely 
therapy within 30 minutes for blood pressure control and postoperative chest tube blood 
loss was higher in CP patients.. In addition, CP patients were extubated and mobilized 
earlier, and less patients in the CP group suffered from oliguria. Lactate and troponin 
levels were not different between the two groups. Also no differences were found for ICU 
and hospital length of stay, ICU readmission, and mortality (Table 2).
Table 2: Results of protocol adherence.
Clinical pathway
(n=81)
Control 
(n=162) 
Difference
p-value
Adherence to clinical protocol:
- electrolytes N, (%)
- blood pressure control N, (%)
- no temp drop >0.3 Celsius, N (%) 
- action on drain blood loss 
- within 30 minutes N, (%)
79 (98)
74 (93)
67 (83)
28/31(90)
76 (47)
80 (49)
115 (71)
8/83 (10)
<0.001
<0.001
0.21
<0.001
Mean percentage protocol adherence 90% 44% 0.01
Results related to outcome
- extubation hrs median [IQR]
 - troponin > 2.0 mcg/L N, (%)
- lactate >2.0 N, (%)
- diurese below minimum N, (%)
- mobilization in 24 hrs, N (%)
- LOS-ICU in hours, median IQR
- LOS-hospital in days, median IQR
- readmission N, (%)
- mortality N, (%)
6.5 [5.0-9.4]
65 (80)
12 (15)
10 (13)
34 (42)
22 [21-25]
7.0 [5.0-9.3]
3 (4)
0 (0)
8.0 [6.0-12.0]
129 (79)
34 (21)
45 (28)
1 (1)
23 [20-27]
6.9 [4.9-9.0]
13 (8.0)
3 (2)
0.03
0.77
0.15
0.03
<0.0001
0.21
0.66 
0.66 
0.46
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Discussion
The main finding of the present study is that the use of existing protocols improves when 
embedded in a clinical pathway. We found that nurse-driven protocol adherence in the CP 
group was significantly better including some clinical outcome measures compared with 
the control group. To our knowledge this is the first study describing the implementation 
and use of a nurse driven postoperative CP in ICU patients which considers many aspects 
of postoperative ICU care, for all types of cardiac surgery. While many protocols exist for 
the post-operative care for cardiac surgery patients, the compliance to these protocols in 
daily clinical practice is troublesome  and compliance is not measured routinely. Recently 
the American Association of Thoracic Surgery recognized the difficulty of implementation 
of guidelines, protocols and processes in an era of changing knowledge and consensus. 
Finding the facilitators and barriers is the first step in the development of a CP as described 
by Grol, Bosch and Evans-Lacko (15-17). Facilitators should be used to reduce the barriers 
in the system and help in building a successful CP. 
Implementation of a CP
The development and implementation of a CP is a complex intervention. The multidiscipli-
nary character is essential, facilitating the accommodation of different protocols, normally 
used by different disciplines. This implies that a culture change is an essential part of its 
implementation strategy. Importantly, a CP is limited to organize the care processes for 
a well-defined group of patients during a specific time period. Cardiac surgery patients 
may represent such a group with limited heterogeneity. Available CPs for cardiac surgery 
are only used for specific types of operation (e.g. coronary artery bypass graft or valve 
replacement) and exclude the care on the ICU. In contrast to general CP’s using day-to-day 
care plans, our CP consisted of an hour-to-hour care plan and was nurse-driven. This study 
shows that despite the complexity of the post-operative cardiac surgery patient with the 
risk of rapid changes in his/her clinical condition, it is feasible to implement a uniform CP 
using a tailored and evidence-based implementation strategy. Support from management, 
clinical staff and “key-nurses’’, with adequate time for teaching and training, has probably 
been the cornerstone of this successful implementation.
Adherence to the CP
Determination of CP adherence during and following implementation is essential to estab-
lish its effects (18). In addition to the presence of key performance indicators, it is possible 
to determine adherence by the use of a variance report. In our study, all items measured, 
improved following implementation. Different from previous variance reports, in which 
only deviations or adverse events are registered, our variance model also allowed for 
pro-active interventions by the nurses within legal boundaries (19, 20). As a consequence, 
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the care for these patients obtained a more multidisciplinary character. It has previously 
been recognized that by giving the nurses a greater responsibility to execute medical 
protocols, the adherence to these protocols improves (21). In our view, their position in 
the current organization structure could be exploited to a greater extent. Therefore, the 
role of the nurses in the development and implementation of the protocol was empha-
sized in our study.  
Outcome of patients following implementation of a CP
In view of the difficulties to demonstrate that use of a CP leads to improved outcome , it 
is generally accepted that enhanced process management  without adverse effects on 
outcome can be considered a successful result of a CP (22, 23). We were unable to detect 
an effect on ICU and hospital LOS, or mortality in our CP patients, because of limited 
statistical power. Nevertheless, several clinical endpoints, including time to extubation, 
diuresis, and mobilization, improved significantly. 
Limitations
Several limitations of our study need to be addressed. We started the CP in the ICU and 
this is only a small period of the hospital treatment of these patients. The most relevant 
limitation is the pre-post design nature of the study. The implementation of a CP is a 
change process for the team and the organization. Therefore, per patient randomization 
is not a feasible study design. To prevent crossover contamination we did therefore use a 
historical control group (patients admitted during the previous months) and not patients 
that were in the ICU but not in the CP during the same period on the ICU ward. Unfortu-
nately, most studies on CP implementation share this limitation (24, 25).
Second, we aimed to demonstrate an effect on intermediate endpoints directly related to 
CP adherence and not on endpoints such as length of stay and mortality. It is important 
to realize that e.g. an effect on ICU length of stay will be difficult to achieve in this group 
of patients, as median ICU-LOS is 1 day, and patients will likely not be discharged from 
the ICU during night time, because discharge from the ICU outside office hours may have 
detrimental effects on outcome (26). Also mortality in cardiac surgery patients is relatively 
low, implying that a large number of patients will be needed to demonstrate a putative 
beneficial effect on survival. A third limitation is the short duration of our study, limiting 
the possibility to demonstrate that the change in culture is secured in the long-term. 
Recently, we have implemented our CP, including variance reporting, process indicators 
and measures of clinical outcome, in our patient data management system, facilitating 
sustained monitoring and feedback of adherence to the CP.
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Conclusion
CP implementation resulted in more timely and better organized postoperative ICU 
treatment. This included an improved blood pressure control, electrolytes in range, 
temperature management, weaning from mechanical ventilation, and a more expedient 
adequate action to chest tube blood loss. We demonstrate that it is feasible to imple-
ment a predominantly nurse-driven hour-to-hour CP in the intensive care unit for cardiac 
surgery patients. This implementation strategy and variance report is a blue print for the 
implementation of a CP for low volume high risk surgical procedures. 
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Sustainability of clinical 
pathway guided care in 
cardiac surgery ICU patients; 
nine years experience 
in over 7500 patients
Abstract 
Objective
To determine trends over time regarding inclusion of postoperative cardiac surgery inten-
sive care unit patients in a Clinical Pathway , and the association with clinical outcome. 
Design
Retrospective cohort study
Setting
Intensive Care Unit of an academic hospital.
Participants
All cardiac surgery patients operated between 2007 - 2015.
Measures and Results
A total of 7553 patients were operated. Three patient groups were identified: patients 
treated according to Clinical Pathway (n=6567), patients excluded from the Clinical Path-
way within the first 48 hours (n=633), and patients never included in Clinical Pathway 
(n=353). Patients treated according to Clinical Pathway increased significantly over time 
from 74% to 95% and the median Log EuroSCORE (predicted mortality score) in this 
group increased significantly over time (p=0.016). In-hospital length of stay decreased in 
all groups, but significantly in Clinical Pathway group (p<0.001). Overall, the in-hospital, and 
1-year mortality decreased from 1.5 to 1.1% and 3.7 to 2.9%, respectively (both p<0.05). 
Patients with a Log EuroSCORE >10 were more likely excluded from Clinical Pathway 
(p<0.001), but, if included in Clinical Pathway, these patients had a significantly shorter 
Intensive Care stay and in-hospital stay compared to excluded patients with a Log Euro-
SCORE >10 (both p<0.001).
Conclusions
The use of a Clinical Pathway for all postoperative cardiac surgery patients in the Inten-
sive Care Unit is sustainable. While more complex patients were treated according to the 
Clinical Pathway, clinical outcome improved in the Clinical Pathway group. 
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Introduction
The annual need for cardiovascular procedures worldwide is estimated at over 12 million 
procedures (1), and over 400000 patients are operated in the United States for coronary 
artery bypass grafting or cardiac valve procedures, which is accompanied with an overall 
30-days mortality rate of 3-4%(2). Cardiac surgery can therefore be considered as high-vol-
ume and high-risk surgery. Following the surgical procedure the journey of the patient 
starts in the intensive care unit (ICU). Postoperative care for these patients is facilitated 
by multiple guidelines and protocols. In the ideal situation, exchange of information and 
protocol use is optimal, resulting in a low post-operative morbidity and a low mortality rate. 
Multidisciplinary teams of physicians and nurses work together in the ICU, and therefore 
the use of transparent patient centered treatment protocols need to be considered as 
an essential component of postoperative care(3). It is thought that implementation of 
a clinical pathway (CP) for cardiac surgery patients in the ICU will improve transparency 
of multidisciplinary protocols in postoperative ICU treatment(4-6). While generally a CP 
indicates a ‘day-to-day’ care plan, in the ICU, a CP needs to be adjusted into an ‘hour-to-
hour’ care plan, describing all multidisciplinary activities needed to be achieved within a 
specific period of time(7). Early and adequate treatment during the first postoperative 
hours may limit progression of organ damage and subsequently reduce morbidity and 
mortality(8-10). Therefore, intensive monitoring and treatment warrant a pro-active atti-
tude and swift execution of interventions. As a consequence, most CPs for cardiac surgery 
patients explicitly exclude this postoperative ICU period(11, 12). 
In our view, treatment according to a CP for postoperative cardiac surgery patients in the 
ICU is feasible. Therefore, we developed and successfully implemented an ICU nurse-
driven CP, for all types of cardiac surgery patients based on evidence based medicine, 
evidence based practice and best practice guidelines (13). This CP includes a unique 
variance report (’Radboud variance model’) describing all multidisciplinary activities in the 
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ICU for all postoperative cardiac surgery patients. This variance model enables nurses and 
residents to pro-actively execute, predefined actions in accordance with and within preset 
boundaries of a variance protocol, without the need to directly consult the responsible 
intensivist first. Previously, we performed a matched control study in 243 patients and 
found that nurse-driven protocol adherence in the Clinical Pathway group was significantly 
better, including some clinical outcome measures, compared with the historical control 
group. This study was not powered to detect a difference between groups in ICU-length of 
stay (LOS), hospital-LOS, ICU readmission, and mortality rate (13). Not all cardiac surgery 
patients will follow the complete duration of the CP and some may never be included. Cur-
rently, this exclusion is based on their clinical assessment, including an expected high-risk 
of dying in patients with a high Log EuroSCORE (14), or complications that occurred during 
the surgical procedure and the clinical expectancy that the CP should not be followed. 
Long-term follow up of the use CPs following their implementation are sparsely described 
and as a result, sustainability of most implemented CPs are unknown (15). Therefore the 
primary aim of this study was to determine trends over time regarding inclusion and 
exclusion of cardiac surgery patients in the CP. Secondary aims included trends over time 
in ICU and hospital length of stay, re-operations, ICU readmissions, hospital and 1-year 
mortality and between groups. Subgroup analyses were performed between included and 
excluded patient groups and for patients with a Log EuroSCORE >10. 
Methods 
Design and patients
A retrospective cohort study was performed including all consecutive cardiac surgery 
patients aged ≥18 year, operated between January 1st, 2007 and December 31st, 2015. 
Patients that underwent a closed procedure (i.e. thoracic endovascular aortic repair pro-
cedure (TEVAR) or a transcatheter aortic valve implantation (TAVI) were not included. 
In 2013 a new patient data management system (EPIC®, Verona, Wisconsin USA) was 
implemented in our hospital, in which an electronic CP for cardiac surgery patients was 
incorporated. Since we considered this as a relevant structure intervention, we also ana-
lyzed the effects of implementation of this Patient Data Management System (PDMS).
Setting 
The ICU of the Radboud University Medical Center is a 32 bed closed format ICU with 10 
beds dedicated for cardiac surgery patients. Annually approximately 900 cardiac surgery 
patients are treated postoperatively in the ICU. Intensivists, residents in training and ICU 
nurses treat these patients in close cooperation with cardiac surgeons and cardiologists. 
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Clinical pathway 
The CP for cardiac surgery patients, including the variance report, was developed and 
implemented in the ICU in 2006, providing nurses the possibility to act within the bound-
aries of preset targets and within the legal borders of the Dutch law, without having to wait 
for approval of the supervising resident or intensivist (13). The variance report includes 
many interventions considering, e.g. early actions on low and high blood pressure, arrhyth-
mia, early actions on thoracic tube blood loss. Following the implementation period, the 
adherence to the CP was above 80%, and it was considered as being successfully imple-
mented. The implementation study was published elsewhere.The main finding was that, 
when embedded in a clinical pathway with a variance report, the use of existing protocols 
improves. Over 70% of the patients were included in the clinical pathway after the imple-
mentation (13). Prediction Models are important in cardiac surgery and ICU patients. For 
this study we used The European System for Cardiac Operative Risk Evaluation, Euro-
SCORE. It is a model to predict the risk of death and survival before cardiac surgery, taking 
into account the patient, comorbidity, and the proposed operation.  Acute Physiology and 
Chronic Health Evaluation (APACHE) Score is a mortality prediction model for ICU patients 
and uses the worst physiologic parameters on day 1 in the ICU.
Monthly updates, regarding several outcome measures are provided to the ICU team. 
These reports give overall information of the total treatment group and reflect on time 
until extubation, ICU and in-hospital length of stay (LOS), hospital mortality and 1-year 
mortality. When changes in trends are observed, e.g. time until extubation, or time to 
discharge from the ICU, analysis according to a Prepare-Act-Reflect cycle (P-A-R-cycle) is 
performed (16). Whenever needed, teaching and guidance were tools of the P-A-R-cycle, 
if deviations were observed. 
We identified three patient groups: group one was completely treated according to the CP 
(‘Clinical Pathway patients’); group two consisted of patients that were initially included in 
the CP, but excluded within the first 48 hours after surgery (‘Secondary excluded patients’). 
In this group, patients were often excluded due to too many or serious deviations from 
the normal course that needed direct treatment supervision by a resident or intensivist 
in close collaboration with the cardiac surgeon and/or cardiologist. Group three consisted 
of patients that were never included in the CP due to serious comorbidity or intra-oper-
ative complications and expectations that CP criteria for treatment could not be met (‘ 
never included patients’). All patients excluded from the CP, were treated according to the 
medical and nursing protocols also used in the CP, however, without using the preset CP 
targets. In CP-excluded patients, nurses and residents were not allowed to start the inter-
ventions as described in the ‘Radboud variance report’ without consulting the attending 
intensivist first, when clinical deviations were observed. 
Chapter 3
48
The implementation of the PDMS in 2013 was considered a complex structure interven-
tion. We decided to analyse the effect of implementation of the PDMS, because we had the 
expectancy that the implementation of a new PDMS might affect all processes regarding 
patient information including care and safety. For this we used a shadow paper system 
alongside the PDMS for the purpose to be able to find all the patients according to their 
inclusion or exclusion group in the system and enable us to analyse them. 
Data collection 
Data for the monthly updates, as well as for this study were retrieved from the ‘COR-
onary artery surgery database RADboudumc’ (CORRAD) (17), and merged with the ICU 
data collected for the National Intensive Care Evaluation (NICE) registry (18). The CORRAD 
database primarily collects cardiac disease specific characteristics, cardiac surgical treat-
ment data (e.g. type of operation, re-operation, blood loss), and CP data, while the NICE 
database collects ICU characteristics (e.g. comorbidity, severity of illness score, (APACHE-II 
and APACHE-IV scores), duration of mechanical ventilation, sepsis and other complications, 
etc).
Statistical analysis
Continuous data are presented as mean with standard deviation (SD), or median with first 
and third interquartile range [IQR], depending on its distribution. Differences in continuous 
variables between more than two groups were tested with ANOVA with Tukey’s post-hoc 
HS analysis, and Kruskall-Wallis with pairwise comparisons. Dichotomous variables were 
tested using Chi-square analysis. All statistical analyses were performed using SPSS version 
22.1 for windows (IBM, SPSS, Chicago, IL, USA).
Results
Between January 2007 and December 2015, a total of 8047 patients underwent a cardiac 
surgery procedure. 7553 patients underwent open cardiac surgery and were postop-
eratively admitted to the ICU, and 494 patients underwent a closed procedure (TAVI or 
TEVAR). All 7553 patients treated with an open cardiac surgery procedure were included 
in this study. In the first period 2007 - 2012, a total of 5207 patients were included, and 
following the implementation of the new electronic PDMS, from 2013 - 2015, a total of 
2346 patients were included (Figure 1).
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Figure 1: Flowchart of the patient population 2007-2015.
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Trends over time regarding inclusion and exclusion of cardiac surgery patients in the CP 
The group of CP patients consisted of 6567 (87%) patients, the group secondary excluded 
patients consisted of 633 (8.4%) patients and 353 (4.7%) patients were never included 
in the CP. Analysis of the demographic characteristics between the three patient groups 
revealed that secondary excluded  and never included patients had a significantly higher 
Log EuroSCORE, APACHE–II and APACHE-IV score (all p<0.001) compared to never included 
patients (Table 1). Patients operated for coronary artery bypass grafting (CABG), were 
more likely treated according to the CP (p<0.001) than patients for other cardiac surgical 
procedures. Patients with a Log EuroSCORE >10 were more likely excluded from the CP 
(p<0.001), (Table 1). In the CP group the Log EuroSCORE and APACHE–II score increased 
significantly over time, p=0.016 and p<0.001, respectively. Increase of the APACHE –II score 
was also observed in the never included patients (Table 1).
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Table 1: Patient characteristics per study group over time, period 2007-2015.
Period 2007-2009
Clinical Pathway 
patients
N=1862
Secondary excluded 
patients
N=307
Never included patients 
N=136
Age, mean (SD) 65 (11)a b 69 (10)f 59 (17)
Male, n (%) 1340 (72)a 192 (63) 88 (65)
Operation type, n (%) 
   CABG
   CABG+Valve
   Single valve
   Thoracic aorta 
   Others
1291 (69)a,b
203 (10.9)a,b
236 (12.7)e,b
39 (2.1)a,b
93 (5.0)a,b
156 (50.8)c
65 (21.2)c
48 (15.6)c
15 (4.9)c
23 (7.5)c
52 (38.2)
18 (13.2)
21 (15.4)
17 (12.5)
28 (20.6)
APACHE-II score, mean (SD) 13 (4)a 16 ( 5)f 14 (6)
APACHE-IV score, mean (SD) Not available Not available Not available
Log EuroSCORE, median [IQR] 2.91 [1.54-5.71]a b 5.85 [2.87-12-41]c 7.16 [3.38-22.49]
Log EuroSCORE >10, n (%) 199 (10.7)a,b 91 (29.6) 56 (41.2)
Chronic Renal Failure, n (%) 33 (1.8)e 11 (3.6) 3 (2.2)
Dialysis, n (%) 5 (0.3)e,f 4 (1.3) 2 (2.5)
COPD, n (%) 186 (10) 42 (13.7) 15 (11)
Diabetes, n (%) 317 (17) 65 (21.2) 23 (16.9)
 Period 2010-2012
Clinical Pathway 
patients
N=2476
Secondary excluded 
patients
N=307
Never included patients
N=119
Age, mean (SD) 66 (11)d e 68 (10)f 64 (13)
Male, n (%) 1794 (73)e 203 (66) 88 (74)
Operation type, n (%) 
   CABG
   CABG+Valve
   Single valve
   Thoracic aorta 
   Others
1646 (66.5)a,b
233 (9.4)e,b
436 (17.6)a,b
86 (3.5)a,b
75 (3.0)a,b
148 (48.2)c
67 (21.8)c
62 (20.2)c
13 (4.2)c
17 (5.5)c
47 (39.5)
12 (10.1)
25 (21)
19 (16)
16 (13.4)
APACHE-II score, mean (SD) 13 (4)a b 15 (5) 15 (6)
APACHE-IV score, mean (SD) 58 (33)a 77 ( 22)c 74 (29)
Log EuroSCORE, median [IQR] 2.97 [1.65-5.93]a b 5.87 [2.70-10.66]f 8.77 [3.67-20.38]
Log EuroSCORE >10, n (%) 273 (11.0)a,b 82 (26.7) 48 (40.3)
Chronic Renal Failure, n (%) 31 (1.3)a,b 17 (5.5) 6 (5.0)
Dialysis, n (%) 5 (0.2)a,b 8 (2.6) 3 (2.5)
COPD, n (%) 249 (10.1)e 52 (16.9) 11 (9.2)
Diabetes, n (%) 456 (18.4) 66 (21.5) 22 (18.5)
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Table 1: Continued.
Period 2013-2015
Clinical Pathway 
patients
N=2229
Secondary excluded 
patients
N=19*
Never included patients
N=98
Age, mean (SD) 66 (11) 65 (12) 65 (11)
Male, n (%) 1608 (73) 11 (58) 64 (65)
Operation type, n (%) 
  CABG
  CABG+Valve
  Single valve
  Thoracic aorta 
  Others
1308 (59.0)b
220 (9.9)
445 (20.1)
176 (7.9)b
67 (3.0)b
10 (52.6)
0 (0)
4 (21.1)
2 (10.5)
3 (15.8)
45 (46.9)
8 (8.3)
18 (18.8)
15 (15.6)
10 (10.4)
APACHE-II score, mean (SD) 16 (4)b 16 (5) 18 (7)
APACHE-IV score, mean (SD) 61 (19)b 63 (13) 71 (31)
Log EuroSCORE, median [IQR] 3.30 [1.75-6.25]b 2.73 [1.61-7.13]f 6.05 [2.95-24.75]
Log EuroSCORE >10, n (%) 255 (11.8)b 2 (13.3)* 39 (40.6)
Chronic Renal Failure, n (%) 21 (1.0) 0 (0)* 2 (2.3)
Dialysis, n (%) 3 (0.1)e 0 (0)* 1 (1.2)
COPD, n, (%) 240 (11.5) 0 (0)* 8 (9.3)
Diabetes, n, (%) 420 (20.1) 4 (21.1)* 19 (22.1)
a Statistically significant ( p<0.001) CP patients compared to secondary excluded patients. 
b Statistically significant ( P<0.001) CP patients compared to never included patients.
c Statistically significant ( p<0.001) secondary excluded patients compared to never included patients. 
d Statistically significant ( p<0.05) CP  patients compared to secondary excluded patients.
e Statistically significant ( p<0.05) CP  patients compared to never included patients. 
f Statistically significant ( p<0.05) secondary excluded patients compared to never included patients.
LogEuroSCORE: patients’ predicted risk of death and survival prior to cardiac surgery, taking into account the 
patient, co-morbidity, and the proposed operation.
APACHE –IV score became available in our registration in 2010 therefore this score is not available in 2007-2009 
data.
* In the group of secondary excluded patients, following implementation of the new PDMS, under-registration in 
this patient group occurred, as a secondary exclusion was not always recorded in the system.
Trends over time of the CP groups
Over time, the percentage of patients treated according to the CP increased from 74% in 
2007 to 95% in 2012 and remained stable until the end of the study in 2015. The percent-
age of patients with a Log EuroSCORE >10 overall, did not increase during the study period 
(p=0.13). Over time significantly more patients with a Log EuroSCORE >10 were treated 
in the CP group, 58% to 86% (p<0.001). The increase of patients with a Log EuroSCORE 
>10 excluded from the CP, did not reach statistical significance in both groups (Figure 2).
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Figure 2: Inclusion and exclusion CP and Log EuroSCORE >10 within groups.
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* :In the group of secondary excluded patients, following implementation of the new PDMS, under registration 
in this patient group occurred, as a secondary exclusion was not always recorded in the system
Outcome 
The overall hospital length of stay (LOS) reduced significantly from median 6 days [IQR 5-9] 
to 5 days [IQR 3-7], (p<0.001). Over time the ICU readmission rate decreased from 3.6% to 
2.4% (p<0.001). The hospital and 1-year mortality decreased from 1.5% to 1.1% (p<0.05) 
and 3.7% to 2.9% (p<0.05), respectively. Over time, less patients were primary excluded 
from the CP (p=0.04). In the CP group median ICU-LOS, in-hospital LOS and mortality 
decreased over time (p<0.001). In the primary excluded patients, ICU-LOS increased, while 
hospital LOS decreased (both p<0.001). The median ICU-LOS in the secondary excluded 
patient group did not change over time, while the in-hospital LOS decreased (p<0.001). 
The incidence of postoperative sepsis and acute kidney injury remained stable over the 
period, varying between 0.6-1.0% and 2.6-3.8%, respectively. 
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There seems to be a trend towards increase in mortality and 1-year mortality and a reduction 
in readmission ICU over time in the excluded patients (Figure 3 and supplemental Table 3). 
Figure 3: Trends in outcome over time for CP patients, never included patients and secondary excluded patients 
divided per 3-year period for the total period 2007-2015 (n=7553).
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Effect of Clinical Pathway in patients with a Log EuroSCORE >10
A total of 1057 patients had a Log EuroSCORE >10. These patients had a higher risk for 
complications and mortality, especially in patients that were not treated according to the 
CP (Table 2). Patients with a Log EuroSCORE >10 treated according to the CP had a shorter 
ICU stay and in-hospital LOS compared to those that were not treated according to the 
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CP (p<0.001).  Time until extubation was shorter in patients treated according to the CP 
and in secondary excluded patients, than in never included patients (p<0.001) . In-hos-
pital mortality and 1-year mortality were significantly lower in the CP group compared to 
excluded patients (both p<0.001) (Table 2).
Effects of implementation of patient data management system
We observed that for more than one year, registration and correct tagging of patients 
in the PDMS, according to their postoperative pathway was cumbersome. This resulted 
in an under registration of secondary excluded patients from the CP (Figure 1). Overall, 
implementation of a new PDMS did not influence the characteristics and outcome data 
within the subgroups. 
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Table 2: Demographic characteristics and results of patients with a Log EuroSCORE >10.
Clinical Pathway 
patients 
N=732
Secondary 
excluded patients 
N=180
Never included 
patients 
N=145
Demographic characteristics
Age, mean, (SD) 71 (11) 73 [66-79)a 66 [60-75]a
Gender, male n, (%) 400(55) 94 (52) 89 (61),
Type of operation.n,(%)
   CABG
   CABG+ Valve
   Valve
   Thoracic Aorta
   Others
232 (32)
140 (19)
178 (24)
137 (19)
45(6)
53 (29)
44 (24)
39 (22)
24 (13)
20 (11)
29 (20)a
18 (12)
38 (26)
44 ( 3)a,b
16 (11)
APACHE-II score, mean (SD) 16 (5) 17 (5) 18 (7)b
APACHE-IV score, mean (SD) 73 (23) 75 (26) 80 (30)
Left ventricle ejection fraction, median [IQR} 50 [40-60] 44 [35-50]b 40 [30-50]b
Log EuroSCORE, median [IQR] 15.0 [11.7-21.6] 18.4 [13.1-32.5]a 26.9 [15.8-40.0]a,
Comorbidity n (%)
   COPD
   Diabetes
   Chronic renal failure
   Dialysis
109 (16.8)
119 (16.3)
25 (3.5)
4 (0.6)
25 (13.9)a
34 (18.9)b
12 (6.7)a
6(3.3%)a
14 (9.9)a
19 (13.5)
7 (4.8)
3 (2.1)a
Postoperative results
Time until detubation in hours median [IQR] 9 [7-13] 10 [7.5-15] 38 [11-99]a,b
ICU-LOS (hrs), median [IQR] 24 [22-47] 72 [26-161]a 96 [42-259]a,c
Hospital LOS (days), median [IQR] 7 [5-13] 14 [9-26]a 13 [8-27]a,c
Postoperative complications and outcome
Re-admission to ICU, n (%) 34 (4.7) 22 (12.2)a 12 (8.3)a,c
Acute Kidney Injury (AKI), n (%) 30 (4.1) 29 (16.1) 26 (18.4)a,
Reoperation, n (%) 69 (9.4) 26 (14.4)b 33 (22.2)a
Postoperative blood loss during first 8-hrs in 
ICU (ml), median [IQR]
420 [240-760] 540 [308-793] 810 [400-1390]a,c
In-hospital mortality, n (%) 22 (3.0) 16 (8.9.) 25(17.2)a,b,c
1-year mortality, n (%) 61 (8.3) 33 (18.3)a 35 (24.1)a,c
a p< 0.001 significantly different between patients not in the clinical pathway versus those treated according to 
the CP. 
b p< 0.05 significantly different between patients not in the clinical pathway versus those treated according to 
the CP 
c p< 0.05 significant difference between patients secondary excluded from clinical pathway and patients primary 
excluded from the CP group.
 d p< 0.05 significantly different between patients secondary excluded from clinical pathway and those treated 
according to the CP.
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Discussion
In the present study of a nine-year period experience with the use of a clinical pathway in 
cardiac surgery patients, we found that the percentage of patients treated according to 
the CP increased over time. While more complex patients with more co-morbidities were 
included in the CP, clinical outcome improved in patients treated according to the CP. The 
composition of the never included patient group consisted of more complex patients with 
clearly a higher risk for postoperative morbidity and mortality. This finding illustrates that 
care-givers can adequately select these patients. 
Clinical pathway-guided care in the postoperative period has been implemented in many 
hospitals. However, usually these CPs do not include the ICU care. CP-guided care in 
cardiac surgery seems to focus on specific groups like CABG, TAVI and valve replacement 
surgery . The outcome measures mainly focus on reduction of morbidity and in-hospital 
LOS through goal-directed therapy in cardiac surgery (12, 19-21). 
The introduction of a CP in our patient group, resulted in improved outcome related to 
in hospital LOS, readmission and mortality and are in accordance with findings in low- 
and intermediate-risk surgical procedures (22). Clinical pathways for standardized care to 
reduce variation in care and outcome are well known in e.g. cardiology. CPs in cardiology, 
mainly focus on management of acute coronary syndromes and reduction of time-to-
stent or time-to-surgery. Implementation of a CP for the treatment of acute coronary 
syndrome resulted in improved protocol adherence (23), improved treatment, as well 
as improved outcome (24, 25). Currently, the implementation and use of a CP in cardiac 
surgery patients is not common practice and literature is scarce and mainly limited to 
specific aspects of care. Moreover, implementation of CP-guided care in the ICU is often 
not included (11). This is not specific to cardiac surgery, in many other high-risk surgery 
procedures, ICU care is seldom part of the CP (26-28). We implemented a CP for all post-
operative cardiac surgery procedures in the ICU, together with an unique variance report, 
and showed that sustainability of CP-guided care after implementation over a nine-year 
period is feasible. This is the first study describing the sustained long term use of a CP for 
cardiac surgery patients.
Many structure interventions like data management, staffing levels and governance-in-
duced regulatory rules will influence work processes and outcome related to these 
structure interventions (29). This has to be taken into account during follow-up, innovation 
and research of sustainable pathways. During our nine years’ journey we had one struc-
ture intervention: the change of a PDMS, with impact on processes and members of the 
whole treatment team. Even though anticipated and pro-actively approached, including 
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training and a shadow paper system, we learned afterwards that some of the data were 
not easily traceable in the system.
More than 9 years after implementation, only 5% of our cardiac surgery patients is not 
included in the CP. Currently, a high Log EuroSCORE does not automatically indicate that 
this patient needs to be excluded from treatment according to the CP. Our clinical out-
come data illustrates that it is feasible to  differentiate the patients that were treated 
according to the CP from those who were not. Any change in the results and outcome 
measures in the different patient groups, initiates analyses of the procedures under-
neath and patient selection. Because the team knowledge and learning community of the 
ICU-nurses increased over time, we were able to start adjusting targets within the CP to 
individual patients, e.g for blood pressure. 
Several limitations of the study need to be addressed. First, this is a retrospective cohort 
study and not a controlled trial, as a result this does not allow to draw firm conclusions that 
treatment according to the CP per se leads to a better outcome. The observed impaired 
outcome in patients not treated according to the CP is most likely the result of improved 
patient selection over time of the truly high-risk patients that were excluded from the CP. 
Nevertheless, we observed over time that an increasing percentage of cardiac surgery 
patients, up to 95%, can be treated according to the CP after surgery, without a negative 
effect on their outcome. Second, this is a single center study performed by a commit-
ted team, potentially limiting its generalizability. As with other changes in treatment and 
responsibilities, the barriers and difficulties of implementation are recognized. 
In summary, the sustained use of a clinical pathway is a dynamic process and changes in 
the underlying evidence should also be part of the evaluation of a CP (30). This continuous 
learning process in CP-guided care will lead us to more personalized pathways for high-risk 
patients and to shared decisions in person-centered care in the future. 
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Conclusions
We showed that the use of a Clinical Pathway for all postoperative cardiac surgery patients 
in the Intensive Care Unit over time is sustainable. While more high risk and complex 
patients were treated according to the Clinical Pathway, clinical outcome improved in the 
Clinical Pathway group. 
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Effects related to ScvO2-guided 
preoperative optimization 
in open transhiatal 
esophagectomy patients: 
an observational 
evaluation study
Abstract
Background
Most studies on pre-operative optimization are in heterogenous high risk surgical patient 
groups and results suggest that interventions aimed to improve the hemodynamic con-
dition may exert beneficial effects . Open transhiatal esophagectomy is associated with 
considerable postoperative morbidity and mortality. Pre-operative optimization of the 
circulation may result in a reduction of in-hospital-LOS, risk for anastomotic leakage and 
prevent  infection/sepsis. The effects of pre-operative optimization in this group of patients 
are unknown.
Methods
Following implementation of pre-operative optimization, 68 patients were compared  to 
32 patients operated prior to implementation. Optimization started one day before the 
esophagectomy in the ICU. A ScvO2 <70% was treated with fluids and inotropics according 
to protocol. 
Results
Sepsis occurred in 4% of optimized and 25% of control patients (p=0.004), anastomic leak-
age occurred in 12% of optimized patients and 25% of control patients (p=0.14). Optimized 
patients were less likely to be re-admitted to the ICU (p=0.07) and had a shorter median 
in-hospital–LOS of 10 [9-15]  vs 16 [13-35] days (p<0.001). A targeted ScvO2>70% was 
achieved in 77% of the optimized patients,  in the optimized group delta ScvO2 increased 
with 4 [0-7]%. Patients not reaching the target ScvO2  were more likely to have a cardio-
vascular medical history (73% vs 37% p<0.02 ). 
Conclusion
In this observational evaluation study targeted on preoperative ScvO2-guided optimisation 
of patients treated with an open transhiatal oesophagectomy, we observed an association 
with a shorter in-hospital length of stay and less infectious complications. These results 
suggest that preoperative optimisation could be beneficial in this specific group of high-
risk surgical patients.
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Introduction
Worldwide an estimated 400,000 patients per year are diagnosed with oesophageal cancer 
with a 5 years mortality rate of up to 80% [1,2]. In the Netherlands 2000 patients per year are 
diagnosed with oesohageal cancer and this number is increasing. While adjuvant chemo-ra-
diation therapy has improved the overall prognosis, patients are assumed more vulnerable 
to peri-operative complications, although this was not confirmed in the CROSS trial [3]. Open 
transhiatal esophagectomy for invasive or high grade dysplasia has been associated with 
substantial postoperative morbidity such as pulmonary edema, pneumonia, anastomotic 
leakage and mortality. For example, anastomotic leakage occurs in up to one-fourth of the 
patients and is associated with prolonged  hospital length of stay and mortality [4].
It is increasingly recognized that the peri-operative care of patients undergoing major 
surgery affects outcome [5-6]. Predominantly, pre-operative optimization of hemody-
namics is thought to improve postoperative outcome, but the exact mechanism of action 
remains unclear. Putative beneficial effects may include improved wound healing and 
less infectious complications related to an improvement in hemodynamics and better 
tissue perfusion. Conversively, aiming for a higher cardiac output might result in a more 
pronounced tendency for bleeding and cardiopulmonary complications. 
The ambiguous results of pre-operative optimization in unselected high-risk surgical 
patients  is possibly related to the heterogeneity of the patients included [10-15], while 
effects in specific patient groups have not been reported. The majority of patients under-
going major abdominal surgery, present themselves with functional intravascular volume 
deficit [16]. Apart from pre-operative fasting, anesthesia, and mechanical ventilation, inad-
equate intake in patients and the effect of neo-adjuvant  chemo-radiation therapy imply 
that this patient group might be most likely to suffer from hypovolemia. For this reason 
we selected patients with oesophageal cancer for pre-operative optimization.
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In view of the limited knowledge of how optimization influences outcome [17] and the 
assumption that pre-operative optimization may exert both beneficial and deleterious 
effects on postoperative complications and outcomes in high risk surgical procedures, we 
studied the association between optimization and a comprehensive set of complications. 
We hypothesized that a higher ScvO2  and cardiac output as a result of pre-operative opti-
mization, would result in less morbidity, specifically related to improved wound healing 
and infection. On the other hand, per-operative blood loss might be negatively influenced 
in the optimized group with a higher cardiac output. Therefore, intra-operative blood loss 
and the need for blood products were also monitored. 
We prospectively evaluated these items with the implementation of ScvO2-derived pre-op-
erative optimization in patients undergoing transhiatal oesophagectomy. Beforehand 
we decided to compare data from optimized patients with patients operated without 
preoperative optimization from the preceding 2 years prior to this change in policy. In 
addition, within the group of optimized patients, we determined the differences in out-
come between patients who did achieve their ScvO2 target and patients who did not. The 
primary outcome of this observational evaluation, study was length of stay in-hospital as 
an overall outcome measure of changes in morbidity. Infectious complications, amount 
of per-operative blood loss, use of blood products, duration of mechanical ventilation, 
postoperative start of enteric feeding,  incidence of re-intubations, ICU re-admission, ICU 
length of stay (ICU-LOS), and in-hospital mortality were secondary endpoints.
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Methods
Patients and study design
All successive patients with T1-3N1-2M0 distal (below Z line) oesophageal cancer and cardiacar-
cinoma with extension into the oesophagus are treated with neo-adjuvant chemoradiation 
according to the CROSS trial [3] followed by transhiatal oesophagectomy with gastric tube 
reconstruction and cervical anastomosis. In our hospital this is the preferred surgical 
procedure for oesophageal cancer. Patients with more proximal located oesophageal 
tumours and patients who had an intra-thoracic anastomosis for limited cardiac cancers, 
were not included in this study. In this group of patients no laparoscopic procedures 
were performed during the study period. Acute resection was an exclusion criterium. All 
patients received a jejunostomy for enteric feeding, starting within 24 hours after surgery. 
Pre-operative chemo-radiation was part of the treatment according to the CROSS trial and 
implemented as standard procedure for all patients in 2009. All patients were operated 
by the same surgeon (JJB) in the Radboud University Medical Center Nijmegen. 
In this before/after observational evaluation study, the outcome of patients treated 
according to the pre-optimization protocol was compared with a control group operated in 
the 2 years prior to implementation. This two year prior period was chosen because most 
changes in ICU treatment, like e.g. low  tidal volume ventilation, SDD  in the years before, 
had been established as common practice.   The operating surgeon had performed over 
100 procedures before the chosen control  period. Half-way 2011 a clinical pathway for 
patients treated for oesophageal cancer  including pre-operative optimization and aspects 
of the “Enhanced recovery program in colorectal surgery” together with standardized 
intra-operative care and a clinical pathway for the surgical ward after discharge from the 
ICU was implemented.
The study was carried out in accordance with the Dutch Guidelines for the review of 
research ethics committees and informed consent. Since this was a retrospective cohort 
study and no additional information was gathered that was burdensome to the patients, 
the medical ethical committee MEC of region Arnhem-Nijmegen waived the need for 
informed consent. Data-analysis was performed anonymously after  de-identification of 
the patient records.
Optimized cohort
Patients were admitted to the intensive care unit (ICU) one day prior to surgery. In the 
ICU, patients received an arterial line (radial artery) and a central venous catheter was 
introduced in the right subclavian or right jugular vein. As a surrogate of cardiac output, 
we determined intermittently the central venous oxygen saturation (ScvO2). Similarly as 
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in several other peri-operative optimization studies [18-19]. Fluid challenges and ino-
tropics were administered according to the intervention flow chart (figure 1). In case of 
(a history of) atrial fibrillation or when sinus tachycardia was observed, milrinone, instead 
of dobutamine, was administered (figure 1). In order to facilitate perfusion and oxygen-
ation in the gastric tube anastomoses, ketanserin as vasodlilator up to 2 mg/hour was 
administered until ICU discharge, when the mean arterial blood pressure was above 65 
mmHg[20]. To further investigate the effects of optimization within the intervention group, 
we compared patients that achieved the predefined goals to those that did not. 
Control cohort of non-optimized patients 
In this control cohort, all patients were pre-operatively admitted to the surgical ward (with 
oral access to fluids and food, but no intravenous fluids) and postoperatively transferred 
to the ICU for postoperative treatment and monitoring.
Pre and postoperative protocol
Indications for pre-operative nutrition or antibiotics did not change during the study 
period. Selective bowel decontamination and low tidal volume ventilation  are part of the 
standard procedures in the ICU and did not differ between the patient groups. Although 
since 2004 ‘Enhanced Recovery Program’ in colorectal Surgery is a standardized procedure 
in the departments of surgery and anesthesiology resulting in a restrictive volume policy 
during abdominal colorectal surgery, this program was not implemented for oesophagec-
tomy patients during the study period [21]. Blood transfusion triggers did not change 
during this period. Furthermore, per- and postoperative pain treatment with ropivacaine 
and sufentanyl via an epidural catheter was administered according to the same protocol 
in both groups. A patient centered analgesic pump was added if the patient was able to 
use this. ICU-discharge criteria did not change during the entire study period. Intra and 
post operative protocol was not ScvO2 guided and the same per-operative protocol for 
anesthesists and postoperative ICU protocol was used in both groups. Pulse, mean arterial 
pressure >65 mmHg and diureses > 0.5 ml/kg/hour  were the main goals for treatment. 
End-points of the study
The primary outcome of this study was length of stay in-hospital as an overall outcome 
measure of changes in morbidity. Infectious complications, amount of per-operative blood 
loss, use of blood products, duration of mechanical ventilation, postoperative start of 
enteric feeding,  incidence of re-intubations, ICU re-admission, ICU length of stay (ICU-LOS), 
and in-hospital mortality were secondary endpoints.
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Figure 1: Haemodynamic treatment algorithm intervention group.
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Statistics
Because of the relatively small sample size, normal distribution of data could not be 
assumed and all continuous variables are reported as median and interquartile range 
[IQR] and tested with Mann-Whitney U. Differences in dichotomous variables were ana-
lyzed with Chi-square test. Analysis of covariance (ANCOVA) was used with log-transformed 
continues outcome variables and dichotomous outcome variables were used for logistic 
regression analysis. 
Because of the explorative nature of this study and to increase the sensitivity to detect 
differences between groups, adjusting for multiple testing was performed. 
All statistical analyses were performed using SPSS version 20.01 for windows (IBM, SPSS 
statistics, Chicago, IL, USA). A p-value <0.05 was considered to indicate statistical signifi-
cance.
Results
Pre-operative phase
The optimized group consisted of 68 consecutive patients and the non-optimized group 
of 32 consecutive patients. In the intervention group 87% of the patients were treated 
for adenocarcinoma comparable to 77% in the control group (p=0.3). There was no sig-
nificant difference in TNM classification between the two groups (table 1, p=0.7). Patients 
in the optimized group tended to be older, were more likely to use anticoagulant therapy 
and more additional nutrition was started in the pre-operative outpatient period. In the 
control group patients consulted the dietician pre-operative in the outpatient clinic when 
weight loss was more than 5 % or oral enteral feeding was not possible. During these years 
the policy changed in a standardized referral to the dietician by the surgeon. Additional 
nutrition was prescribed as carbohydrate and protein enriched oral drinks, 4 patients 
received parenteral nutrition during one week. Pre-operative immuno-nutrition was not 
part of the nutritional support. For unknown reasons, patients in the intervention group 
appeared less likely to have used antibiotics pre-operatively,. More patients suffered from 
chronic pulmonary diseases in the optimized group. Other baseline characteristics were 
comparable between groups (table 1). 
ScvO2 was ≥ 70% in 32 (47%) patients at baseline. Hemodynamic optimization resulted 
in a significant increase in ScvO2 of a median of 4.0 [0-7.0]% from 70 [66-73] to 73 [71-
77]%. Target ScvO2>70% was achieved in 49 (77%) of the patients. Maximum heart in 
the optimized group was lower during the ICU stay 93 [79-105] vs 98 [95-113], p=0.02 . 
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Minimum  Systolic blood pressure during ICU stay was  higher in the intervention group 
107 [93-119] vs 92 [81-111], p=0.02. In the group of pre-operative optimized patients a 
median of 1415 [IQR 904-1993] ml fluids was administered pre-operatively and 9% of the 
patients received inotropics. The control group was not monitored pre-operatively, did 
not receive inotropics or i.v. fluids, but had free oral access to fluids and food (table 1).
Table 1: Demographic and preoperative characteristics.
Control group
(n=32)
Intervention group 
(n=68)
Differences
(p-value)
Age in years 60 [53-64] 63 [57-69] 0.08
Male (n, %) 26 (81%) 58 (85%) 0.77
BMI kg/m2 25 [22-27] 26 [24-28] 0.14
APACHE-II score * 14 [10-16] 10 [8-12] * 0.002
Baseline ScvO2 (%) n.a. 70 [66-73] n.a.
Preoperative chronic comorbidity (n,%)
   Diabetes mellitus 
   Pulmonary disease 
   Cardiac vascular disease 
6 (19%)
1 (3%)
9 (28%)
11(16%)
15 (22%)
29 (43%)
0.78
0.02
0.19
Preoperative medication
Preoperative iv fluid (ml) Free oral access, no iv fluids 1415 [904-1993] n.a.
Preoperative inotropics 0(0%) 6(8.8%) 0.17
Beta blocker (n,%) 7 (22%) 18 (27%) 0.80
Oral anticoagulant therapy (n,%) 2 (6%) 19 (28%) 0.02
Additional nutrition (n,%) 2 (6%) 23 (34%) 0.003
Antibiotics (n,%) 4 (13%) 0 (0%) 0.02
Neoadjuvant chemoradiation (n,%) 17 (53%) 48 (71%) 0.62
Data are expressed as median and interquartile range [IQR] unless otherwise stated.
* APACHE-II score was measured postoperatively on the ICU in the control group, and was preoperatively meas-
ured in the intervention group due to the preoperative optimisation on the ICU. BMI = body mass index; IV = 
intravenous; n.a. = not available
Peroperative phase
The duration of operation was not significantly different between groups (table 2). Patients 
in the optimized group received less fluids during the operation (median 2750 [2150-
3500] vs 4000 [2900-5250] ml; p<0.001) and were more likely treated with vasopressors 
compared with the control group (88% vs 41%; p<0.0001). The use of fluids was at the 
discretion of the attending anaesthesiologist who did not have information on the preop-
erative fluid balance. Although more patients in the optimized group used anti-coagulants 
(p=0.02), blood loss was less (median 600 [450-900] vs 910 [600-2000] ml; p=0.002), and 
the volume of blood products administrated was lower compared to the control group 
(median 275 [275-519 vs 600 [300- 1200] ml; p=0.001). The number of patients that 
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needed blood products was also less in the optimization group compared to the control 
group (6% vs 34%; p<0.001, table 2). Extubation of the patients was at the discretion of 
the attending anaesthesiologist a the end of the procedure. If the patient was not extu-
bated after surgery the attending intensivist decided when the patient could be extubated 
according to the existing extubation protocol.
Table 2: Intraoperative characteristics and postoperative results. 
Control group
(n=32)
Pre-optimised 
group (n=68)
Differences
(p-value)*
Operation duration (min) 169 [144-183] 184 [159-208] 0.04
Blood loss during operation (ml) 910 [600-2000] 600 [450-900] 0.002
Administration of blood products
- Number of patients (n,%)
- Blood product administered (ml)
11 (34%)
600 [300-1200]
4 (6%)
275 [275-519]
0.03
0.001
Haemoglobin (mmol/l) level at time of transfusion 5.1 [4.7-5.8] 4.8 [4.5-5.3] 0.21  
Intraoperative vasopressors (n,%) 13(41%) 60 (88%) <0.0001
Intraoperative inotropics (n,%) 5 (16%) 10 (19%) 0.58
Total of administered fluid (ml) 4000 [2900-5250] 2750 [2150-3500] <0.0001
POSTOPERATIVE RESULTS
Complications (n,%):
•	 Pulmonary 
•	 Empyema
•	 Cardiovascular 
•	 Superficial wound infection
•	 Anastomotic leakage
•	 Stenosis anastomose
•	 Re-laparotomy
•	 Mediastinitis
•	 Pleural oedema
•	 Sepsis
•	 15 (47%)
•	 2 (6%)
•	 5 (16%)
•	 7 (22%)
•	 8 (25%)
•	 8 (25%)
•	 6 (19%)
•	 3 (9%)
•	 12 (38%)
•	 5 (16%)
•	 32 (47%)
•	 5 (7%)
•	 18 (27%)
•	 6 (9%)
•	 8 (12%)
•	 20 (29%)
•	 5 (7%)
•	 1 (2%)
•	 29 (43%)
•	 3 (4%)
•	
•	 1.0
•	 1.0
•	 0.31
•	 0.11
•	 0.14
•	 0.81
•	 0.17
•	 0.09
•	 1.0
•	 0.004
Re-intubation (n,%) 5 (16%) 6 (9%) 0.32
Epidural dysfunction (n %) 7 (22%) 14 (21%) 1.0
Additional analgesics (n,%) 9 (28%) 31 (46%) 0.04
Total fluid balance (ml) at discharge ICU in ml 3010 [1632-4362] 1810 [545-3190] 0.03
Duration of mechanical ventilation in hours 8.0 [3.5-23.7] 5.2 [3.7-7.5] 0.04
Start of postoperative enteric nutrition (hours) 7.0 [1.4-29] 3.4 [1.0-21] 0.13
Re-admission ICU (n,%) 8 (25%) 6 (9%) 0.06
LOS ICU in days 2 [1-7] 2 [2-3] 0.72
LOS in-hospital in days 16 [13-35] 10 [9-15] <0.0001
Mortality in hospital (n,%) 3 (9%) 0 (0%) 0.01
Data are expressed as median and interquartile range [IQR] unless otherwise stated.
* Log-transformed continues outcome variables were tested using ANCOVA and dichotomous outcome variables 
were tested using logistic regression analysis, both adjusted for lung problems and use of anticoagulant therapy. 
LOS = length of stay
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Postoperative phase
Although the optimized patients were admitted to the ICU one day prior to surgery (accord-
ing to protocol), their total ICU-LOS was similar to the control group (table 2). Patients in the 
optimization group needed less fluids postoperatively, and had a significantly less positive 
total fluid balance (median 1810 [545-3190] vs 3010 [1632-4362] ml; p=0.03) at ICU dis-
charge. The incidence of sepsis was significantly lower (4% vs 25%; p=0.004). No difference 
was found between the two groups according to anastomotic leakage, but in the optimized 
group all patients with a leakage (12%) had Type I leakage, localized in the cervical area. 
Two patients within the control group had Type II leakage, one patient had dissemination 
of infected effusion in the pleural cavity and one patients had an abdominal sepsis because 
of leakage of the jejunostomy because of enteral feeding impaction. Optimized patients 
were extubated sooner (median 5.2 [3.7-7.5] vs 8.0 [3.5-23.7] hrs; p=0.04), less likely to be 
re-admitted to the ICU (10% vs 25%; p=0.07), and their hospital length of stay was shorter 10 
[9-15] vs 16 [13-35] days (p<0.0001). Three patients (9%) in the control group died (two with 
sepsis and one with cardiac complications), while none of the patients died in the optimized 
group (p=0.03). No other differences were found between both groups.
Relation between achieved ScVO2 and outcome
Due to protocol violation, no preoperative ScvO2  was measured in 4 patients during the 
pre-optimization phase. In total, 49 (77%) patients achieved the target ScvO2. Patients with 
a history of cardiovascular disease were more likely not to achieve a Scv02 >70%  compared 
to optimized patients with no history of cardiovascular disease (p<0.01), (table 3). Preop-
erative fluid administration was similar in patients that achieved the ScvO2 target (median 
1440 [907-1998] ml), compared to patients who did not reach the target ScvO2 (median 
1287 [790-2165] ml). In total 6 (9%) optimized patients were treated with inotropics, of 
which 4 patients did show an increase of ScvO2 (from 64 % to 69 %), but did not reach the 
target ScvO2. No differences in outcomes were found between patients who achieved the 
ScvO2  target or a rise of delta ScvO2 of more than 4%  and who did not (table 3).
Table 3. Differences in characteristics and outcome related to achieved and increase in ScvO2
ScvO2
≤70%
(n=15)
ScvO2
>70%
(n=49)
Differences 
(p-value)
ΔScvO2
≤ 4 %
(n=32)
ΔScvO2
>4%
(n=31)
Differences
(p-value)
Age in years, median [IQR] 67 [58-71] 61 [56-69] 0.21 60 [52-69] 65 [59-69] 0.13
Gender male (n, %) 13 (87) 41 (84) 0.78 25 (78) 29 (94) 0.08
APACHE-II score, median [IQR] 11 [7-11] 10 [8-13] 0.58 10 [6.8-11.2] 10 [8-13] 0.37
Diabetes mellitus (n,%) 5 (33) 6 (12) 0.06 3 (9) 8 (26) 0.09
Pulmonary disease (n,%) 4 (27) 9 (18) 0.49 5 (16) 8 (26) 0.32
Cardiovascular disease (n,%) 11 (73) 18 (37) 0.01 12 (38) 17 (55) 0.17
Beta-blockade (n,%) 9 (60) 9 (18) 0.02 9 (28) 9 (29) 0.93
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Oral anticoagulant therapy (n,%) 9 (60) 10 (20) 0.03 7 (22) 12 (38) 0.15
Total fluid given ml. 
preoperative, median  [IQR] 
1287
[790-2165]
1440
[907-1998]
0.73 1396
[996-1787]
1561
[787-2090]
0.51
Fluid balance (ml) 
preoperative, median [IQR]
620
[222-945]
420
[-400-775]
0.28 471
[222-795]
680
[-125-1105]
0.52
OUTCOME *
Anastomotic leakage (n,%) 1 (7) 7 (14) 0.44 3 (9) 5 (16) 0.42
Wound infection (n,%) 1 (7) 4 (8) 0.85 4 (13) 1 (3) 0.17
Sepsis (n,%) 0 (0) 3 (6) 0.33 2 (6) 1 (3) 0.57
Fluid balance in ml at 
discharge ICU, median [IQR]
970
[216-3745]
1943 
[1128-3333]
0.36 1830
[545-3745]
1410
[530-3070]
0.54
Re-admission  (n,%) 2 (13) 5 (10) 0.73 5 (16) 2 (7) 0.25
LOS-ICU (n,%) 2 [2-4] 2 [2-2] 0.87 2 [2-2] 2 [2-3] 0.52
LOS-in hospital (n,%) 10 [8-17] 10 [9-14] 0.65 10 [9-15] 10 [9-15] 0.66
IQR = interquartile range;  LOS = length of stay
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Discussion
In this before/after study we evaluated the association between pre-operative hemod-
ynamic optimization and the occurrence of predefined complications and outcome in 
transhiatal esophagectomy patients related to their duration of hospitalization as the 
primary endpoint measure. The in-hospital length of stay was significantly less in pre-op-
eratively optimized patients. We observed that hemodynamic optimization was associated 
with a significant reduction in the occurrence of sepsis. Mechanical ventilation time was 
reduced and while optimized patients were admitted to the ICU one day earlier, total 
ICU-LOS was not different between the two groups. No deleterious effects related to a 
higher cardiac output were observed in the optimized patients. In contrast, hemodynamic 
optimization was associated with less per-operative blood loss and a reduction in the use 
of blood products, even though more patients used anticoagulant medication. Finally, we 
observed a reduction in the ICU readmission rate and mortality rate. 
We postulated, in accordance with a meta- analysis [22], that a positive effect of hemod-
ynamic optimization could be achieved best when organ failure, tissue perfusion defects, 
or infectious complications had not yet occurred, especially in patients with a considerable 
mortality risk. Optimization of the ScvO2 in the pre-operative and postoperative period 
to a level above 70%, was demonstrated to reduce the number of complications and 
length of hospital stay in a heterogeneous group of high risk surgical patients [18,23,24]. 
While patients with oesophageal cancer are more likely to be volume depleted, the effects 
of pre-operative optimization with a ScvO2  target above 70% has not been investigated 
in this specific group of patients. As fluid administration is a cornerstone in pre-opera-
tive optimization, it remains important to realize that fluid therapy may be considered a 
two-edged sword, as a too liberal fluid policy may exert deleterious effects [25,26]. The 
enhanced recovery after surgery program  aims to avoid  peri-operative volume over-
load. Restrictive fluid therapy is thought to result in less intestinal edema and enhanced 
recovery. Importantly, our study confirms previous reports [19,27,28] that pre-operative 
optimization, including fluids and inotropics, results in a lower need for fluids during and 
following surgery. We do not have an explanation for the use of more vasopressors follow-
ing the intervention. The anesthesists had no knowledge of the amount of fluids that had 
been given to the patients in the ICU, excluding that they were more likely to administer 
a vasopressor because of that.
Although some  differences in outcome between the optimized and control group were 
clinically significant and suggest that pre-operative hemodynamic optimization through 
better tissue perfusion results in less infectious complications, this association is less 
straightforward than it might appear. For example, within the optimized group of patients 
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we found no differences in outcome between patients who achieved  the target of ScvO2 
>70%, compared with those who did not. Moreover, no differences were detected between 
the patients with an increase in ScvO2 more than 4%, compared to less than 4%. This sug-
gests that a ScvO2 above 70% or an increase in ScvO2 by itself may not be beneficial per se. 
In other words, these results could indicate that pre-operative optimization is beneficial 
for patients undergoing esophagectomy, but may not be directly related to reaching a 
ScvO2 >70%. A similar phenomenon was also observed in a study using a lactate clearance 
driven protocol in sepsis patients. The interventions aimed to improve lactate clearance in 
sepsis patients resulted in a better outcome, while the decrease in lactate concentration 
was similar compared to the control group [29]. Taken together, these results suggest that 
interventions aimed to improve the hemodynamic condition may exert beneficial effects. 
The chosen marker (either SvO2 in our study or lactate in the sepsis study) however, may 
not adequately reflect the improvement of the patient’s condition. For example we did not 
look at microcirculation or inflammatory response in the intervention group, which could 
both have a role in the improvement of the patients in the optimized group. 
Several other limitations of our study need to be addressed. First and most relevant, the 
study design introduces many opportunities for bias, as this is a non-matched pre-post 
design cohort study even though data in the intervention group were collected prospec-
tively. Although no other differences in treatment protocol occurred during the study 
period, we cannot exclude that medical or organizational interventions, unknown to us, 
did affect our results. During the same period changes in treatment in different patient 
groups were observed which were not part of any protocol or implementation strategy 
which could have affected the results of this study. Because the treatment of our patient 
group has a pathway through many departments,  half-way 2011 a clinical pathway for 
patients treated for oesophageal cancer  was implemented. This clinical pathway  com-
bines  pre-operative optimization in the outpatient clinic, the ICU and aspects of the “fast 
track” surgery protocols based on  the “Enhanced recovery program in colorectal surgery 
( ERAS)” together with standardized intra-operative care and a clinical pathway for the 
surgical ward after discharge from the ICU.
Also, patients were not randomized and several differences in baseline characteristics 
were present between the two groups. The influence of additional nutrition (more patients 
in intervention group) and antibiotics (more patients in control group) are difficult to 
determine. Adherence and non-adherence to the existing protocols could have been 
different due to education or individual pre-occupation. More patients in the intervention 
group used anticoagulant therapy, but still blood loss and need for blood products was 
less in this group. Also, other differences, apart from the preoperative optimization were 
present, e.g., use of vasopressor therapy during the operation, that may have influenced 
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the end points of the study. The enhanced recovery program for colorectal surgery with 
emphasis on prevention of fluid overload and use of vasopressors during surgery was 
implemented before our optimization study in oesophageal cancer patients started. This 
may have influenced the peroperative treatment choices of the anaesthesiologist and 
could have resulted in the use of early or more vasopressors. The central line in situ could 
have lowered the incentive for the anaesthesiology team to measure ScvO2 and treat low 
peroperative values even when mean arterial pressure was sufficient with vasopressors. 
Nevertheless, this is the first study examining the effect of optimization within a specific 
group of high-risk surgical patients and the results related to infectious and bleeding 
complications are in line with the observed effects of outcome measures in this specific 
group. Differences in ICU treatment, surgeons protocol adherence in different centres 
would introduce confounding factors and bias as well and due to the small number of eli-
gible patients per centre, a randomized controlled trial is unlikely to be conducted for this 
specific group of patients. In this observational evaluation study targeted on preoperative 
ScvO2-guided optimization of patients treated with an open transhiatal esophagectomy we 
observed an association with a shorter in-hospital length of stay and less infectious com-
plications,  shorter mechanical ventilation time, and lower mortality. Blood loss and use of 
blood products was less, not more, in patients that received preoperative hemodynamic 
optimization. These results suggest that preoperative optimization could  be  beneficial in 
this specific group of high risk surgical patients. Nevertheless, a clear relationship between 
achievement of target  ScvO2 and clinical outcome could not be established. Because of 
this, it is difficult to make clear cut recommendations for current daily practice.
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Implementation 
and evaluation of a 
Clinical Pathway for 
pancreaticoduodenectomy 
procedures: 
a prospective cohort study
Abstract
Introduction
Medical and nursing protocols in perioperative care for pancreaticoduodenectomy are 
mainly mono-disciplinary, limiting their integration and transparency in a continuous 
healthcare system. The aim of this study was to evaluate adherence to a multidisciplinary 
clinical pathway for all pancreaticoduodenectomy patients during their entire hospital stay 
and to determine if the use of this clinical pathway is associated with beneficial effects on 
clinical end-points.
Materials and Methods
A prospective cohort study was conducted in 95 pancreaticoduodenectomy patients 
treated according to a clinical pathway, including a variance report, compared to a histor-
ical control group (n=52) with a traditional treatment regime.
Results
Process evaluation of the clinical pathway group revealed that protocol adherence 
throughout all units was above 80%. Major complications according to Clavien-Dindo 
Classification grade ≥ 3, decreased from 27% to 13%; p=0.02. Hospital length of stay 
was significantly shorter in the CP group, median 10 days [IQR: 8-15], compared with the 
control group, median 13 days [IQR: 10-18]; p=0.02.
Conclusion
The use of a clinical pathway in pancreaticoduodenectomy patients was associated with 
high protocol adherence, improved outcome and shorter hospital length of stay. Variance 
report analysis and protocol adherence with a Prepare-Act-Reflect-Cycle are essential in 
surveillance of outcome. 
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Introduction
Pancreaticoduodenectomy for pancreas tumours and periampullary tumours is consid-
ered high-risk surgery and is associated with high morbidity (30-70%), and a mortality 
of 1-5% in specialized centres (1,2). Centralization of pancreas surgery and advances 
in surgical techniques resulted in more patients being operated for advanced staged 
tumors (40, 60). Patients with more co-morbidity receiving pre-operative chemotherapy 
and/or vascular reconstructions in advanced disease, need more complex periopera-
tive care. Currently this is facilitated by multiple guidelines, and medical and nursing 
protocols. This complexity demands an overall multidisciplinary approach and clear 
communication.
Different departments are involved in the treatment during the patients’ journey through 
the surgical ward, operation theatre, Post Anesthesia Care Unit (PACU) and Intensive 
Care Unit (ICU). However, large differences in the actual use of these protocols are pres-
ent between the different units and medical and nursing staff members (5,6). Moreover, 
while multidisciplinary teamwork for these patients is essential, the development and 
implementation of a clinical pathway (CP) involves many aspects of the total patient care 
and should therefore be multidisciplinary by doctors and nurses as well.
A clinical pathway may facilitate the care for this group of high-risk surgery patients by 
unifying different protocols into one multidisciplinary protocol for all units, the patient will 
visit during the hospital stay. This may result in an increased protocol adherence, less mor-
bidity and improved outcome. Key elements of a CP are guidelines, evidence based clinical 
protocols and best practice rules, together with a coordinated sequence of activities of 
the multidisciplinary team (7). Registration, monitoring and evaluation of adherences, 
variances and outcomes are part of a CP and can be part of a process driven pathway (8). 
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A multidisciplinary CP has therefore many evaluation moments and scheduled actions. To 
keep the patient on the ‘pathway’, the CP mandates a registered response of the nurse or 
doctor if results are outside the range of the prescribed boundaries.
Many CPs have been developed for high volume with low-risk and with average-risk health 
care procedures in order to reduce complications (9-12). The postoperative phase of 
the patient spent in the ICU or PACU however, are seldom part of a CP (13). A clini-
cal pathway including the PACU/ICU stay, mandates an hour-to-hour care plan during 
the post-operative stay in the ICU/PACU (14). Many standardized care plans related to a 
pancreaticoduodenectomy have been published, focussing on the use of an enhanced 
recovery program after surgery (ERAS) with elements like early mobilization, early enteral 
feeding, pain treatment and reduction of iv-fluid administrations to shorten the length 
of hospital stay (15-19). In these care plans, a reduction of hospital length of stay (LOS), 
morbidity or mortality was not always observed. Crucially, the ICU period of these patients 
was not integrated in these protocols. 
The aim of this study was first to determine the feasibility to develop and implement a 
multidisciplinary CP including a variance report for all pancreaticoduodenectomy patients 
during their entire hospital stay. Second, to determine if the use of this CP is associated 
with an improvement of patient’s morbidity and outcome. 
Methods
Setting and patients 
The Radboud University Medical Center in Nijmegen is a 1000 bed university hospital, 
including a 32 beds closed format ICU, a 5 beds PACU, and a 30 beds gastro-intestinal (GI)
oncology surgical ward. An anaesthesiologist with a resident are supervising the PACU. The 
ICU is supervised by the intensivists, with intensivists-in-training, and residents. They all 
work in close relation with the surgical team. On the surgical ward, nurses, physician assis-
tants and young residents are caring for patients undergoing a pancreaticoduodenectomy, 
under daily supervision of the senior GI-oncology medical staff. Since the centralization in 
2012 of pancreas surgery in the Netherlands, approximately 80 pancreas operations (60 
malignant cases) are operated annually in the Radboudumc. As a result, the logistics and 
perioperative care of our pancreatic surgical program needed reflection and rescheduling.
Development of the Clinical Pathway
The development of the multidisciplinary CP for pancreaticoduodenectomy was a multi-
step procedure with the use of lessons learned from the development and implementation 
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of the cardiac and esophageal CP’s, previously developed in Radboudumc, and started 
in 2013. 
The first step was redefining and searching for evidence underneath the surgical, anaes-
thesiology and intensive care unit protocols in the perioperative period. This was a 
multidisciplinary procedure, undertaken by the physician assistants, senior nurses, ‘key’ 
nurses and medical staff (20-27). Instead of a traditional “day-to-day-care” plan for the 
surgical ward, an “hour-to-hour” care plan had to be developed, including the PACU and 
ICU care. It was important to identify potential barriers and facilitators in these settings, 
in order to tailor the implementation strategy (28-31). An evidence based implementation 
strategy according to Grol was used (32). Second, a unique variance report (‘Radboud 
variance report’; Appendix 1) had to be incorporated and developed together with the 
CP (33). This Radboud model of variance report enables nurses, physician assistants and 
young residents to execute predefined actions in accordance with and within the preset 
boundaries of a variance protocol, without having to wait for approval of the responsible 
physician first (Dutch law and order for health care professionals BWBR0006251 chapter 
IV, article 35). 
Until 2012, a surgical pancreas matrix for (peri)operative care was used at the surgical 
ward. The historical control group was treated according to this matrix including the surgi-
cal medical and nursing protocols without the variance report. In the PACU and ICU these 
patients were treated according to different PACU and ICU protocols. This pancreas matrix, 
was used as backbone for further multidisciplinary development of the CP. As part of the 
development and implementation strategy a small group of ‘key’ nurses responsible for 
other CP’s reflected on the concepts of the pancreas CP and variance report as part of a 
Prepare-Act-Reflect Cycle (P-A-R-cycle). 
The pancreas CP had to be a continuum from admission to discharge from the hospital. 
Essential elements included: restrictive intra-operative fluid use, strict pain control, early 
mobilization, early drain and tube removal, and early enteral feeding. Post-operatively, 
early warning scores (EWS) are measured at least once during every 8 hour shift or more 
frequent,whenever indicated by the nurses, with strict directives for action by nurses 
according to the variance report (34). 
Patients with a malnutrition universal screening tool (MUST) score above 2, need an active 
feeding intervention according to the quality system of health care in the Netherlands. 
We decided that patients with a MUST above 2 should start with total parenteral nutrition 
(TPN) within 24 hours after surgery. Publications on calorie deficit and enteral feeding or 
TPN after surgery in ICU patients, often do not take in to account malnutrition and MUST 
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score >2. Our protocol prescribes that if the gastric tube can be removed, the patient need 
to start with oral/enteral feeding, and TPN need to stop as soon as the oral intake of the 
patient is above 1000 kcal. (22, 23, 35-38). TPN should be started on day 3 if patients had 
a MUST score of 1 and enteral feeding had not been started on day 3. All patients with a 
gastroparesis without signs of sepsis or ileus on day 7 will be given a naso-jejunal tube by 
the gastroenterologist through the gastro-jejunostomy and start enteral feeding (39). In 
contrast to ERAS based protocols, deviations from the CP had to lead into prompt actions 
according to the variance report.
Implementation of the Clinical Pathway
After informative meetings for medical and nursing staffs, including reflections on the 
positive aspects of previous CPs, bedside training started on the surgical ward and PACU/
ICU in 2014. Implementation of the pancreas CP would introduce an essential change 
in daily practice for most nurses, physician assistants and medical staff. The first step in 
teaching was getting acquainted to the CP vision that would result to one continuous multi-
disciplinary protocol (32). In nursing and medical staff meetings updates of the project 
were discussed, and feedback was welcomed by the CP developers. During this teaching 
period, especially new PACU specific aspects arose for the pancreas CP, including new 
variance report criteria, and as an interactive process of PAR cycles, these criteria were 
incorporated in the pancreas CP during the development. In this try-out period, feedback 
was asked and given every four weeks during the multidisciplinary team meetings of the 
project. After 4 months of teaching and try-out period, it was concluded that it was feasi-
ble and safe to use the pancreas CP with the Radboudmodel variance report for patients 
during their entire clinical stay, including the PACU/ICU. With the completion of this imple-
mentation step, the pancreas CP was considered being implemented and our study on 
the use of the CP and variance report for all pancreaticoduodenectomy patients started 
on the first of September 2014, 18 months after the start of the development of the CP, 
including many PAR cycles. Patients treated for other pancreas procedures than pancre-
aticoduodenectomy were considered candidates to have the benefits of the pancreas 
CP during their stay in PACU/ICU and ward, but were not included in this study. Protocol 
adherence was measured per pathway action. We considered protocol adherence if a 
deviation from the CP resulted in the correct action, according to the CP, or if no action 
was needed and no action was started. No protocol adherence was defined as: wrong 
actions or no actions if actions were needed. Deviations from the CP had to be described 
in the variance report or patient record.
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Design
This is a pre-post design study. After the implementation of the pancreas CP, patients 
treated according to the CP were compared with a historical control group of patients 
treated with standard perioperative care for pancreaticoduodenectomy according to the 
original pancreas matrix and monodisciplinary protocols and operated between 2009-
2012.
End-points
Primary endpoint was to determine the feasibility and safety, including incidence of 
post-operative complications, according to Clavien-Dindo classification, of the use the 
CP (40). Secondary endpoints were in length of stay (LOS) in-hospital, postoperative fluid 
balance, gastroparesis, protocol adherence to mobilization, drain removal, radiologic and 
surgical re-interventions, ICU readmission, hospital readmission and mortality rate.
Statistics
Continuous variables were described as median and inter quartile range [IQR] and tested 
with the Mann-Whitney U test. Differences in dichotomous variables were analyzed using 
Chi-square test. Due to the exploratory nature of this study, and to increase the sensitivity 
to detect differences between groups, no correction for multiple testing was performed. 
With our convenience sample size of 95 patients in the CP-group and 52 patients in the 
control-group, our study had 80% power to demonstrate a 7% absolute reduction of 
post-operative complications.  All statistical analyses were performed using SPSS version 
20.01 for windows (IBM, SPSS statistics, Chicago, IL, USA).
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Results
Development results of the Clinical Pathway
Nurses, physiotherapists, dieticians and medical staff specialized in pancreas surgery con-
tributed to the development of the pancreas CP and the variance report. This resulted in a 
set up of clear and safe boundaries in taking clinical treatment decisions and an up scaling 
system to consultation with a key-nurse or senior staff members, if actions according to 
the variance report did not seem right.
First, the pancreas CP for medical and nursing decisions was written according to existing 
evidence based protocols, best practices and guidelines. Finally, a multidisciplinary var-
iance report was incorporated (Appendix table 1: summary of the differences between 
clinical pathway and control surgery and Appendices 2-3: variance report).
For the analysis of the developmental process we evaluated barriers and facilitators for 
protocol adherence. For this, interviews and questionnaires were used, focussing on possi-
ble barriers and facilitators for protocol adherence to the new CP. An important facilitator 
was the motivation of nursing and medical staff to ask for guidance and training in the 
use of this protocol. The most important barrier was that using the protocols was expe-
rienced as a time consuming processes of getting acquainted with the system, resulting 
in feelings of loss of autonomy for doctors and nurses. Key-nurses together with medical 
leadership were essential for awareness, feedback and motivation during development, 
implementation and the use of the CP.
Implementation results of the Clinical Pathway
First, the medical aspects of the CP were implemented on the ward followed by the nursing 
aspects. Because the lack of experience with CPs, the care providers working on the PACU 
received more time for training and bedside teaching and started later with implementa-
tion. Key-nurses at the surgical ward gave guidance and were partner for the key-nurses 
of the PACU.
Evaluation after the implementation process was performed every 2 months during the 
first 6 months, and after this period whenever needed. These evaluations resulted mostly 
in questions or new ideas for a change in the CP from the units or when less compliance 
was observed. The variance report was an important tool for evaluating compliance. When 
compliance of one of the CP domains was below 80%, feedback was given by the key-nurse 
or surgeon through focussed teaching sessions for nurses and residents.
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After a period of 18 months the pancreas CP was implemented and evaluation of protocol 
adherence was 80% for PACU/ICU periods and 60% for the surgical ward. The latter was 
mainly influenced by a low compliance to drain removal (<50%). According to the pancreas 
CP, drain removal was allowed if amylase level in the drain was below 500 U/L and volume 
below 200 ml/day. Deviations turned out to be primarily a system problem of postponing 
drain removal during weekends. After recognition of this system problem an active policy 
started and protocol adherence on this item improved to above 80%.
Following the implementation, in September 2014, the outcome study of the pancreas CP 
was started (Figure 1 implementation flow chart).
Figure 1: implementation of pancreas CP and study flowchart.
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Clinical outcomes 
Between September 2014 and September 2016, in total 95 elective consecutive pan-
creaticoduodenectomy patients were treated within the pancreas CP. Semi-acute 
pancreaticoduodenectomies (for bleeding tumours) and other types of resections (e.g. 
total pancreatic resections or pancreaticoduodenectomies with resection of a secondary 
colo-rectal tumor) were no part of the study. A cohort of 52 consecutive elective pan-
creaticoduodenectomy patients treated before the CP implementation period between 
2009 and 2012 was identified as historical control group. Their perioperative treatment 
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had been according to the underlying matrix protocol that was used as base for the 
development of the CP. Three surgeons in the pre-CP period operated the pancreaticodu-
odenectomy patients. Results between these surgeons did not differ,and perioperative 
care was regulated by protocols. These surgeons were also responsible for pancreas 
surgery in the clinical pathway period.
Baseline characteristics between the two groups were not significantly different, apart 
from a higher number of CP patients receiving Portal vein resection or Celiac trunk/ Supe-
rior Mesenteric Artery (SMA) vessel exploration (table 1).
Table 1: Baseline characteristics of pancreas CP and control groups of pancreaticoduodenectomy.
Clinical Pathway
N=95
Control
N=52
P
Age, median [IQR] 66 [57-72] 66 [58-72] 0.98
Male, n (%) 56 (58.9) 35 (67.3) 0.26
Stent/ (PTC) percutaneous drainage, n (%) 59 (61.5) 28 (53.8) 0.34
Pulmonary comorbidity, n (%) 13 (13.7) 4 (7.7) 0.52
Cardial comorbidity, n (%) 13 (13.7) 10 (19.2) 0.62
Vascular comorbidity, n (%) 29 (30.5) 16 (30.8) 0.80
Diabetes, n (%) 21 (22.1) 16 (31.4) 0.4
Preoperative chemotherapy, n (%) 4 (4.2) 0 
Portal vein resection, n (%) 20 (21.1) 1 (1.9) <0.001
Celiac trunk/ SMA exploration, n (%) 6 (6.3) 0
Legends: IQR = First and Third Inter Quartile Range, PTC = Percutaneous Transhepatic Cholangiography, SMA = Superior 
Mesenteric Artery
Intra-operative data
The median intra-operative amount of fluids administered was 3900 ml [IQR 3000-4600] in 
the CP patients versus 5200 ml [IQR 4000-6000] in the control group (p<0.001). Post-op-
erative fluid balance and fluid balance on day 1 postoperative were also significantly lower 
in the CP group versus the control group (p<0.001; table 2). Although more portal vein 
resections and Celiac trunk and  explorations along the superior mesenteric artery were 
performed, blood loss was less in the CP patients: 755 ml [IQR 500-1100] versus 1303 ml 
[IQR 656-2402] (p<0.001, table 2).
Post-operative data
Adherence of pain and hemodynamic interventions according to the variance report was 
100% at the PACU/ICU, and a step up approach regarding pain control was adequately 
used according to CP protocol. Hemodynamic interventions in accordance with the var-
iance report was not needed and not started in 17% of the CP patients, and 57% of the 
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CP patients needed an extra hemodynamic intervention which was subsequently started 
according to CP protocol. In total 26% of the patients were treated with vasopressors 
on arrival in the PACU/ICU which could be reduced during their stay. Significantly more 
CP patients were swing mobilized within 24 hours compared with the control group,re-
spectively 83% versus 19%, p=0.001. Especially poor pain control and patients’ feelings 
of weakness, early after the operation, were recorded as reasons not to start swing or 
mobilization at the surgical ward. Trigger for complications was the EWS, in 32% of the 
patients in the CP group the EWS was above 3. Interventions on a high EWS were adequate 
and according to the variance report > 95% of the patients.
Table 2: Intra-operative results of pancreas CP and control groups of pancreaticoduodenectomy.
Fluid and vasopressor management Clinical pathway
N=95
Control
N=52
P
Intra-operative fluids in ml, median [IQR] 3900 [3000-4600] 5200 [4000-6000] <0.001
Fluid balance, at the end of the procedure, median [IQR] 405 [-107-833] 1926 [1253-2818] <0.001
Intra-operative blood loss, median [IQR] 755 [500-1100] 1303 [656-2402] <0.001
Intra-operative vasopressor use, n (%) 94 (99) 48 (92) 0.22
Considering clinical outcome, major complications according to the Clavien-Dindo Classi-
fication grade 3 or more occurred less frequently (13% vs 27%, p=0.02) in the CP group, 
compared to the control group (51). One patient had a Clavien-Dindo 4b complication as 
a result of pancreatic leakage complicated by sepsis with EWS >6 on day 7 and hemor-
rhagic bleeding on day 14 in the CP group. This complication was successfully treated by 
radiologic coiling of the gastroduodenal arteria and splenic artery.
Less patients suffered from gastroparesis grade B and C in the CP group compared to the 
control group 9% versus 62 %, p<0.001, as were radiologic interventions: 11 % versus 27 
%, p=0.04. In the control group the gastric tube was not removed when production was 
reduced but was left in place and blocked and could be removed if after measurement of 
retention after 8 and 16 hours being was less than 100 ml per 8 hours. Pancreatic leakage 
and chylus leakage, readmission to ICU and readmission to hospital did not significantly 
differ between the CP group and control group. Median times to drains removal were also 
not influenced. The mortality rate was low and not different between groups (table 3). 
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Table 3: Postoperative data of pancreas CP and control groups of pancreaticoduodenectomy.
Clinical pathway
N=95
Control
N=52
P
Postoperative PACU, n (%) 81 (85) 29 (55) 0.002
Mobilization swing, according to protocol (within 24 hours) n (%) 78 (83) 10 (19) 0.02
Mobilization out of bed in days, median [IQR] 2 [1-2] 2 [2-3.3] 0.001
Gastroparesis (ISGPS): n (%)
•	 Type A
•	 Type B
•	 Type C
20  (21)
7 (7)
2 (2)
15 (29)
18 (35)
14 (27)
<0.001
Pancreas leakage, n (%) 12 (13) 5 (10) 0.82
Drain in situ, days, median [IQR] 6 [4-10] 7 [5-12] ns
Clavien Dindo Classification n (%)
3a
3b
4b
5
9 (10)
1 (1)
1 (1)
1(1)
9 (19)
4 (8)
0
0
0.02
Radiologic reïntervention, n (%) 10 (11) 14 (27) 0.04
Relaparotomy, n (%) 3 (3) 4 (8) 0.01
Readmission ICU, n (%) 7 (7] 7 (14) ns
Readmission Hospital, n (%) 12 (13) 9 (18) ns
LOS in hospital, days, median [IQR] 10 [8-15] 13 [10-18] 0.02
30-days mortality, n (%)
90-days mortality, n (%)
1 (1)
2 (2)
0 (0)
1 (2)
ns
Discussion
This study illustrates that development of a CP for pancreaticoduodenectomy is an itera-
tive multidisciplinary process, starting with a dynamic protocol with improvements through 
Prepare-Act-Reflect cycle evaluation and change moments. Implementation of the pan-
creas CP in all units involved in the entire (peri-) operative process (OR, PACU/ ICU/ surgical 
ward) took 18 months. Process evaluation of the prospective CP group revealed that 
protocol adherence, was successfully achieved in >80% for most of the criteria throughout 
the clinical stay. Comparison of both cohort groups on main clinical outcomes showed 
that major complications according to the Clavien-Dindo Classification grade 3 or more 
and hospital LOS in the CP group was significantly lower compared to the control group. 
In addition, implementation of the CP was associated with a reduction of gastroparesis, 
an improved post-operative fluid balance and patients in the CP-group were more likely 
to receive early mobilization and adequate actions on EWS above 3. These data illustrate 
that implementation of a CP in this specific group of patients is feasible, safe and likely to 
be beneficial for the patient.
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Analyzing reasons not to follow the variance report was part of this study. Human fac-
tors were often reasons for deviation from the report. For example, insecurity of young 
professionals on decisions leading to postponing gastric tube removal. The prevention 
of gastroparesis is part of a very active P-A-R-cycle in the CP. Nurses, young doctors and 
patients want to prevent discomfort for the awake patient while re-positioning of the tube, 
even if early removal is according to protocol. The action was a team reflection on the 
discomfort of a needless gastric tube for too long and as a result, delay in starting early 
oral nutrition and well being.
Postponing early mobilization because of patients’ pain or weakness did occur. In all situ-
ations the iterative process of repeated and specific education was important to explain 
the reasons behind the CP and guidance. 
Considering the diverse landscape of clinical pathways and surgical care plans, it is difficult 
to compare the different studies. In studies, related to implementation of clinical pathways, 
not all hospital wards involved in the clinical process (like PACU/ICU) were included, which 
negatively influences the continuous care process for the patient. Also different treatment 
regimes make reliable comparison and evaluation of different CP’s difficult. Regarding 
the available studies we found only studies not covering the whole clinical stay, excluding 
parts of the post-operative period. Also usually merely some specific aspects like ERAS, 
drain and gastric tube removal were addressed (18). A standardized care plan for pan-
creaticoduodenectomy patients was retrospectively studied in another study focussing 
on predictors of LOS in-hospital (15). Specific ERAS pathways, without PACU/ICU periods 
involved, focussed on in hospital LOS, outcome mortality and morbidity. While these were 
unchanged, measurement of protocol adherence was not part of the study (16). Braga et 
al. evaluated the compliance to the enhanced recovery protocol and concluded patients 
with low compliance had a higher incidence of complications (41).
Our results are in pursuance of previous studies that showed that a CP or standard-
ised care plan for pancreaticoduodenectomy patients resulted in an earlier start of solid 
enteral feeding and a shorter hospital LOS and less readmissions. Importantly, protocol 
adherence to predefined targets has not been part of these studies as was analysis of the 
reasons not following the protocol and its association to outcome.
Comparing our study to these studies, a similar effect on reduction of complications, hospi-
tal LOS, readmissions, gastroparesis, time to enteral feeding and time to mobilization was 
found. Our present study also illustrates that it is feasible to implement a CP that covers 
the entire clinical admission, applying different targets of the various involved units (e.g. 
focus on hemodynamic and respiratory vital parameters at the PACU/ICU, versus focus 
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on EWS and ERAS criteria at the surgical ward). Nurses were also able to start adequate 
therapy in accordance with the variance rapport when early warning scores deviated from 
the target. Moreover, new to the other studies is that this study, via the variance report 
method, exposed the barriers and facilitators of CP adherence. In addition, these two 
monthly formal meetings to evaluate variance report deviations and their barriers and 
facilitators, enabled us to discriminate the difference of loss of compliance to a protocol 
due to complicated discourse of operations, versus loss of professional adherence to the 
CP protocol.
The current study has several limitations. Most importantly, this is a single-centre 
pre-post-intervention study. The intensity and duration to develop the CP, as well as the 
implementation process limit the feasibility of using other study designs. In addition, the 
historical group was not formally matched, which together with the fact that no randomisa-
tion was carried out, induces a higher risk of confounding factors. No relevant differences 
in patient characteristics between the different study periods were observed. However, 
the case load per surgeon increased which could be considered as a possible confounding 
factor. We considered the development of a CP as the most appropriate intervention to 
re-schedule the process. Prospective complication registration was part of the daily super-
vised perioperative care as well as the discharge procedure in both groups. Moreover the 
prospective database on outcome and complications of the control group (2009-2012) 
served as a document to identify barriers and facilitators for building the clinical pathway. 
Furthermore, no relevant changes in other procedures, staffing levels, technical infra-
structure or other major changes that could influence patient management occurred and 
during the whole study period there were no changes in interventions that are known to 
influence morbidity or mortality in the ICU such as strict glucose regulation, early goal-di-
rected therapy, use of corticosteroids, prone positioning and low tidal volume ventilation. 
Second, no a priori power calculation was carried out, implying that the risk for a type 1 
or 2 error has not been overcome. Using our convenience sample, we did calculate that 
our study has 80% power to demonstrate a 7% change in complication rate, while we 
observed that the complication rate halved. Nevertheless, the sample size of the study and 
the discussed design issues should make us aware of the possible overestimation of the 
outcome differences. In contrast, this does not necessarily apply for the process analysis 
part. As no comparison of the CP group was made to the control group, the conclusions 
of the process analysis merely indicate that CP development, implementation and high 
level of adherence to such a CP, throughout all units involved in the perioperative process 
is feasible within a relative short period and up to a high standard.
Implementation and evaluation of a Clinical Pathway for pancreaticoduodenectomy procedures
95
5
Lessons learned 
This study shows us, in line with the implementation of our cardiac surgery CP and 
esophageal surgery CP (42), that it is feasible to develop and implement a CP for pancer-
aticoduodenectomy procedures for all involved units like the PACU/ICU and surgical ward 
through the entire clinical perioperative period. In all units the CP targets need to be 
aligned and the use of a variance report discriminates complications-related to failure of 
professional adherence. Implementation is an iterative process that takes time to become 
comfortable in use for all involved units. Key-nurses together with medical leadership were 
essential for awareness, feedback and motivation during development, implementation 
and the use of the CP.
Future perspectives
In order to overcome the methodological drawbacks of this study and to validate the CP 
methods, a multicenter stepped-wedged cluster randomised controlled trial would be 
ideal. However, due to the complexity of the implementation and intervention with barrier 
and facilitator analysis in different hospitals and units, interpretation of the results will be 
difficult. Exploring the validity of similar CP’s is in line with the need for quality assurance 
of standardised treatment regimes with high protocol adherences. 
For the near future, continuous monitoring, wearables, electronical medical data recording 
with pop-up facilities warning medical and nursing staff for deviations from the clinical 
pathway, will likely be of help in building more complex pathways. Possibly, patients with 
high co-morbidity will be able to follow their personalized clinical pathway with the help 
of dedicated staff.
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Conclusion
The use of the CP was associated with a reduction of perioperative morbidity. Essential 
new tools include a variance report analysis, scheduled barrier and facilitator analyses, 
and the iterative PAR cycle protocol development, performed by a multidisciplinary team. 
Development, implementation and use of a CP throughout the hospital stay for patients 
undergoing pancreaticoduodenectomy is a multistep procedure in which we showed that 
this is feasible and safe.
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Appendix 
Table 1 : Similarities and differences between clinical pathway and control period
Clinical pathway Control
Outpatient clinic
Tumour Board Treatment Advice ( PACON) Tumour Board Treatment Advice ( PACON)
Oral and written patient information Oral patient information
Dietician contact: MUST screening tool, nutrition 
advice and if needed supplemental feeding oral or 
enteral.
Dietician contact if needed supplemental feeding oral 
or enteral
Frailty screening tool
Medication Verification
Training advice : Home trainer use, 1 hour walking  
per day
Surgical ward
Use of ERAS protocol Use of ERAS protocol
Preoperative Lanreotide ® Preoperative Lanreotide ®
Thrombosis prophylaxis Nadroparine® 5700 E Thrombosis prophylaxis Nadroparine® 2850 E
6:00 day of operation : last Preop® or clear liquid 
intake, anti-thrombosis compression stockings.
Pain management and control according to protocol 
together with Pain Service Team
Pain management together with Pain Service Team
Early Warning Score once per 8 hours and whenever 
indicated together with actions by nurses
Early Warning Score once per 8 hours and whenever 
indicated action by resident
Patient communication between doctors, nurses and 
handover situations according to Reason, Story, Vital 
Signs, Plan ( RSVP)
Patient communication between doctors, nurses and 
handover situations not specified
Mobilisation after surgery: swing  and out of bed 
within 24 hours
Mobilisation after surgery: swing  and out of bed 
within 24 hours
Gastric tube: if production < 200 ml in 12 hours 
remove of tube
Gastric tube: if production is reduced, start clamp  
tube and remove if retention is < 100 ml in 8 hours 
(after two consecutive periods of 8 hours)
Drain removal if production < 200 ml and amylase < 
500 U/L per day
Drain removal if amylase < 500 U/L per day and 
operating surgeon agrees
Nutrition : MUST > 2 start TPN on day 1 postoperative Nutrition: enteral feeding will start on day 1 if the 
patient has a jejunostomy. Oral fluids according to 
ERAS
MUST = 1: if gastric tube has not been removed on 
day 3 start TPN
If no enteral intake is possible on day 6 start TPN has 
to start on day 7
All patients: if the gastric tube cannot be removed 
because of gastroparesis on day 7 without signs of 
sepsis or ileus: placement of an jejunal tube through 
the gastro-jejunostomy by the gastroenterologist and 
start enteral feeding
Glucose control Glucose control
Discharge Criteria Discharge Criteria not specified
Use of the variance report if actions are not according 
to protocol.
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Table 1 : Continued
Clinical pathway Control
Operating room
Use of ERAS protocol Use of ERAS protocol
Pain control by Epidural Catheter Pain control by Epidural Catheter 
Central venous line in the vena jugularis, if indicated 
PiCCO
Antibiotic prophylaxis 15-60 min pre-incision. 
Cephazolin® and Metronidazol®. If a stent or 
percutaneous transhepatic drain has been placed in 
the ductus Choledochus use Piperacilline/Tazobactam 
as prophylaxis.
Antibiotic prophylaxis 15-60 min pre-incision. 
Cephazolin® and Metronidazol®. Otherwise if 
indicated by the surgeon
Target postoperative fluid balance between 0 and 
500 ml
Postoperative fluid balance not specified but 
according to ERAS
Handover to PACU personal by surgeon and 
anaesthesiologist according to RSVP
Handover to PACU personal by anaesthesiologist
PACU/ICU
Entrance in PACU: every 15 min: RR and heart rate 
control until stable, than every  30 min RR and pulse
Entrance in PACU: Every 15 min: RR and pulse control 
until stable than every  30 min RR and pulse
Continuation of Antibiotics will be part of the sign out 
procedure after surgery
Continuation of Antibiotics at the decision of the 
surgeon
Normothermia (>36.0 degree Celsius), bearhugger or 
heating system if necessary
Normothermia (>36.0 degree Celsius), bearhugger or 
heating system if necessary
Every hour (1st until 24th hour): 
Respiratory status after  extubation: saturation, 
respiratory frequency,  coughing and deep breathing 
exercises 
Hemodynamics:  heart rhythm, heart frequency, RR, 
ScvO2 ( if indicated). 
Excretions: urine, drain, gastric tube  
 Every hour (1st un till 24th hour): 
Respiratory status after  extubation: saturation, 
respiratory frequency,  coughing and deep breathing 
exercises 
Hemodynamics:  heart rhythm, heart frequency, RR, 
ScvO2 (if indicated). 
Excretions: urine, drain, gastric tube  
Temperature  Temperature 
Pain and sedation:  NRS pain score Pain and sedation:  NRS pain score
RASS and CAM ICU  RASS 
Mean arterial Pressure (MAP) between 70 mmHg 
and 100 mmHg  and heart frequency between 60 
and 90 per minute. Different targets than the CP 
prescribes possible after approval of the supervising  
anaesthesiologist .
Mean arterial Pressure (MAP) targets need approval of 
the supervising  anesthesiologist.
MAP should be above 70 mmHg : if below start 
norepinefrine. 
i.v. fluids:  ERAS protocol
Balance between 0 and + 500 ml /24 hours
Urine production has to be above  0.5 ml/kg/hour. 
Protocol “oliguria PACU”
Urine production has to be above 0.5 ml/kg/hour. 
Protocol “oliguria PACU”
First choice of inotropics: dobutamine   First choice of inotropics: supervising  anesthesiologist
Stress-ulcer prophylaxis Pantoprazol® 1 dd 40 mg iv/
po
Stress-ulcer prophylaxis Pantoprazol® 1 dd 40 mg iv/
po
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Table 1 : Continued
Clinical pathway Control
PACU/ICU (Continued)
Nausea and Vomiting:
3/day 4 mg ondansetron® iv (Maximum until  36 
hours after surgery)
3/day metoclopromide  3/day 10 mg iv (3/day 5 mg iv 
when kidney function reduced) (cave QT time)
Nausea and Vomiting:
If indicated : 3/day 4 mg ondansetron ® iv
If indicated : 3/day metoclopromide  3 day 10 mg iv 
(3/day 5 mg iv when kidney function reduced) (cave 
QT time)
Anti -thrombosis prophylaxis Nadroparine 5700IE Anti -thrombosis prophylaxis Nadroparine 2850 IE
Mobilization according to protocol: starts within 
24-hours
Gastric tube: See CP surgical ward  Gastric tube
Drain:  2 abdominal drains
Drain production control every hour : aspect and 
volume, 100-200 ml/hours. If production >200 ml/
hours or >400 ml/4 hours contact surgeon 
Drain:  2 abdominal drains
Drain production control every hour : aspect and 
volume, 100-200 ml/hours. If production >200 ml/
hours or >400 ml/4 hours contact surgeon 
Electrolyte control and interventions Electrolyte control and interventions
Glucose regulation: normoglycaemia (glucose 5.0-10.0 
mmol/l)
Glucoseregulation: normoglycaemia (glucose 5.0-10.0 
mmol/l)
Discharge criteria: handover procedure according to 
RSVP, vital signs accepted by the surgical ward.
Discharge criteria according to PACU
Use of the variance report if actions are not according 
to protocol.
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Introduction
Peri-operative management in high-risk surgery is confused by many clinical algorithms, 
protocols, guidelines and decision making rules (1). Clinical Pathways (CP) were developed 
in the 1990s to integrate these different nursing and medical protocols in multidisciplinary 
care plans for low- and intermediate-risk surgery. Originally they were designed to balance 
the quality of care and costs by focussing on better use of resources, a maximum quality of 
care and minimization of delay in diagnosis and treatment(2,3). Development and success-
ful implementation of a CP for high-risk surgery may improve the quality of care as well, 
potentially reducing serious complications and improving Patient Reported Outcome.
The “European Pathway Association” states, that a CP is a method for patient-care manage-
ment of a well-defined group of patients during a well-defined period of time. A clinical 
pathway explicitly states the goals and key elements of care based on Evidence Based 
Medicine (EBM) guidelines, best practice and patient expectations by facilitating the com-
munication, coordinating roles and sequencing the activities of the multidisciplinary care 
team, patients and their relatives (2).
Modern high-risk surgery where the patient will visit many departments, including the 
intensive care unit,  demands a multidisciplinary approach. Surgical specialists are no 
longer capable nor in charge of the entire clinical process. Communication and exchange 
of information during the treatment of the high-risk surgical patient depends on various 
specialists like anesthesiologists, intensive care specialists and consultants from e.g. endo-
crinology and nephrology. During the clinical patients’ journey various departments (with 
many different caregivers), such as the surgical ward, operating theatre, Post Anaesthesia 
Care Unit (PACU) and Intensive Care Unit (ICU), are involved in treating high-risk surgical 
patients. At present, these units have their own protocols, guidelines and key-performance 
indicators in most hospitals. Apart from content differences on same topics (e.g. trom-
bosis prophylaxis) in these monodisciplinary protocols, there are also large differences 
in the actual use of and compliance to these protocols, which are presently causing large 
treatment variation both among medical and nursing staff care-givers. These differences 
in use are often unnoticed by the caregivers in the care process the patient receives, and 
Prepare-Act-Reflect (P-A-R) cycles are seldom properly implemented.
Evidence from literature
The use of CPs has been discussed in the literature for more than two decades and the 
definition has become blurred. Pro and con discussions about using CPs are often the result 
of fear that the use of a CP becomes a business model, or that pathway companies will 
build CPs that are not aligned to the work process of the departments in a hospital. As a 
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result, Work-as-imagined (WAI) designed by experts and built into guidelines, will differ from 
Work-as-Done(3).  The difference  will be based on interpretation of EBM and best practice 
guidelines, resources  and fear of loss of autonomy of care-givers that peri-operative care 
will become the result of a cooking class with only one chef, (4, 5).
The method of analysis of a complex process intervention as a CP is still subject of discussion 
(6, 7). However, looking in more detail at the literature, although reports are still scarce, the 
evidence of favourable outcome due to CPs is becoming stronger and new research will be 
added in the near future. (8, 9).
Many CPs have been developed for predictable trajectories, where clinical interventions must 
be given in a timely manner, and this implies that a CP is often a day-to-day care plan for a 
specific disease or medical procedure (10). So far, many CPs have been developed for high 
volume, low- and average-risk healthcare procedures to reduce variations in care, compli-
cations, length of stay (LOS) or costs (11-14). Clinical pathways with the aim to standardize 
care and to reduce variation in care and outcome are also well known in e.g. cardiology and 
pulmonology. CPs in cardiology, with focus on management of acute coronary syndromes 
and reduction of time-to-stent or time-to-surgery, did show an improve of protocol adher-
ence and an improved outcome (15-17). An international multicenter cluster randomized 
controlled trial in 22 hospitals, with the aim to reduce 6-month readmission rate after 
COPD exacerbation, showed a significant reduction in the 30-day readmission rate with-
out a reduction in 6-month readmissions. Evidence-based key interventions were better 
performed after implementation of a CP compared to usual care (18).  CPs in day-care 
surgery, hip surgery, hysterectomy and colorectal surgery show reductions in postopera-
tive morbidity and LOS (19). Furthermore, multimodality strategies like ERAS programmes 
(enhanced recovery after surgery) are nowadays the core interventions in many CPs  for 
middle- and high-risk surgical procedures like colorectal and pancreatic surgery  (20, 21). 
Unfortunately, these CPs,  including the ERAS programme, lack the complete spectrum of 
all clinical aspects during the entire clinical stay of the patient, as well as the multidisciplinary 
approach needed in high-risk surgery. These limitations may be responsible for unclear 
outcome benefits of CPs and ERAS (9).
A process intervention like the development and implementation of a CP for high-risk sur-
gery could potentially reduce serious complications and LOS. Today, many complex CPs 
in high-risk surgery do not include the ICU period in their CP. In most CPs in the ICU, only 
aspects of ICU care are implemented in care bundles, such as mechanical ventilation, 
the treatment of sepsis and septic shock, analgesia or treatment of pneumonia (22-31). 
Unfortunately, CP literature describing the total clinical  journey of the high-risk surgical 
patient, including the ICU period, is not available.
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Clinical pathway development and implementation processes
Three essential phases can be identified  before a dynamic and sustainable CP is properly 
in use,: the development, implementation and maintenance (working) phase.
Essentially, in developing a CP, a multidisciplinary team of doctors and nurses, with clear 
clinical leadership, assimilates different monodisciplinary protocols and guidelines to one 
overall multidisciplinary CP. Analysis of barriers and facilitators at the different units should 
be part of the development and implementation strategy. P-A-R cycles performed by 
key-nurses and key-doctors have to be part of this iterative process of pathway implemen-
tation and use, and are essential for a dynamic CP. These cycles will inform users about the 
actual use and need for readjustment of protocols based on changes in the underlining 
evidence or best practice guidelines. Communication between the different units, for 
alignment of treatment during the clinical stay,  is key to a successful development and 
implementation of a multidisciplinary CP. Whereas the  PACU/ICU mandate an hour-to-
hour care plan for the initial postoperative period, the post-operative surgical wards need 
a day-to-day care plan. Hemodynamic, respiratory and adequate pain control criteria are 
essential during these intra- and early post-operative periods. Criteria such as hand-over 
guidelines, early warning scores, pain assessment, feeding and mobilization protocols 
are essential ingredients, becoming more important when the patient is transferred to 
the surgical ward. 
To complete development and strengthen the compliance process a variance report 
overarching both the pre-operative, intra-operative (anaesthesia) and all post-operative 
periods should, ideally, be incorporated into the CP. With such variance reports, deviations 
from the CP are recognised and interventions, necessary to get back on the pathway, 
are instructed instantly. Variance reports thus enable nurses and young doctors to start 
treatment without waiting for time consuming approval from the consultant.
During implementation and maintenance phases  P-A-R cycles are essential for dynamic 
improvement of the CP. Compliance measurements, derived from the  variance report, 
are useful tools in PAR cycles for improvement. While working with the CP, and because 
the pathway is known to the patient and their families, their input can be integrated in the 
P-A-R cycle improvement by using Patient Reported Outcome Measures (PROM).
In the Radboud University Medical Center, we developed and implemented three multidis-
ciplinary CPs in high risk surgical procedures for cardiac, esophagus and pancreatic surgery, 
which also  included the PACU/ICU periods. The development of the CP for all cardiac sur-
gery patients in  this high-risk  and high volume patient group  acted as the blue print for 
the development of other low-volume, high-risk surgery related CPs in the intensive care. 
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The development and implementation phases were considered successful after achieving 
compliances to variance reports of at least 80%. 
Evaluation of the clinical outcome of the CP in cardiac surgery patients resulted in more 
timely and better organized postoperative ICU treatment: improved  blood pressure con-
trol, a more expedient adequate action to chest tube blood loss and faster weaning from 
mechanical ventilation (22). In CP cohorts of esophagus and pancreatic surgery a reduc-
tion in hospital LOS, as well as a significant reduction of major complications according to 
Clavien Dindo, was observed.
A successfully implemented CP in high-risk surgery can improve the quality of care, show 
a reduction in complications and will probably lead to a better Patient Reported Outcome 
and less waste of resources. New designs based on an iterative dynamic process for devel-
opment and implementation, using variance reports with preset instructions, using barrier 
and facilitator analyses and P-A-R cycles, render systems with compliances > 80% and high 
levels of evidence of improved clinical outcomes. Essentially, all care-givers throughout 
the entire clinical process must be involved and aligned, as is the patient and their family, 
resulting in a Patient-centred-CP.
Conclusion
Although the concept of CPs goes back for more than two decades, a broad implementation 
of CPs in high-risk surgery which includes an ICU period  has not been the subject of research 
in the past period to date. However, implementation of a CP including the ICU period in high-
risk surgery has  potential benefits and these benefits are not limited to cost-effectiveness. 
The potential for improvement in the clinical outcome can be tremendous.
 
Future perspective
To bring the development and clinical effectiveness of CPs to a higher level, new technologies 
can help in the development and implementation of CPs  for the high-risk surgical patient. 
Patient data management systems ( PDMS) have to be aligned to the dynamic CP. More 
complex pathways can be built with the use of continuous monitoring systems on surgical 
wards using validated digital wearables. Variance reports have to be built on trend analyses 
of continuous monitoring data derived from all units including operating theatre, PACU/ICU 
and surgical wards. Deviations from the pathway can be recognised sooner, resulting in early 
interventions to put the patient back on the pathway according to individualized preset goals. 
In this way CPs will empower nurses, physician assistants and residents in safe treatment 
decision making. Patients will experience more security during the treatment process and will 
be empowered by being able to follow their personalized clinical pathway. We assume that CPs 
can be an important tool and process intervention in patient safety and patient centred care.
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Summary
Clinical pathways, or care pathways (CPs), are developed to provide optimal care for a spe-
cific patient group and overcome unwanted differences of given care between individual 
patients and individual care-providers. Originally, CPs were designed to balance the quality 
of care and costs by focusing on better use of resources, aiming for  optimal quality of care 
and minimization of delay in diagnosis and treatment. Development and implementation 
of clinical pathways are considered complex process interventions and are usually devel-
oped for predictable, non-complex procedures. We developed and implemented several 
CPs integrating nursing and medical protocols into multidisciplinary care plans for high-risk 
surgery patients in the intensive care unit (ICU). The content of the ICU related CPs does 
not just consist of  multi-disciplinary or intra-disciplinary protocols and best practices, but 
is also a ‘day-to-day’ care plan describing all care, interventions or activities needed to be 
achieved within a specific period of time to provide optimal patient care. We hypothesized 
that a process intervention, like the development and implementation and use of a CP for 
high-risk surgery, may improve the quality of care, and will potentially lead to a reduction 
of serious complications. The CP is based on best practice rules, guidelines and evidence 
based medicine. In the ICU, a CP could be a uniform protocol together with an hour-to-
hour schedule of interventions or actions on deviations for a specific group of patients. 
This schedule should focus on recognition of deviations from the pathway by nurses and 
should enable them to start treatment within the boundaries of prescribed variances. 
The development, implementation and evaluation of a CP in the ICU should be part of a 
Prepare-Act-Reflect cycle (P-A-R cycle), and should be dynamic to facilitate further improve-
ments of care. Structure interventions in the system together with changes in guidelines 
(Work-as-Imagined, WAI) will effect Work-as-Done (WAD) relating to the CP, and all should 
result in agile adaptations.
The first part of this thesis will focus on the feasibility of the development and implementa-
tion of a postoperative hour-to-hour CP for cardiac surgery patients. We will also focus on 
trends over time after implementation of a CP in high volume, high-risk surgery.  Analysis 
of facilitators and barriers within the structure or process are part of this thesis.
The second part of this thesis focuses on the development and implementation of CPs 
in low volume, high-risk surgical procedures such as pancreas surgery and esophageal 
surgery. We describe the use of a preoperative optimization protocol for open transhiatal 
esophagus resections in a closed-format ICU and the development and implementation 
of a CP for pancreaticoduodenectomy procedures from outpatient clinic to discharge 
after surgery. In both studies we did also analyze the effects relating to the outcome for 
the specific patient groups.
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The development, implementation and evaluation of a postoperative CP together with a 
variance reportfor all cardiac surgery patients in the ICU is described in Chapter 2. The 
variance report enabled nurses to execute predefined actions in accordance with and 
within preset boundaries. The CP in this high-volume, high-risk patient group describes 
all multidisciplinary activities in the postoperative ICU process and primarily focuses on 
recognition of deviation from the pathway by nurses and their timely treatment within 
the boundaries of the prescribed variances. The aim of this study was firstly to develop 
and implement a CP for all cardiac surgery patients in the ICU, together with a unique 
variance report (’Radboud variance model’), describing all multidisciplinary activities in the 
ICU, and to achieve a protocol adherence above 80%. In addition, we analysed the results 
of protocol adherence in relation to outcome in the intervention group compared with 
a propensity matched historical control group treated according to the existing nursing 
and medical protocols in the year before the implementation of the CP. In a period of 
four months 84 consecutive CP patients were included and compared with 162 matched 
control patients admitted in the year before implementation. CP patients were more likely 
to receive timely and adequate treatment for derangements in electrolytes (96% vs 47%, 
p<0.001), blood pressure (90% vs 49%, p<0.001) and more timely treatment for chest tube 
blood loss (90% vs 10%, p<0.001). This study was not powered for differences in hospital 
and ICU length of stay, ICU readmission or mortality.
We demonstrated that it is feasible to implement a predominantly nurse-driven hour-
to-hour CP in the ICU for cardiac surgery patients. In addition, the use of the CP for all 
cardiac surgery patients resulted in more timely and better organized postoperative ICU 
treatment. This included improved blood pressure control, electrolytes within range, tem-
perature management, weaning from mechanical ventilation and more expedient action 
to chest tube blood loss. This implementation strategy and variance report developed in 
this high-volume, high-risk patient group served as a blue print for the development and 
implementation of a CP for low volume high-risk surgical procedures.
After implementation of a postoperative CP for cardiac surgery patients we studied trends 
and changes over time in the total group of over 7500 cardiac surgery patients treated 
in the nine years after the implementation of the CP. This study is described in Chapter 
3. Primary aim of this study was to determine trends over time regarding inclusion and 
exclusion of patients in the CP. Patient characteristics were analyzed in three-year peri-
ods. Secondary aims included determining the trends over time and between groups 
in ICU and hospital LOS, re-operations, ICU readmissions, hospital mortality and 1-year 
mortality. Effects over time and clinical outcomes were determined within patients that 
were included in the CP, secondary excluded patients, or never included patients, as 
well as a subgroup analysis of patients with a high Log EuroSCORE >10. A retrospective 
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cohort study was performed in 7553 patients, operated between January 1st, 2007 and 
December 31st, 2015. The three identified patient groups were: patients treated according 
to the CP (n=6567), patients excluded from the CP within the first 48 hours after surgery 
(n=633), and patients that were never included in the CP (n=353). The implementation 
of the Patient Data Management System (PDMS) in 2013 was considered as a complex 
structure intervention, so we decided to analyse the effect of implementation of the PDMS 
as well, because we had the expectancy that the implementation of a new PDMS might 
have an impact on all processes regarding patient information, including care and safety. 
Following implementation of the CP in 2006, the percentage of patients treated according 
to the CP increased from 74% in the first year 2007 and stabilized at a percentage of 95% 
in 2012 to 2015. The median [IQR] Log EuroSCORE of patients treated according to the 
CP increased from 2.91 [1.54-5.71] to 3.30 [1.75-6.25] (p=0.016), indicating that over time 
care-givers are less reluctant to treat more complex patients according to the CP. Despite 
the fact that more patients with more comorbidities were included, the in-hospital LOS 
decreased from median 6 days [IQR 4-8] to 5 days [IQR 3-7] in the patients treated accord-
ing to the CP (p<0.001). Overall, the in-hospital and 1-year mortality decreased from 1.5 
to 1.1% and 3.7 to 2.9%, respectively (both p<0.05). Still, patients with a Log EuroSCORE 
>10 were more likely excluded from the CP (p<0.001). Patients with a Log EuroSCORE 
>10 treated according to the CP had a shorter ICU stay and in-hospital LOS compared to 
excluded patients with a Log EuroSCORE >10, (p<0.001). For more than one year following 
implementation of the PDMS, registration and correct tagging of patients according to 
their postoperative pathway was cumbersome. Nevertheless, implementation of the new 
PDMS did not influence the outcome data in the patient groups. In the subgroup analysis 
we observed that most high-risk patients were able to follow the CP. This continuous 
learning process in CP-guided care will lead us to more personalized pathways for high-
risk patients and to shared decisions in person-centered care in the future. In addition, 
this study illustrates the sustainability following implementation of a CP in cardiac surgery 
patients over time. While more complex patients were treated according to the CP, clinical 
outcome improved. Needless to mention that other factors may also have contributed to 
better outcomes over these years.
In the fourth chapter we describe an observational evaluation study on preoperative 
central venous oxygen saturation (ScvO2)-guided hemodynamic optimisation in a group 
of patients treated with an open transhiatal esophagectomy for carcinoma or high-grade 
dysplasia. Patients were admitted to the ICU for preoperative hemodynamic optimization. 
We studied the association between preoperative optimization and a comprehensive set 
of complications in 68 patients and compared this intervention group with a historical 
control group of 32 patients treated without preoperative optimization in the two years 
prior to the intervention. Our hypothesis was that preoperative optimization in a group 
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of low volume, high-risk surgical patients could result in less postoperative complications. 
Optimization started one day before the esophagectomy in the ICU. The matrix used for 
optimization enabled nurses and residents to start fluids and/or inotropic agents accord-
ing to protocol if the ScvO2 was below 70%. In the optimization group, median preoperative 
fluid infusion was 1415 ml [904-1993] and 8.8% of the optimized patients needed an 
inotropic to reach an ScvO2>70%.  A targeted ScvO2>70% was achieved in 77% of the 
optimized patients. In the optimized group, delta ScvO2 increased with 4 [0-7]%. Patients 
not reaching the target ScvO2 were more likely to have a cardiovascular medical history 
(73% vs 37% p<0.02 ). Post-operatively, sepsis occurred in 4% of optimized and 16% of 
control patients (p=0.004), anastomic leakage occurred in 12% of optimized patients and 
25% of control patients (p=0.14). Furthermore, optimized patients appeared less likely 
to be re-admitted to the ICU (p=0.07) and had a shorter in-hospital–length of stay of 
median 10 [IQR 9-15] vs median 16 [IQR 13-35] days (p<0.001). Mechanical ventilation 
time in the optimized group was median 5.2[ IQR3,7-7,5] vs 8.0 [IQR 3.5-23.7] hours in 
the control group (p<0.03). There was no postoperative mortality in the optimized group, 
three patients died in the control group. We concluded that preoperative hemodynamic 
optimization was associated with shorter in-hospital length of stay, less infectious compli-
cations, shorter mechanical ventilation time and even lower mortality. Of interest, despite 
aiming for a higher cardiac output, blood loss and use of blood products was less in 
patients who received preoperative haemodynamic optimisation. These results suggest 
that preoperative optimisation could be beneficial in this specific group of high-risk surgical 
patients. Nevertheless, it should be emphasized that caution is warranted, as this was a 
single-center, pre-post intervention study.
The development and implementation of a CP in the ICU and in the Post Anesthesia 
Care Unit (PACU) for pancreatico-duodenectomy patients is described in Chapter 5. The 
pancreas CP was a continuum from hospital admission to hospital discharge. Essential 
elements of the CP included: restrictive intra-operative fluid use, strict pain control, early 
mobilization, early drain and gastric tube removal, and early enteral feeding all according 
to the Enhanced Recovery After Surgery (ERAS) protocol (Kehlet&Dahl, Lancet 2003). Early 
warning scores (EWS) were determined post-operative at least once during every 8 hour 
shift and whenever thought necessary by the nurses, with strict directives for action by 
nurses according to the variance report, both in the surgical ward, Post Anesthesia Care 
Unit and ICU. A prospective cohort study was conducted in 95 pancreaticoduodenectomy 
patients treated according to the CP, compared with a historical control group (n=52) 
with a traditional treatment regime. Primary endpoint was the incidence of post-opera-
tive complications, according to Clavien-Dindo classification (Dindo & Clavien, Annals of 
Surgery 2004). Secondary endpoints were, post-operative fluid balance, occurrence of 
gastroparesis, protocol adherence for mobilization, drain removal, radiologic and surgical 
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re-interventions, ICU readmission, in-hospital length of stay (LOS), hospital readmission 
and mortality rate. Process evaluation of the clinical pathway group revealed that protocol 
adherence throughout all components of the CP was above 80%. Major complications 
according to Clavien-Dindo Classification grade ≥3, was significantly lower in the CP group 
(13%) compared with the control group (27%); p=0.02. Hospital-LOS was significantly 
shorter in the CP group, median 10 days [IQR: 8-15], compared with the control group, 
median 13 days [IQR: 10-18]; p=0.02. The use of the CP was associated with a significant 
reduction of perioperative morbidity as  reduction of gastroparesis (p<0.001) and less 
radiologic drainage interventions (p=0.04). Essential new tools included a variance report 
analysis, scheduled barrier and facilitator analyses, and the iterative P-A-R cycle protocol 
development, performed by a multidisciplinary team. We concluded that the development, 
implementation and use of a CP throughout the hospital stay for patients undergoing 
pancreaticoduodenectomy, is a multistep procedure which is feasible and safe. 
In Chapter 6 we reflect on the need for sustainable clinical pathways and the develop-
ment of personalized care pathways in high-risk surgery. Although the concept of CPs 
goes back more than two decades, a broad implementation of CPs in high-risk surgery 
which includes an ICU period  has not been the subject of research in the past period to 
date. Implementation of a CP, including the ICU period in high-risk surgery, has  potential 
benefits and these benefits are not limited to cost-effectiveness. The chance to improve 
clinical outcomes is real. The European Pathway Association, e.g. on acute care, COPD 
and hip fractures, concluded that evidence-based key interventions are better performed 
after implementation of a CP compared to usual care. We argue that a successfully imple-
mented CP will improve the quality of care, including a reduction of complications. It 
appears plausible that this will be related to improved patient reported outcome and 
more efficient use of resources. For successful implementation, all caregivers throughout 
the entire clinical process need to be involved and aligned, as well as the patients and 
their family. Augmented use of nursing potential is also paramount. Deviations from the 
pathway can be recognised more swiftly, resulting in more timely interventions to put the 
patient back on the pathway according to individualized preset goals. In this way, CPs will 
empower nurses, physician assistants and residents in safe treatment decision making. 
Patients will experience more security during the treatment process and will be empow-
ered by being able to follow their personalized clinical pathway. 
The general discussion and future perspectives are described in Chapter 8, with focus 
on the relationship between process interventions such as the development and imple-
mentation of clinical pathways and clinical outcome. 

General discussion 
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General discussion
Development and implementation of clinical pathways, or care pathways (CPs), are con-
sidered complex process interventions. In the 1990s CPs were developed to integrate 
nursing and medical protocols in multidisciplinary care plans, most often accomplished 
in predictable trajectories (1). In this thesis we describe the development and implemen-
tation of high-risk surgery related clinical pathways in the Intensive Care Unit (ICU). We 
focus on clinical pathways as a complex process intervention and a component of the 
Donabedian’s trias: structure, process and outcome (2, 3). Development and implemen-
tation of a clinical pathway in the ICU in high-risk surgery is a multi-step procedure. The 
first step is the mutual decision of physicians and nurses to align protocols so that they 
can work uniformly, the second step is the multidisciplinary search for available evidence 
and best practice guidelines that have to be built into the future multidisciplinary CP. Fol-
lowing these two essential steps, the actual building of the CP can start. The method of 
implementation has to be part of the development of the multidisciplinary CP, before the 
implementation can finally start. During implementation of a standardized dynamic CP, 
the use of an associated Prepare-Act-Reflect (P-A-R) cycle with a purpose for continuous 
improvement is an essential aspect for a sustainable CP. 
In this thesis we describe the development and implementation of high-risk surgery 
related CPs in the ICU and discuss steps we consider important for a successful CP devel-
opment and implementation. We argue that adequate use of CPs can become a tool in the 
continuous improvement of quality of care, by the use of P-A-R cycles. Clinical outcome 
measurements together with P-A-R cycles of CPs may provide steering information and 
this can lead to transparency of given care. Research on outcome measures of CPs does 
have important limitations, mainly because of methodological issues.
Development of high-risk surgery related CPs in the Intensive Care Unit
For the development and implementation of the CPs in our hospital, nursing and medical 
protocols were reviewed and often redefined and, when available, based on Evidence 
Based Medicine (EBM), Evidence Based Practice (EBP) and best practice guidelines. 
Work-as-Imagined (WAI), often developed by experts and transformed into best practice 
guidelines, is defined as the formal work, that what managers and regulators believe 
should happen (4). WAI will have to to be redesigned and tailored to specific local circum-
stances and resources by a multidisciplinary team of physicians and key-nurses, before 
a CP can be built. We consider the identification of potential facilitators and barriers in 
the particular setting of an ICU, an important first step towards the development of our 
CPs (5). Clinical leadership and the conviction that peri-operative CPs play a role in the 
improvement of quality and safety in specific patient groups, together with a reduction of 
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the burden of registration, were identified as facilitators during our first steps in develop-
ment and implementation of clinical pathways. An overall negative attitude existed against 
further protocolizing and regulation of both medical and nursing work. The existing pro-
tocols and associated registrations were experienced by nurses and physicians as time 
consuming processes that did not result in clear benefit for the patient.  Perceived loss of 
autonomy following implementation of a CP was considered another important barrier 
that needed to be addressed and taken care of before development and implementation 
of a CP could start.
Implementation of a CP as a process intervention 
During the design of a CP it is important to realize that this is a process intervention with 
the intention to strengthen the system. Although physicians and nurses want to do the 
right things at the right time, the circumstances and resources may not always be optimal. 
Caregivers need feedback mechanisms about the effects of their actions and whether or 
not preset goals are achieved. We presume that P-A-R cycles, together with a proper use 
of the variance report, can give this feedback to frontline caregivers and patients. In this 
way peri-operative expectations, complications and clinical outcomes in relation to adher-
ence to the CP, can lead to a dynamic sustainable intervention. Associations with pursuit 
for only productive and financial indicators could make care-providers (as being frontline 
individuals) sceptical about new process interventions like CPs. Choosing efficiency above 
safety in a process may weaken it and can lead to a vulnerable system and human error 
can be the result (6, 7). This will have an influence on adherence and adequate use of a 
CP and possibly on outcome indicators.
Clinical pathway-guided care in the post-operative period has been successfully imple-
mented for several groups of patients in many hospitals and for different medical 
conditions(8). In studies relating to implementation of clinical pathways in high-risk sur-
gery patients, not all hospital wards involved in the clinical process (like PACU/ICU) were 
included (9-12). The main reason for this can be the assumption that in these departments 
the swiftness and complexity of the occurrence of derangements may not allow diagnosis 
and treatment according to a CP. Also, different treatment regimes and different surgi-
cal interventions make reliable comparison and evaluation of CPs difficult. The currently 
available studies relating to CPs do not cover the complete hospital stay, as they exclude 
important parts of the post-operative period. Studies of ICU care, related to CPs, focus 
on aspects of ICU care such as mechanical ventilation or implementation of care bundles 
such as the treatment of sepsis and septic shock(13, 14). The clinical outcome measures 
in low- and average–risk surgery mainly focus on reduction of morbidity and in-hospital 
length-of-stay (LOS). The relationship between protocol adherence and outcome of a 
CP is seldom part of the study (15-17). In our High-risk patient group we  were able to 
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demonstrate a reduction in morbidity, readmissions and LOS. We assume that the high 
protocol adherences demonstrated in our studies were related to the use of a variance 
report which enables nurses to execute predefined actions in accordance, and within, 
the preset boundaries of a variance protocol without the need to consult the responsible 
physician first.
The first CP in the ICU in our hospital was developed for a specific group of high-volume, 
high-risk surgery patients. We were able to redesign and tailor the process of peri-op-
erative care in the ICU into a CP. The development of the CP together with a “Radboud 
Variance report” for all cardiac surgery patients in the ICU, irrespective of the type of 
cardiac surgery, was initiated by our ICU-nurses because they wanted to have more clin-
ical responsibilities. Special attention was paid to the facilitators and barriers during the 
implementation, training, and bedside teaching. We ascertained that the CP gave more 
guidance and led to better protocol adherence by using a variance report that empow-
ered nurses to start treatment within legal boundaries. It became more explicit what they 
could do themselves, and exactly when they should consult the resident or staff-member. 
The overall protocol adherence improved significantly from 44% to 90% (p=0.01) after 
the implementation of the CP. We considered the adherence to the CP as Work-as-Done 
(WAD), in other words: informal work, how caregivers get the job done in relation to 
resources and workflow. Because of the high adherence, the CP almost resembles the 
work that has be defined by experts and transformed by them into guidelines: WAI (18). 
After implementation of the post-operative CP for cardiac surgery we studied trends and 
changes over time. We demonstrated that during our 9 years of use of a post-operative 
cardiac surgery clinical pathway, an increasing proportion of high-risk patients were able 
to follow the CP successfully, and that 95% of the patients are able to follow the CP. While 
more complex patients were treated according to the CP, clinical outcome improved. 
Development and implementation of a pre-operative optimization protocol in open tran-
shiatal esophageal resections, a procedure representing low-volume, high-risk surgery in 
the ICU, was our next step. The ICU team had a wish to improve outcome in this patient 
group by initially analyzing their own process and adding preoperative optimization as 
intervention. Clinical outcomes improved, as shown by the reduction of in-hospital LOS 
and readmission rate to the ICU. We also identified the effects of other interventions 
in other patient groups in our hospital, such as the Enhanced Recovery After Surgery 
(ERAS) program in colorectal surgery, used by anesthesiologists and general staff in the 
surgical ward. Aspects of the ERAS protocol were used in many, but not all patients, 
in our optimization study. Unintended crossover contamination likely took place, and 
we conclude that CPs cannot be considered, nor studied, as isolated interventions in a 
closed-format ICU. We expected that the implementation of a CP for high volume, high-risk 
surgical procedures in the ICU could act as a blue print for low volume, high-risk surgical 
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procedures in the ICU, Post Anesthesia Care Unit (PACU), and general ward. Therefore, 
we developed and implemented CPs for typical low-volume, high-risk procedures: open 
transhiatal esophagectomy procedures and pancreas surgery. In these patient groups 
we observed a high protocol adherence, improved clinical outcome and shorter hospital 
length of stay associated with the implementation of the CP. Implementation is an iterative 
process that takes time to become comfortable in use for all involved units. Key-nurses 
together with medical leadership were essential for awareness, feedback and motivation 
during development, implementation and the use of all CPs.
Clinical Leadership and protocols were already present and used before we developed the 
CPs, so several questions may emerge: What made the difference in protocol adherence 
and outcome following CP implementation? Are CPs applicable in other departments 
and hospitals as well? Frontline caregivers expressed that they wanted to work more uni-
formly and extend their clinical responsibilities. As a multidisciplinary group they invested 
time and energy in the development of a CP and built a variance report, tailored to their 
workflow. Educational sessions and meetings about the content and use of a CP were 
essential aspects of the development and implementation strategy. Key-nurses present 
at the ward for questions and help were crucial during implementation and continuation 
after implementation. The ‘Radboud variance report’ (see appendix), together with the 
development strategy was the blue print for the low-volume, high-risk surgery related 
CPs in the intensive care unit of our hospital. In our view, this strategy greatly facilitates 
development and implementation of CPs. In our expectations, this should be feasible in 
many departments and hospitals (Figure 1) .
Sustainability of CPs
Implementation of a CP may improve the use of multidisciplinary protocols for post-opera-
tive care for high-risk surgical patients in the ICU, however, up to now, sustainability of a CP 
is unknown. The research on sustainability of CPs is clearly hampered by other processes 
and structure interventions that may occur over time. Many structure interventions like 
data management, staffing levels and governance-induced regulatory rules will influence 
work processes and outcomes relating to these structure interventions. This has to be 
taken into account during follow-up, innovation and research of sustainable pathways. 
Clearly, other (unknown) factors may have contributed to these results as well.
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Figure 1: Development flowchart of clinical pathways.
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Limitations
The two most important limitations of all the studies described in this thesis are the 
fact that they are single center studies and the pre-post intervention study design. The 
intensity and duration to develop the CP, as well as the implementation process, limit the 
feasibility of using other study designs. Per patient randomisation and adequate blinding 
is clearly not feasible. A multi-center study applying a stepped-wedge approach would be 
needed to reach the highest quality of design. Another important limitation of our study 
is the fact that implementation of a CP is a culture change process for both the team and 
the organization. During a change process, crossover contamination will already influence 
the results in the control group, especially if the control group is treated during the devel-
opment period of the pathway. It is a human reaction: if you feel that something is better 
then you will not wait to apply it. Ethical issues are also relevant. A CP based on EBM, EBP 
and best practice guidelines  will resemble Work-as-Imagined developed by experts. As 
a consequence, the control group will not receive care and treatment based on these 
standards. We therefore used a historical control group for all described studies, because 
per patient randomization is considered not a feasible, nor ethical study design. Unfor-
tunately, most studies on CP implementation share this limitation (19-23). The discussed 
design issues should make us aware of the possible overestimation of the observed clinical 
outcome differences. The wish to work uniformly in relation to culture change as aspects 
of a CP, makes multicenter studies of implementation and outcome of CPs a complicated 
procedure. Stepped wedged design may overcome this dilemma. Unfortunately, a very 
important ingredient will be the multidisciplinary involvement in the  development of a CP, 
tailored to Work-as-Done. Clinical leadership, together with communication by key-physi-
cians and key-nurses from the participating hospital to frontline caregivers could be the 
most important step in a successful stepped-wedged implementation of CPs. Complex 
process interventions like CPs were originally designed to balance quality of care and costs 
by focusing on better use of resources. We did not focus on costs or use of resources. We 
did focus on the flow of the patients’ journey in relation to CP adherence and outcome, 
not associated with currencies and governance related control systems.
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Future Perspectives
Despite the above mentioned limitations, empirical evidence and conclusions are firm: 
the use of a CP in high-risk surgery is feasible and safe. Moreover, it is likely related to a 
better clinical outcome. The analysis of facilitators and barriers in the development pro-
cess could be the reason for a better protocol adherence and could be associated with 
better caregiver satisfaction. These effects of empowerment of nurses and physicians 
together with quality in work balance (viewed as being valued) could be studied within 
CPs. Measurement of team climate, annual interviewsand  trends in absenteeism could 
be analyzed within departments. The P-A-R cycle can also be an instrument to identify 
human errors, which are often actually process or system errors and reduction of these 
errors should be part of a dynamic remodelling of a CP.
Patient-Centred-Care-Pathways
The described pathways in this thesis were originally developed to integrate nursing and 
medical protocols in to multidisciplinary care plans for high-risk surgery patients, with the 
intention of working uniformly, safely and with the intention of resulting in better clinical 
outcomes. Another intention was the empowerment of ICU nurses, based on education, 
communication and trust in each other as a professional. Future CPs should be built 
around, but also with, patients. Shared-decision-making and person-centered-care needs 
to be the key components of a CP. Patient representatives (or key-patients) may claim their 
part in the development of CPs together with key-physicians and key-nurses and P-A-R-
cycle results have to be shared with them. This may seem a contradiction to the described 
CPs, where standardized, safe and efficient care were the main goals. In the ICU, where 
swift hemodynamic and respiratory changes are often observed followed by adequate 
actions, patients and their relatives will probably have a different role in the development 
of a CP. But, for the future we should focus on the definition of a Care Pathway by the 
European Pathway Association (EPA):  “A clinical pathway explicitly states the goals and key 
elements of care based on Evidence Based Medicine (EBM) guidelines, best practice and 
patient expectations by facilitating the communication, coordinating roles and sequencing 
the activities of the multidisciplinary care team, patients and their relatives.
We should be aware that some patients are not fit for all the aspects of a CP. The preset 
goals for patients with more co-morbidities can be different. In our sustainable cardiac sur-
gery CP we were able to identify a patient group which was never included in the CP. These 
patients were expected to be unable to follow our clinical pathway and some received a 
personalized pathway. Communication and information to the patients and their families 
about this expected more difficult journey in this group of patients will open the path-
way to shared-decision-making. Person-centred limitations in care, and sometimes the 
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mutual decision not to start treatment, can be the result of this shared decision. This has 
to be part of the shared-decision making process and should be clear for patients and 
their treatment team of physicians and  nurses, before starting the person-centered CP. 
Work-as-Done should resemble as much as possible Work-as-Imagined and should be 
integrated in a safe patients’ journey for all patients not only for those fit for a specific CP. 
Patient reported outcome measures will probably be the tool for research in this field.
Care Pathways as a tool to enhance Resilience in our care system
Medical misadventures within our medical system do have tremendous effects on the 
resilience of a team and processes. Traditional risk management will focus on the weak-
est link in the system, resilience analysis will draw its attention towards a “soft landing ” 
to reduce collateral damage and adapt and recover after an incident (24). The time to 
recover from such an event is different between caregivers, departments, and hospitals. 
We assume that a CP can have an effect on the resilience profile, developed by Imola et 
al.  A CP may reduce adaptation time from an adverse event, by the adequate use of the 
P-A-R-cycle and knowledge of the work process as Work-as-Done (25). 
Figure 2: Resilience profile. L.Ilmola  IIASA IRGC (2016). Resource Guide on Resilience. Lausanne: EPFL Interna-
tional Risk Governance Center. v29-07-2016.
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This emphasizes the importance in understanding why things usually go right and in the 
right flow, and our obligation to develop the circumstances that as many things as possible 
can go right (Safety-II). Instead of the primary focus on analyzing causes and contributory 
factors of adverse outcome where the safety management response will be the elimination 
of the cause and building improved or more barriers ( Safety-I) as currently applied (26). 
Safety-II should become the driver of the development and use of CPs in the patients’ jour-
ney. Because a dynamic variance report in a CP will drive on preset goals and early actions 
to stay on the safe side of the pathway, instead of building more barriers (especially more 
registration , checkboxes and banners) to prevent more harm.
The role of CPs in quality and safety in relation  to our health care reimbursement system
The financial system relating to reimbursement and costs in health care is not directly 
associated with a small amount of key performance indicators for protocol adherence, 
adequate use of care pathways or outcome. Nowadays, the existence of written protocols 
and guidelines in the different care processes seem to be, together with registration of many 
indicators, the condition needed for reimbursement and accreditation. Many indicators 
have to be provided repeatedly to different control systems that are not intertwined or 
connected with each other. Moreover, many indicators are not recognized as key-perfor-
mance indicators by frontline care professionals. The ever increasing registration burden 
and subsequent outgrowth of systems, jobs and commissions to analyse the registered 
items (based on Work-as-Imagined (WAI)) are seldom related to the difficult choices that are 
made by frontline caregivers (resulting in Work-as-Done (WAD). An important step forward 
could be the implementation of CPs, with only a small amount of selected key performance 
indicators built into the system by frontline caregivers (and patients) and, actually related to 
quality and safety. Deviations or variances from preset goals for care and clinical outcome 
(as part of the CP) could be the only registered items by frontline caregivers. The essence will 
be that the use of the CP, with a P-A-R cycle, is a team effort based on doing the right things 
at the right time with an incentive for continuous improvement. Governance registration 
rules and outcome presentations should be related to protocol adherence and the well 
chosen key-performance indicators related to the CP. As a result, reimbursement or finan-
cial incentives should be on patients’ health in times of illness with the least complications 
and setbacks. If dynamic CPs are built into our hospital electronic systems (both intra-dis-
ciplinary and multidisciplinary), and connected with each other, this will lead to better team 
work, communication and circumstances, further facilitating protocol adherence. As a con-
sequence, provided care is expected to be more efficient and safe. The short cycle P-A-R 
cycles relating to the key performance indicators chosen by frontline care-givers, will result 
in useful feedback and agile interventions to put the patient, together with the process, back 
on the pathway track. Control systems that seem to be in control nowadays can be reduced 
and better systems can be used through reinforcement of frontline care-givers instead. 
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New process interventions in provided care, like CPs, should not increase workload and 
stress on our health care system and health care providers, and have to be based on 
flow and should be patient-centered. This flow, observed in the patients’ journey, should 
resemble agile short-cycle new power. This will hopefully replace the old power associated 
currency and control systems held by few (27). Research on the use of CPs in relation to 
provided care during illness, could be the beginning of a new reimbursement system in 
health care.
The result of a successful CP implementation will be the establishment of new principles 
and the cycle can start again. In this continuous dynamic cycle of CP development and 
renewal, patients, together with caregivers, have to be the builders of these pathways. 
Contact with information technology personnel in their hospitals has to be on a short cycle 
basis, to make it possible for these ICT colleagues to build the variance report together 
with the chosen Key-performance-indicators (KPis) of the pathways into the Patient Data 
Management System (PDMS) aligned to the clinical workflow. This provides patients and 
caregivers with steering information on Kpis and clinical outcome. This essential infor-
mation for patients and caregivers (being an aspect of the P-A-R-cycle) has to be more 
real-time. This shared knowledge will be the base for building shared decision making, 
patient-centered-care together with aspects of value-based- health-care into the clinical 
pathways 3.0.
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Figure 3: Flowchart: Clinical Pathway 3.0
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Ontwikkeling, implementatie en evaluatie van intensive care gerelateerde 
klinische paden voor chirurgische ingrepen met een hoog risico: 
effecten van een proces interventie. 
Klinische paden of zorgpaden zijn ontwikkeld om optimale zorg te geven aan een spe-
cifieke patiënten groep met als doel verschillen in aangeboden zorg tussen individuele 
patiënten en individuele zorgverleners weg te nemen. Oorspronkelijk zijn klinische paden 
ontwikkeld om de verschillen tussen kwaliteit van zorg en de kosten van zorg in balans 
te brengen. Daarbij ligt doorgaans de focus op een beter gebruik van voorzieningen, 
maximale kwaliteit van zorg en het minimaliseren van de tijd tussen diagnose en behan-
deling. Zowel de ontwikkeling, als de implementatie van klinische paden worden gezien 
als complexe procesinterventies en worden meestal ingezet in voorspelbare, niet com-
plexe procedures in de zorg. Wij ontwikkelden en implementeerden verschillende klinische 
zorgpaden waarbij verpleegkundige en medische protocollen geïntegreerd werden in 
een multidisciplinair zorg plan voor patiënten die een chirurgische procedure moeten 
ondergaan met een hoog peri-operatief risico op complicaties. De inhoud van een zorgpad 
bestaat niet uitsluitend uit multidisciplinaire- of intradisicplinaire protocollen, maar is even-
eens een  dag- tot- dag zorgplan dat alle behandelingen en  acties beschrijft, die nodig zijn 
binnen een vooraf bepaalde periode, om optimale zorg te kunnen leveren aan de patiënt. In 
onze ICU werd daarom naast het zorgpad een zogenaamd “variantie rapport” ontwikkeld, 
dat het verpleegkundigen mogelijk maakt om, binnen de grenzen van de BIG-wet ( Wet 
individuele beroepen Gezondheidszorg), handelingen te starten.  Alle patiënten in de 
beschreven onderzoeken ondergingen een vorm van hoog-risico chirurgie en werden in 
de peri-operatieve fase opgenomen op de intensive care unit (ICU) van ons ziekenhuis 
voor bewaking en ondersteuning van hun vitale functies. Onze hypothese was dat een 
procesinterventie als de ontwikkeling en implementatie van een klinisch pad op de ICU 
voor hoog-risico chirurgie, samen met het daadwerkelijk gebruik daarvan, de kwaliteit van 
zorg zal verbeteren. Dit kan leiden tot een vermindering van het aantal ernstige complica-
ties en verkorting van de opname duur. Een klinisch pad is gebaseerd op evidence based 
medicine (EBM), best practice afspraken (BP) en richtlijnen, doorgaans opgesteld door 
experts. Dit betekent in de ICU, dat een klinisch pad kan bestaan uit een uniform muti-
disciplinair protocol samen met een vastgelegd uur-tot-uur schema voor een specifieke 
patiënten groep.  In dit klinisch pad staat beschreven welke interventies en acties nodig 
zijn, indien veranderingen en afwijkingen van het pad gesignaleerd worden . Dit schema 
zal moeten focussen op herkenning van vitale bedreigingen en afwijkingen (deviaties) van 
het klinisch pad door verpleegkundigen en zal hen in staat moeten stellen vroegtijdig een 
behandeling te kunnen starten. Dit alles binnen de grenzen van de voorgeschreven vari-
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anties waarop gehandeld mag worden. De ontwikkeling, implementatie en evaluatie van 
een klinisch pad in de ICU zal onderdeel moeten zijn van een Prepare-Act-Reflect cyclus 
(P-A-R cyclus). Dit moet een dynamisch proces dat verdere verbeteringen in de te geven 
zorg faciliteert. Structuurinterventies in een systeem, zoals verandering in aantal zorgver-
leners, aantal specifieke operatieprocedures of Patiënt Data Management Systeem, samen 
met veranderingen in onderliggende evidence en richtlijnen, zullen effect hebben op de 
uitvoering van protocollen door mensen op de werkvloer. Richtlijnen worden doorgaans 
ontwikkeld door experts en hebben tot doel uniformiteit van werken echter daarbij wordt 
doorgaans niet naar de lokale situatie en/of de bestaande lokale systemen gekeken. De 
ideale situatie ontstaat als aan alle randvoorwaarden wordt voldaan en het werk kan 
worden uitgevoerd conform de bestaande standaarden of best practices welke gebaseerd 
zijn op  wetenschappelijke onderzoek en consensus, het zogenaamde Work-as-Imagined 
(WAI). Hiertegen over staat de invulling van WAI op de werkvloer. Het uitvoeren van het 
werk naar beste kunnen met de bestaande mogelijkheden en voorzieningen, het zoge-
naamde Work-as-Done (WAD). Indien we deze gedachte vertalen naar een goed klinisch 
pad dan zullen alle acties moeten bijdragen aan en resulteren in  snelle aanpassingen, 
indien afwijkingen geconstateerd worden. Hiermee komt WAD zo dicht mogelijk bij WAI.
In het eerste deel van dit proefschrift ligt de focus op het bepalen van de mogelijkheid en 
haalbaarheid om een klinisch pad te ontwikkelen en te implementeren met een post-ope-
ratief uur-tot-uur plan voor hartchirurgische patiënten in de ICU. Vervolgens leggen we de 
focus op trends in de tijd, na implementatie in hoog-volume hoog-risico chirurgie zoals 
hartchirurgie. Analyse van in positieve zin bijdragende, (faciliterende) omstandigheden 
en bestaande barrières binnen deze structuur of op proces niveau zijn onderdeel van 
dit proefschrift. 
Het tweede deel van dit proefschrift beschrijft de ontwikkeling en implementatie van kli-
nische paden in laag-volume, hoog-risico chirurgie in de ICU, zoals pancreas chirurgie en 
slokdarmchirurgie,  waarbij het klinisch pad van de hartchirurgie als blauwdruk is gebruikt. 
We beschrijven de ontwikkeling van een pre-operatief optimalisatieprotocol, voor pati-
enten die een open slokdarm resectie ondergaan met buismaag reconstructie in een 
closed-format ICU. Daarnaast beschrijven we de ontwikkeling en implementatie van een 
klinisch pad voor operaties aan de pancreaskop (Whipple procedure), van verwijzing naar 
de polikliniek Heelkunde tot aan ontslag uit het ziekenhuis.  In beide studies bestuderen 
we tevens effecten gerelateerd aan de verschillende uitkomstmaten in deze patiënten 
groepen.
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In hoofdstuk 2 wordt de ontwikkeling en implementatie van een klinisch pad met een vari-
antierapport, beschreven samen met de evaluatie van een post-operatief klinisch pad voor 
alle hartchirurgische patiënten in de ICU. De ontwikkeling van dit klinisch pad hangt sterk 
samen met de wens van de intensive care verpleegkundigen in ons ziekenhuis, om meer 
autonomie te krijgen in het behandelproces van de patiënt. Het variantierapport maakt 
het mogelijk voor verpleegkundigen om, vooraf beschreven acties uit te voeren in overeen-
stemming met vooraf afgesproken vastgestelde grenzen. Een voorbeeld is het starten van 
vaso-actieve medicatie bij lage bloeddruk of middelen die de stolling bevorderen, indien na 
hartchirurgie het bloedverlies uit de drains te hoog is. Deze acties worden gestart zonder 
tussenkomst van een arts, uiteraard bij twijfel of onvoldoende effect wordt de (volgende) 
te ondernemen stap overlegd met een arts. Bij afwijken van het te verwachten postope-
ratieve pad, in deze hoog-volume hoog-risico chirurgische patiëntengroep, beschrijft het 
klinisch pad alle multidisciplinaire activiteiten in het postoperatieve ICU proces, die dan 
ondernomen kunnen worden om de patiënt weer op het juiste pad te brengen. Een kli-
nisch pad in de ICU van het Radboudumc heeft tot doel dat, bij vroegtijdige herkenning 
van een mogelijk afwijkend beloop (deviaties), door verpleegkundigen behandeling gestart 
kan worden, die voorheen beschouwd werd als een aan artsen voorbehouden interventie. 
Deze behandelingen, zonder tussenkomst van een arts, vallen binnen de grenzen van de 
Nederlandse BIG-wet ( Wet Individuele Beroepen Gezondheidszorg). Het doel van deze 
studie was ten eerste de haalbaarheid van het ontwikkelen en implementeren van een 
klinisch pad voor alle hartchirurgische patiënten in de ICU. De ontwikkeling van het klinisch 
pad gebeurde gelijktijdig met de ontwikkeling van een uniek variantierapport (’Radboud 
variance model’) door de ontwikkelaars, artsen en verpleegkundigen. In dit model worden 
alle multidisciplinaire activiteiten in de ICU beschreven. Het ontwikkelproces, samen met 
de scholing en implementatie, duurde ruim 18 maanden. De verwachting was dat door het 
klinisch pad en het geven van behandelingsbevoegdheden aan verpleegkundigen, adhe-
rentie aan onderliggende protocol hoger zou zijn. Het doel was dat protocol adherentie 
boven 80% zou komen. Daarnaast  analyseerden wij de resultaten van deze protocolad-
herentie in relatie tot de uitkomsten in de interventiegroep, die volgens het klinisch pad 
werd behandeld. Deze groep werd vergeleken met een “propensity matched” historische 
controle groep. De controle groep werd een jaar voor de implementatie van het klinisch 
pad behandeld, conform de bestaande  separate niet-geïntegreerde verpleegkundige 
en medische protocollen en zonder “variantierapport” waarop zij mochten handelen. In 
een periode van 4 maanden werden 84 opeenvolgende patiënten geïncludeerd in het 
klinisch pad en deze werden vergeleken met 162 gematchte controle patiënten, die in 
het jaar voor de implementatie werden behandeld. We constateerden dat bij klinisch 
pad patiënten vaker en eerder (binnen 30 minuten) adequate behandeling werd gestart 
door verpleegkundigen, bij aanwezigheid van afwijkende electrolyt waarden (96% vs 47%, 
p<0.001), eerder adequate acties op bloeddruk veranderingen werden gestart (90% vs 
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49%, p<0.001) en een snellere behandeling werd ingezet, indien sprake was van een toe-
genomen bloedverlies uit de thoraxdrains (90% vs 10%, p<0.001). Deze studie was niet 
gepowered om verschillen in opnameduur in het ziekenhuis of de ICU, heropname ICU 
of mortaliteit aan te tonen. Deze studie ging om haalbaarheid van het ontwikkelen van en 
implementatie van het klinisch pad.
We concludeerden dat het haalbaar is een, voornamelijk door verpleegkundigen uit-
gevoerd, uur-tot-uur klinisch pad te implementeren in de ICU voor postchirurgische 
hartchirurgische patiënten. Tevens toonden we aan dat het gebruik van een KP voor alle 
hartchirurgische patiënten resulteerde in een snellere start van de behandeling en beter 
georganiseerde postoperatieve behandeling in de ICU voor deze patiëntengroep. Dit bete-
kende een betere bloeddrukregulatie, betere electrolytregulatie, temperatuurregulatie van 
de patiënt, snellere weaning van de beademing en extubatie evenals snellere adequate 
acties op verhoogd bloedverlies uit thoraxdrains. Deze implementatiestrategie, samen 
met het gebruik van een “variantierapport” ontwikkeld in een hoog-volume hoog-risico 
patiëntengroep, werd gebruikt als blauwdruk voor de ontwikkeling en implementatie van 
een klinisch pad voor laag-volume en hoog-risico chirurgische procedures gerelateerd 
aan de ICU. 
Na de implementatie van het klinisch pad voor de postoperatieve hartchirurgische pati-
enten in de ICU, wilden we trends en veranderingen over een tijdsperiode bestuderen in 
de totale groep van meer dan 7500 hartchirurgische patiënten, die behandeld werden in 
ons ziekenhuis in de negen jaren die volgden op de implementatie van het klinisch pad. 
Deze retrospectieve cohort studie wordt beschreven in hoofdstuk 3. Het primaire doel 
van de studie was trends te bestuderen in inclusie en exclusie van patiënten in het klinisch 
pad. De patiëntenkarakteristieken werden geanalyseerd per periode van drie jaar. Het 
secundaire doel van de studie was om trends te bepalen gedurende de tijd en tussen 
de groepen, met betrekking tot opnameduur op de ICU en opnameduur in het zieken-
huis, re-operaties, heropnames ICU, de ziekenhuismortaliteit en de 1-jaars mortaliteit. De 
effecten gedurende deze tijdsperiode en de klinische uitkomsten werden onderzocht in 
drie patiëntengroepen, patiënten  die geïncludeerd werden in het klinisch pad, patiënten 
die secundair geëxcludeerd werden binnen 48 uur na de operatie , of patiënten die nooit 
geïncludeerd werden in het klinisch pad. Tevens werd een subgroep analyse verricht in 
de groep patiënten met een hoge Log EuroSCORE >10. Deze retrospectieve cohort studie 
werd verricht in de totale groep van 7553 patiënten, die geopereerd werden tussen 1 
januari 2007 en 31 december 2015. We identificeerden drie patiëntengroepen: patiënten 
die behandeld werden volgens het klinisch pad (n=6567), patiënten die geëxcludeerd 
werden uit het klinisch pad binnen de eerste 48 uur na chirurgie (n=633) en een groep 
van patiënten die nooit geïncludeerd werden in het klinisch pad (n=353). De implementatie 
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van een nieuw Patiënt Data Management Systeem (PDMS) in 2013 beschouwden wij als 
een complexe structuurinterventie, daarom hebben we besloten ook te kijken naar de 
effecten van de implementatie van het nieuwe PDMS binnen onze registratie. We hadden 
de verwachting dat de implementatie van het PDMS gevolgen zou kunnen hebben voor 
allerlei processen die een rol spelen bij patiënten informatie inclusief patiëntenzorg en 
veiligheid.  Na de implementatie van het klinisch pad steeg het percentage patiënten, dat 
behandeld werd conform het klinisch pad, van 74% in het jaar na de implementatie van 
het pad, naar 95% in 2012 en bleef stabiel gedurende de laatste 3 jaren van dit onder-
zoek. De mediane [IQR]Log EuroSCORE van patiënten die behandeld werden volgens 
het klinisch pad steeg van 2.91 [1.54-5.71] naar 3.30 [1.75-6.25] (p=0.016). Dit toont aan 
dat zorgverleners minder bedenkingen hadden om meer complexe patiënten volgens 
het klinisch pad te behandelen. Ondanks het feit dat patiënten met meer comorbidi-
teit volgens het klinisch pad werden behandeld, daalde de ziekenhuis opnameduur van 
mediaan 6 dagen [IQR:4-8] naar mediaan 5 dagen [IQR:3-7] in de klinisch pad groep 
(p<0.001). Over het algemeen daalden in de klinisch pad groep de ziekenhuismortaliteit 
en de 1–jaars mortaliteit respectievelijk van 1.5 naar 1.1% en van 3.7 naar 2.9%, (beiden 
p<0.05). Patiënten met een Log EuroSCORE>10 werden doorgaans vaker geëxcludeerd 
van het klinisch pad (p<0.001). Patiënten met een Log EuroSCORE>10, die in het klinisch 
pad behandeld werden, hadden een kortere ICU opname duur en ziekenhuis opname-
duur vergeleken met de geëxcludeerde patiënten met een Log EuroSCORE>10, (p<0.001). 
We observeerden dat, registratie en correcte labeling van patiënten in het PDMS, naar 
hun postoperatieve zorgpad ( inclusie of exclusie) moeizaam was ( ondanks een papie-
ren schaduwsysteem). De implementatie van het nieuwe PDMS had geen invloed op de 
uitkomstdata binnen de subgroepen. In de subgroepanalyse observeerden we dat ook 
de hoog risico patiënten met een Log EuroSCORE > 10 in staat bleken het klinisch pad 
succesvol te volgen. Uiteindelijk verwachten we dat dit continue leerproces van klinisch 
pad-geleide zorg ons zal leiden naar meer gepersonaliseerde zorgpaden voor patiënten 
met een hoge Log EuroSCORE en naar gezamenlijke beslissingen tussen patiënt en arts en 
meer gepersonaliseerde zorg in de toekomst. Deze studie illustreert de duurzaamheid van 
een klinisch pad na implementatie voor hartchirurgische patiënten. Klinische uitkomsten 
verbeterden terwijl meer complexe patiënten behandeld konden worden volgens het 
klinisch pad. We realiseren ons dat andere factoren binnen zorgprocessen ook kunnen 
hebben bijgedragen in de verbetering van de uitkomsten gedurende deze jaren.
In hoofdstuk 4 wordt een observationele evaluatie studie beschreven, gericht op 
pre-operatieve optimalisatie van de centraal venueze zuurstof saturatie (ScvO2), in een 
groep patiënten een transhiatale oesophaguscardia resectie met buismaagreconstructie 
ondergingen, in verband met de aanwezigheid van  slokdarmkanker, cardia-carcinoom of 
hooggradige dysplasie. De gedachte was dat verbetering van de zorg binnen de intensive 
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care afdeling, invloed kan hebben op de uitkomsten voor deze patiëntengroep, ook al is 
dit slechts een onderdeel van het totale proces. De verwachting dat de patiënt in betere 
hemodynamische conditie de operatie in gaat, kan dat een positief effect hebben. De 
patiënten werden daarom pre-operatief opgenomen op de ICU voor hemodynamische 
optimalisatie. We onderzochten de relatie tussen pre-operatieve optimalisatie met een 
specifieke set van postoperatieve complicaties, in een geselecteerde groep van 68 opeen-
volgende patiënten. Deze interventie groep werd vergeleken met een historische controle 
groep van 32 patiënten, die geopereerd werden zonder dat ze  pre-operatief geoptima-
liseerd werden in de 2 jaar voorafgaande aan deze optimalisatie studie. Onze hypothese 
eruit dat pre-operatieve optimalisatie in een geselecteerde groep van laag-volume 
hoog-risico chirurgische patiënten, zou resulteren in minder postoperatieve complicaties. 
Optimalisatie startte één dag vooraf aan de slokdarm resectie met buismaagreconstruc-
tie in de ICU. We gebruikte een matrix die verpleegkundigen en arts-assistenten in staat 
stelde om de optimalisatie te starten door het toedienen van vloeistof infusie en/of inot-
ropica, indien de gemeten ScvO2 minder was dan 70%. In de geoptimaliseerde groep was 
de mediane [IQR] vloeistof infusie 1415 ml[904-1993] en 8.8% van de geoptimaliseerde 
patiënten kreeg inotropica om de ScvO2 te verhogen. Een ScvO2  >70% werd bij 77 % van 
de geoptimaliseerde patiënten bereikt en de delta ScvO2  nam toe mediaan [IQR] 4 [0-7]%. 
Patiënten die geen ScvO2 >70% behaalden, hadden vaker cardiovasculaire comorbiditeit 
(73% vs 37%,p=0.02). Postoperatief trad sepsis op bij 4% van de geoptimaliseerde patiën-
ten en bij 16% van de controle patiënten (p=0.004), naadlekkage werd gediagnostiseerd bij 
12% van de geoptimaliseerde patiënten versus 25% van de  controle patiënten (p=0.14). 
Verder leek er sprake van een trend dat geoptimaliseerde patiënten minder vaak werden 
heropgenomen op de ICU (p=0.07) en hadden deze patiënten een korter verblijf in het 
ziekenhuis, namelijk mediaan 10 [IQR 9-15] vs mediaan 16 [IQR 13-35] dagen (p<0.001) 
in de controle groep. De postoperatieve beademingduur van de geoptimaliseerde groep 
was mediaan 5.2 [IQR 3.7-7.5] vs 8.0 [IQR 3.5-23.7] uren in de controle groep (p=0.03). 
Er was geen postoperatieve 30-dagen mortaliteit in de geoptimaliseerde groep, terwijl 
drie patiënten overleden in de controle groep. We concludeerden dat pre-operatieve 
hemodynamische optimalisatie geassocieerd was met een kortere opname duur in het 
ziekenhuis, minder infectieuze complicaties, kortere beademingsduur en een lagere mor-
taliteit. Het bloed verlies en het gebruik van bloed producten was  niet toegenomen in de 
groep patiënten, die preoperatief hemodynamisch geoptimaliseerd werden op geleide 
van hun ScvO2 in de ICU. Deze resultaten suggereren dat preoperatieve optimalisatie 
voor deze specifieke patiënten groep  van hoog-risico chirurgische patiënten van voordeel 
zijn en een reductie geeft van verschillende specifieke uitkomstparameters. We moeten 
hierbij wel opmerken dat dit een single-center, pre-post interventiestudie betreft en dat 
interventies die gedurende die periode werden ingevoerd op andere afdelingen, zonder 
dat wij daarvan op de hoogte waren, eveneens effect kunnen hebben gehad.
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In hoofdstuk 5 beschrijven we het proces van ontwikkeling en implementatie van een 
klinisch pad in de ICU en in de Post-Anaesthesia-Care-Unit (PACU) voor patiënten die 
een pancreaticoduodenectomie ondergingen. Het klinisch pad pancreaschirurgie had 
vanaf het begin tot doel een continue flow door het ziekenhuis te creëren, van verwijzing 
naar de polikliniek tot aan ontslag uit het ziekenhuis na de operatie. De essentiële ele-
menten van dit klinisch pad waren: intra-operatieve en peri-operatieve vloeistofrestrictie, 
conform het Enhanced Recovery After Surgery (ERAS) programma, strikte pijn regulatie, 
vroege mobilisatie, vroege drain en maaghevel verwijdering en het vroeg starten van 
orale intake (zoals in ERAS, Kehlet & Dahl, Lancet 2003). Postoperatief stond eveneens 
vroege herkenning van de Vitaal Bedreigde Patiënt centraal. Early warning scores (EWS) 
werden minstens één maal per 8 uur gemeten en indien nodig vaker, op indicatie van 
de verpleegkundige. Dit ging samen met duidelijke instructies voor het actief starten 
van de behandeling in overeenstemming met het “variantierapport”. De ontwikkeling 
en implementatie van dit klinisch pad, dat meerdere afdelingen betrof duurde meer 
dan 12 maanden. Een prospectieve cohort studie werd verricht in een groep van 95 
opeenvolgende patiënten, die behandeld werden conform het klinisch pad in de periode 
september 2014 tot en met september 2016. Deze groep werd vergeleken met een his-
torische controle groep (n=52) die behandeld was met het traditionele regime volgens 
de matrix die ten grondslag lag aan het klinisch pad. Het doel van het onderzoek was, het 
bepalen of de implementatie van het klinisch pad veilig en effectief was, in relatie met de 
incidentie van postoperatieve complicaties zoals beschreven volgens de Clavien-Dindo 
classificatie ( Dindo& Clavien, Annals of Surgery 2004). Secundaire eindpunten waren, 
de hoogte van postoperatieve vochtbalans, het optreden van gastroparese, de pro-
tocol adherentie voor mobilisatie, drain en maaghevel verwijdering, radiologische en 
chirurgische re-interventies, ICU heropname, opname duur ziekenhuis, ziekenhuis 
heropname en mortaliteit. De procesevaluatie van de klinisch pad groep toonde aan 
dat protocoladherentie bij alle componenten van het klinisch pad, op de verschillende 
door de patiënt bezochte klinische afdelingen, boven 80% was. Ernstige complicaties 
volgens de Clavien-Dindo Classificatie graad ≥3, was significant lager in de klinisch pad 
groep (13%) in vergelijking  met de controle groep (27%); p=0.02. Opname duur in het 
ziekenhuis was eveneens significant korter in de KP groep, mediaan 10 dagen [IQR: 
8-15], vergeleken met de controle groep, mediaan 13 dagen [IQR: 10-18]; p=0.02. Het 
gebruik van het klinisch pad voor pancreaticoduodenectomie was geassocieerd met een 
significante reductie van perioperatieve morbiditeit, zoals een reductie van gastroparese 
(p<0.001) en minder radiologische drainages (p=0.04). Essentiële nieuwe onderdelen 
van dit klinisch pad waren een geplande barrière en facilitator analyse, inclusie van een 
“variantierapport” analyse en herhaalde P-A-R cycli in het ontwikkelen en implementeren 
van het protocol, uitgevoerd door een multidisciplinair team. We concludeerden dat de 
ontwikkeling, implementatie en het gebruik van het klinisch pad gedurende het gehele 
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ziekenhuisverblijf voor patiënten die een pancreaticoduodenectomie onder gaan, een 
meerstaps procedure is welke uitvoerbaar en veilig is gebleken.
We reflecteren op de behaalde resultaten en de mogelijke noodzaak voor duurzame klini-
sche paden,  evenals de ontwikkeling van gepersonaliseerde zorgpaden voor hoog-risico 
chirurgie in hoofdstuk 6. Alhoewel het concept van van klinische paden al meer dan twee 
decennia bestaat, heeft brede implementatie  op de ICU tot op heden niet plaats gevon-
den binnen de hoog-risico chirurgie. Doorgaans worden uitsluitend bepaalde aspecten 
van intensive care behandeling, zoals beademing of vroege sepsis behandeling volgens 
een bundel, geïmplementeerd. Potentiële voordelen beperken zich niet tot kosteneffec-
tiviteit, de mogelijkheden op het gebied van verbeteren van klinische uitkomsten zijn 
groot. De  European Pathway Association, die paden ontwikkelde  in o.a. acute zorg, COPD 
en heupfracturen, concludeerde, dat essentiële interventies, op basis van Evidence Based 
Medicine of Evidence Based Practice, beter worden uitgevoerd na implementatie van een 
klinisch pad vergeleken bij standaard geprotocolleerde zorg.  Wij bediscussiëren dat een 
succesvol geïmplementeerd klinisch pad de kwaliteit van zorg kan verbeteren, en kan 
leiden tot een reductie van complicaties. Het is aannnemelijk dat dit tevens resulteert in 
verbetering van de Patient Reported Outcome Measures ( PROMs) en minder verspilling 
van voorzieningen. Het is daarbij essentieel dat alle betrokken zorgverleners, binnen het 
klinisch proces, aangehaakt zijn evenals de patiënt en zijn famlie. Als het proces duidelijk 
is voor iedereen, dan zullen afwijkingen van het zorgpad sneller herkend worden en dit 
zal dan resulteren in snellere interventies om de patiënt terug te brengen in het zorgpad, 
in overeenstemming met de voorafgestelde geïndividualiseerde doelen. Op deze wijze 
kan een klinisch pad bijdragen aan de empowerment van verpleegkundigen, physician 
assistents en arts-assistenten en daardoor aan veilige beslissingen voor de behandeling 
van de patiënt die tijdig worden toegepast. Patiënten zullen zich mogelijk veiliger voelen 
gedurende het behandelproces en kunnen in staat gesteld worden om hun gepersonali-
seerde klinisch pad te volgen. 
De algemene discussie met tevens ideeën voor de toekomst worden beschreven in 
hoofdstuk 8 met focus op de relatie tussen proces interventies zoals de ontwikkeling en 
implementatie van klinische paden en klinische uitkomsten. We bediscussiëren stappen 
die wij daarin belangrijk vinden. 
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Appendix klinisch pad hartchirurgie 
Figure 1: Klinisch padKlinisch pad Variantie
Cardio Thoracale Chirurgie
Variantie HD stabiliteit Actie beleid arts, tijdstip en actie
□ 1 PC  Hb < 5,0 mmol/l  …uur
□ 1e  NaCl 0,9%  250 ml………uur
□ 2e  NaCl 0,9%  250 ml………uur
□ 3e  NaCl 0,9%  250 ml………uur
actie beleid arts, tijdstip en actie
actie beleid arts, tijdstip en actie
Nieuwe  ritme- geleidingsstoornissen
□  maak ECG                                                                 
□  overleg met arts
Ritmestoornis:                                                        
□
PM ritme: paced en/of sensed niet goed
□  controleer werking / protocol                                                                 
□  overleg met arts
                                                     
□
Variantie Uitscheiding actie beleid arts, tijdstip en actie
Urineproduktie< 0,5 ml kg □  controleer doorgankelijkheid
□  overleg met arts □
1e  4 uur p.o.
Thoraxdrainproduktie : 
*  1e uur ≥ 150 ml/uur,
*  2e/3e uur ≥100ml/uur 
*  daarna elk uur ≥50 ml/uur  
(zonder reden zoals, detuberen etc) 
□  sereus drainvocht - licht arts in                                     
geen sereus drainvocht dan :                                                                  
□  controle ACT → > 150 sec.                                          
□  controleer op overgevoeligheid protamine / garnalen                             
□  → geef 2500 E protamine iv                                                            
indien onvoldoende resultaat of normale ACT :                 
□  controleer ACT, PTT, APTT, Hb, Ht en trombo's                                                
□  overleg arts PC's op voorraad op BTD 
□ ACT :  .......sec. -   tijd : .... 
□ 2500 E protamine:    tijd : ...
                                                                                                                                                                                                                                                                                          
□                                                                                        
□
ST segment afwijkingen
□  maak ECG                                                                      
□  overleg met arts                                                                                                   
□  stel ST segment alarm bij volgens protocol                              
□ NTG gestart                                                  
□ Troponines vervolgen                                       
□ extra pijnbestrijding 
Thoraxdrainproduktie  = 0 ml / uur □  controleer doorgangkelijkheid drains                                 
□  overleg met arts indien drainproduktie 0 ml. blijft
Oorzaak :
ABP ↑ en CVD en wedge normaal en           
HF < 90/min
□  sluit ischemie , onrust, pijn en rillen uit.!  
□  inotropie?, iom arts afbouwen  
□  goede LVF: start nicardipine (cave SaO2↓ door 
shunting)    
□  slechte of matige LVF : overleg met arts                           
□  bij onvoldoende resultaat overleg met arts
□   
                                                                                                                                                                                                                           
Bij toediening Nicardipine:                                      
□  SpO2 daling > 5%  < 2 uur na start 
nicardipine
□
Overige combinaties van HD afwijkingen  (ook 
sinusritme > 90/min)       □  controleer uitgangssituatie, overleg met arts □
ABP ↓  en CVD ↓  wedge ↓  en CI ↓                                                                       
of                                                                                               
ABP ↓ en CVD ↓  of normaal en CI normaal     
□ indien Nicardipine: afbouwen / stoppen                           
□ indien NTG of andere vasodilatantia : overleg 
arts                         
□ bij HB < 5,0  1 PC geven                           
□ bij HB > 5,0  mmol/l of onbekend: 250 ml NaCl 
0,9%
(maximaal 750 ml  NaCl  0,9% of 1 PC en  500 ml   
NaCl 0,9%)
voorzichtig vullen bij matige of slechte ventrikel 
Bij onvoldoende resultaat : arts waarschuwen   
ABP ↑ en CVD en wedge normaal en           
HF > 90/min
□  sluit ischemie , onrust, pijn en rillen uit.                                          
□  inotropie?, iom arts afbouwen  
□  i.o.m. arts metoprolol toedienen
□                                                                            
□                                                                                                                                                                                                                                                                                                  
□                                                                     
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Figure 1: Continued
Variantie Pijn en Sedatie actie beleid arts, tijdstip en actie
Rass score + 1 tot + 4                                                                      
 (onrustig tot strijdlustig )
binnen 2 uur op IC:                                                       
□  overleg met arts 
□                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Variantie Temperatuur actie beleid arts, tijdstip en actie
Centrale temperatuur  < 36 0 C □  overleg met arts over propofol toediening □
Centrale temperatuur  > 38,0 o C □  overleg met arts □
∆ temp  >  7 0 C □  overleg arts □
Variantie respiratoire status actie beleid arts, tijdstip en actie
Patiënt niet gedetubeerd < 6 uur omdat:
□  Te slaperig ( Rass >- 2) □  sedatie stoppen , na 30 min. opnieuw beoordelen
□  Detubatie vereisten niet gehaald □  overleg met arts □
Variantie resp. status NA detubatie actie beleid arts, tijdstip en actie
Saturatie  < 94 %
□  bespreek eventuele oorzaak met patënt 
□  controleer zuurstof toediening
□  sluit pijn, onrust en shunting (nicardipine) uit
□  controleer luchtlekkage thoraxdrain
□  stimuleer tot effectief ophoesten
Indien onvoldoende resultaat:
□  geef non-rebreathing masker of aquapack 100 
%
□  check SpO2 bij opname op vorige afdeling (C -1)
□  accepteer iom arts een lagere saturatie
Oorzaak: 
□  Afbouwen of stoppen nicardipine
□  NPPV
□  Re- intubatie
Saturatie > ……………..….%
Rass score -1 tot -5                                                                             
(slaperig tot niet wekbaar)          
binnen 3 uur op IC                                                         
□  indien sedatie zie kopje "patiënt krijgt sedatie 
toegediend"                                              
na 3 uur op IC en geen sedatie                                           
□  overleg met arts
□       
□                                                                                
Patiënt klaagt over (onduidelijke) pijn op de 
borst ondanks toegediende pijn medicatie
□  volg acties bij  zie ST-segment afwijkingen,                              
indien onvoldoende resultaat :                                           
□  geef 50 mcq fentanyl i.v.                                                       
□  herhaal 50 mcq fentanyl iv na 5 min. bij  
pijnscore > 4         
□  blijft POB bestaan , overleg met arts                                                                  
□  nadere diagnostiek is noodzakelijk
Pijnscore  > 4 ondanks medicatie door:
wondpijn
□  geef 50 mcq fentanyl i.v.                                                   
□  herhaal 50 mcq fentanyl iv  bij score > 4                           
ondanks extra pijnbestrijding:                                           
□  overleg arts om morfinedosis te verhogen                                                   
□  overleg arts, nadere diagnostiek is noodzakelijk
□         
□                                                                                        
Patiënt krijgt sedatie toegediend                        
□   vanaf OK                                            
□   start IC 
□  continueren bij temp < 36,0 
0 C                                        
□  afbouwen /stoppen indien temp > 36,0
0 C  
    (stijgende trend , HD en drainlekkage binnen 
criterium)
□  Sedatie afbouwen   ….…uur
                 
□  Sedatie gestopt …    …....uur
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Figure 1: Continued
Ademfrequentie  > 30 / minuut 
□  Saturatie < 94 %  zie variantie bij sat.  < 94 %
□  Saturatie  > 94 %: 
     ○ bespreek eventuele oorzaak met patiënt
     ○ sluit pijn, onrust en angst uit
     ○ luchtlekkage drain ? of onbekend overleg met 
arts
□
Ademfrequentie  <  12  / minuut 
□  Saturatie  < 94 % 
     ○  zie oorzaken bij sat. < 94 %
     ○  activeer patiënt 
□  Saturatie > 94 %
     ○  observeer patiënt, (CAVE toediening 
opiaten)
□  licht arts in bij apneus en/of AH freq.  < 6 / 
min.
□
Variantie Algemeen actie beleid arts, tijdstip en actie
Patiënt is misselijk □  geef 4 mgr ondansetron i.v. 
□  bij onvoldoende resultaat overleg met arts
□ maagsonde inbrengen 
Variantie Laboratoriumuitslagen actie beleid arts, tijdstip en actie
Hemoglobine   <  5,0  mmol/l
□  alleen in combinatie ↓ HD parameters / Hb <5,0 
mmol/l   → 1 PC 
□  overleg met arts indien HD stabiel
□
Trombo's         <   75 109 /l □  overleg met arts □ 
Glucose    >  8.0 mmol /l
1e meting ( bij opname ) glucose > 8.0 mmol/l 
□  meting herhalen na 2 uur 
Indien 2e meting of iedere andere 
glucosemeting  nadien  > 8.0 mmol/l :
□  start en volg glucoseregulatieprotocol
als de glucose niet afwijkend is wordt deze 6 
uur na opname opnieuwe bepaald.
Kalium (K)    < 3,7 mmol/l □  start en volg kalium suppletie  protocol
Kalium (K)    > 5,0 mmol/l  □  licht arts in □
Magnesium (Mg)  < 0,85  mmol/l □  start magnesium suppletie protocol als er suppletie wordt gestart wordt het Mg 6  uur na starten opnieuw bepaald
Fosfaat  (P)     <  0,75  mmol/l □  start fosfaat suppletie protocol als er suppletie wordt gestart wordt het fosfaaf 6 uur na het starten opnieuw bepaald
Troponine  T      >  400
□  troponine T  bepalen à  6 uur (volgens schema) totdat 
het niet meer stijgt
     Bij eerst volgende bepaling troponine T , CK 
meeprikken 
□
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List of abbreviations
CP  Clinical Pathway
WAI  Work as imagined
WAD  Work as Done
ERAS   Enhanced Recovery After Surgery
P-A-R-cycle  Prepare-Act-Reflect- Cycle
LOS  Length of Stay
ICU  Intensive Care Unit
PACU  Post Anesthesia Care unit
Log EuroSCORE  patients’ predicted risk of death and survival prior to cardiac surgery
EWS  Early Warning Score
CS  Cardiac Surgery
CABG   Coronary Arterial Bypass Graft
TEVAR  Thoracic Endovascular Aortic Repair
TAVI  Transcatheter Aortic Valve Implantation
PDMS  Patient Data Management System
APACHE  Acute Physiology and Chronic Health Evaluation Score
CORRAD  CORonary artery surgery database RADboudumc
NICE  National Intensive Care Evaluation
[IQR]  Interquartile range
SD  Standard deviation
SDD  Selective Decontamination of the Digestive Tract
ScvO2  central venous oxygen saturation 
MUST  malnutrition universal screening tool
TPN   Total Parenteral Nutrition
SMA   Superior Mesenteric Artery
OR  Operating Theatre
EBM   Evidence Based Medicine
EBP   Evidence Based Practice
KPi   Key Performance indicator
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Dankwoord 
Peri-operatieve zorg doe je nooit alleen. De IC-opleiding  heeft me geleerd over afde-
lingen heen te kijken en samen te werken. Vandaar dat ik mijn dank wil uitspreken aan 
iedereen die in meer of mindere mate betrokken is geweest bij het tot stand komen van 
dit proefschrift.
Prof. dr. P. Pickkers, beste Peter, dank voor je wezenlijke bijdrage aan het tot stand komen 
van mijn proefschrift door dit klinische onderzoek te brengen binnen de kaders van weten-
schappelijk onderzoek. Een klinisch georiënteerde chirurg-intensivist begeleiden die graag 
opereert, processen verandert,  implementeert  en controleert,maar voor opschrijven (en 
herschrijven) van de bevindingen minder tijd vrijmaakt, is geen sinecure gebleken. Dank 
voor je kritische opmerkingen, de punten op de i, komma’s in grafieken en veranderende 
invalshoek als ik dacht een stuk te hebben opgeleverd. Het was een uitdaging om de 
complexe omstandigheden binnen de paden lineair op te schrijven. Dank dat ook jij hebt 
weten vol te houden.
Prof. dr. C.J.H.M. van Laarhoven, beste Kees, het zorgpaden project dat gestart was op 
de IC heb ik verder mogen ontwikkelen binnen heelkunde in de slokdarmketen en pan-
creasketen. Met onze volle  agenda’s, hielp het om af en toe een lastige Whipple operatie 
met vena portae resectie samen uit te voeren. Zodat we weer van elkaars drijfveren op de 
hoogte zijn. Je betrokkenheid is een belangrijke bijdrage geweest bij het tot stand komen 
van dit proefschrift. Mijn dank hiervoor.
Dr. M. van den Boogaard, beste Mark, je bent de initiator geweest van de zorgpaden binnen 
de cardio-thoracale chirurgie op de Intensive Care in het Radboudumc en hebt zeer veel 
bijgedragen aan de verdere ontwikkeling en verzelfstandiging van IC-verpleegkundigen. 
Je hebt me duidelijk gemaakt hoe belangrijk zorgpaden zijn en hoe we dit kunnen onder-
zoeken. Het terugbrengen van de enorme hoeveelheid data, die we hebben over onze 
klinische paden en opschrijven maakt dat “less is more” soms een lastige, maar dankzij 
jou, wel haalbare klus bleek. Als researcher heb je inmiddels je eigen deliriumonderzoek 
tot toonaangevend in de wereld ontwikkeld. Inbouwen van een assessment van kwetsbare 
ouderen binnen het project (her-)ontwikkelen zorgpaden in het Radboudumc zal mede 
dankzij jou mogelijk worden. Dank voor al je inspanningen.
Prof. dr. J.G. van der Hoeven, beste Hans, als Silverback Gorilla heb jij de zorg en het 
onderzoek op Intensive Care van het Radboudumc op een hoger plan gebracht. Je rol in 
de ontwikkeling van de IC gerelateerde paden is essentieel geweest. Je bent de klinische 
leider die al vroeg heeft ingezien dat empowerment van verpleegkundigen en artsen 
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de basis is om mensen om je heen te laten groeien en om uiteindelijk daardoor betere 
resultaten te krijgen in de uitkomst  van de patiënt. Dank voor je visie, betrokkenheid  en 
vooral je inspiratie bij het tot stand komen van dit proefschrift.
Dr. L.J.B.M.L Noyez, beste Luc, als cardiothoracaal chirurg en “data manager” van de 
CORRAD database heb je geholpen om alle losse eindjes op orde te krijgen. Het maakte 
voor mij Cussum analyses van geïncludeerde en geëxcludeerde patiënten groepen moge-
lijk, ook al staan ze niet in dit boekje. Het zou prachtig zijn als we een Log PancreasSCORE/
HIPECSCORE/SlokdarmSCORE kunnen ontwikkelen die cussum analyse ook voor die groe-
pen mogelijk maakt. Met name invoering van het nieuwe PDMS had een behoorlijk effect 
op onze registratie en  vindbaarheid in systemen, dat maakte het belang van de controle 
mogelijkheid van de juistheid van de data in CORRAD weer eens duidelijk. Jammer dat de 
laatste update begin 2018 vanuit die database een feit was.
Prof.dr. P.Kabat, beste Pavel, dank voor je inkijk in de wereld van systeem analyse. Als ver-
binder en uitdrager van Science Diplomacy  draag je bij aan een betere wereld en betere 
toekomst voor ons allen. Het is een veilig idee, dat sinds enkele jaren in de luwte van onze 
onstuimige wereldleiders, wetenschappers uit verschillende landen samenwerken aan het 
verbeteren van allerlei systemen onder jouw leiding in Wenen en vanaf 1 september 2018 
in Genève. Ondanks je zeer drukke internationale bestaan, was je bereid deel te nemen 
in deze manuscriptcommissie.
Ik dank ook de overige leden van de manuscriptcommissie: Prof. dr. G.P. Westert en Prof. 
dr. W.J. Morshuis en de leden van de promotiecommissie voor hun kritische beoordeling 
van het manuscript en  voor hun bereidheid te willen opponeren.
Femke Becking-Verhaar, mede dankzij jou staat er een prachtig dynamisch Pancreaspad 
op de afdeling heelkunde waar we trots op mogen zijn. In je rol als key-nurse herken je 
de verbetermogelijkheden en ben je een coach voor je collega’s en artsen. Dank hiervoor. 
Femke Stokking, je rol als key-nurse van het slokdarm pad is gelukkig met je overstap 
naar de medium care afdeling niet uitgespeeld. Dank dat je het belang van de verbinding 
tussen afdelingen in het ziekte proces van de patiënt blijft uitdragen en naar een hoger 
plan wil blijven brengen. 
Suzanne Meijer-Weijting en Angela van Bergen, dankzij jullie inspanningen zijn de paden 
voor cardio-thoracale chirurgie en slokdarmchirurgie op de Intensive Care duurzaam 
gebleken. Van elkaar leren en elkaar vertrouwen maakt het mogelijk dat we de volgende 
stappen in de her-ontwikkeling van paden en het verminderen van registratie kunnen 
zetten.
Dankwoord
163
9
Marion van Limburg en Danielle Haverkamp-van Meer. Onze eerste Physician-assistents, 
spinnen in het afdelingsweb, benaderbaar en relativerend, cruciaal voor een dynamische 
afdeling als de onze. Dank voor alle verbetertips en jullie toezicht om alles werkbaar te 
houden.
Nicole Tijhuis, Miranda Celen, Jeanette Vreman, dank voor jullie input. Van eerste inzichten, 
waarom protocollen onvoldoende worden opgevolgd, stuur informatie proberen te krijgen 
uit Labrador (pre-EPIC), analyse van barrières, lessen uit de IC, tot het bouwen van een 
pad. Soms is ook voor een chirurg een pas op de plaats nodig om verdere vooruitgang 
te kunnen boeken. Ik zie uit naar de gezamelijke herontwikkeling van de paden met een 
rol voor de patiënt, reductie van registratie en het inbouwen van shared decision making.
Hettie Custers, je hebt met je intensive care achtergrond geleerd om naar het geheel van 
de processen rondom een operatie patiënt te kijken en daardoor heb je meerwaarde 
binnen de ontwikkeling en uitvoering van de paden voor hoog-risico chirurgie. Dank dat je 
als medicus binnen het operatiekamer–complex in de directe peri-operatieve zorg, onze 
gastro-intestinaal chirurgische patiënten op het juiste pad houdt. Het is altijd een veilig 
idee als jij aan tafel staat, op de achtergrond meekijkt of de scepter zwaait op de PACU.
Ik wil iedereen van polikliniek Heelkunde en de verpleegafdelingen Heelkunde, PACU 
en IC bedanken voor hun rol als doktersassistente, verpleegassistent, verpleegkundige, 
aandachtsvelder, Key-nurse, chirurg, anesthesist of intensivist in de zorg rondom onze 
patiënten in de IC-gerelateerde zorgpaden. Juist ons aller betrokkenheid en ervaring zijn 
essentieel bij onze klinische paden.
Casemanagers van de heelkunde, Jacques, Marjolein, Karin samen met Manon van de 
Oncologie. Je gunt iedere patiënt een Casemanager als gids en aanspreekpunt om de 
paden goed te volgen, een luisterend oor, ontzorgen van de dokters en noem maar op. 
Arjan de Boer, als enthousiaste kwaliteitsmedewerker van de heelkunde, was je in staat 
om de wens om sturing te krijgen over onze processen, om te zetten in het “ databeestje” 
door gegevens uit EPIC te destilleren. Immers geen dynamisch pad zonder P-A-R-cyclus 
en uitkomstmaten. Daarnaast is je ondersteuning middels een Cappuccino, die je met flair 
serveert, door niemand te evenaren.
Hoog-risico chirurgie kun je veilig uitvoeren met dedicated mensen in dedicated teams. 
Ik ga geen namen noemen: dames van het heelkunde Operatieteam: DANK! Immers een 
dag niet geopereerd is  uiteindelijk een ander soort dag.
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Dames en heer van het secretariaat onder de inspirerende leiding van Claudia, waar zou 
ik zijn zonder jullie? 
Rob Bleichrodt, je rol in mijn ontwikkeling is groter dan je waarschijnlijk zelf denkt. Je hebt 
me de kans gegeven om in het Radboudumc als eerste chirurg-intensivist in Nederland 
een baan als chirurg voor complexe abdominale chirurgie te combineren met een baan 
als intensivist. Een dubbelrol en soms een duivels dilemma. Je hebt laten zien “it always 
seems impossible untill it’s done”(Nelson Mandela).
Frans Qué, dank voor de introspectie en reflectie gesprekken om mijn doelen te kunnen 
bereiken. In de luwte groeien en coalities sluiten is vaak verstandiger dan recht op je doel 
af.  De Sun Tsu is inmiddels een leidraad geworden in het veld waarin ik mij beweeg. Zie 
hier, het boekje is af.
Mijn paranimfen Shalini en Bernadette. Shalini, wie had gedacht dat we elkaars paranimfen 
zouden worden toen ik je op het schoolplein van Veerle ontmoette. Dank voor je enthou-
siasme, je aanmoediging en het blijven stellen van de vragen: “hoe ver ben je nu en wat 
moet je nog”. Dank ook voor de energie die jij samen met Norman, Anuscha en Minou 
aan ons geven en voor de verre reizen en vakanties die we samen hebben ondernomen. 
Bernadette, skiënd in Les Gets, wandelend op de Veluwe of gewoon in de tuin met een 
glas wijn. Altijd goed als jij en je mannen er zijn en we over processen, die waar dan ook 
beter kunnen, discussiëren. Dames, dank dat jullie me terzijde willen staan.
Papa, alhoewel je kwetsbaarder wordt weet je dat de basis voor dit boekje bij jou en mama 
ligt. Als rechtlijnige werktuigbouwkundige was je in de jaren zeventig al volop bezig met de 
PDCA-cyclus rondom processen. Waarschijnlijk heb ik dat onbewust toch opgepikt. Ik hoop 
dat je samen met Bonus Oma Clara nog een fijne tijd in goede gezondheid zult hebben. 
Dank voor alles, het is goed zo.
Lieve Veerle, reizende strijdster. Ook jij hebt de invloed van het schrijven van dit boekje 
in ons huis gemerkt. Als je dacht dat ik tijd had om iets leuks te doen , had ik vaak niet 
de rust. Toch geniet ik volop van je. Je bijdehante relativerende teksten en handige tips 
komen waarschijnlijk uit de andere genenpool en zullen je in de toekomst helpen de juiste 
keuzes te maken. Je lijkt toch ook op mij: ook jou agenda is overvol maar dan met sporten, 
muziek, vriendinnen en school en je weet het allemaal te combineren. Als moeder ben ik 
trots en superblij met een dochter als jij. 
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Lieve Robert, de meeste dank ben ik aan jou verschuldigd. Je hebt niet voor dit pad geko-
zen, maar moest voor een groot deel meewandelen en daarbij naast je volle baan het 
reilen en zeilen thuis opvangen. Het is vaak ten koste gegaan van je hobby’s catamaran 
zeilen of met de Roughneck het water op. Als technisch bedrijfskundige en tevens coach 
hield je me vaak een spiegel voor en liet je me zien wat omdenken, lean en agile voor een 
organisatie (en voor mijzelf) kunnen betekenen. Dit proefschrift en met name de toekomst 
van zorgpaden, is sterker geworden door onze reflecties aan de keukentafel. Dank voor 
je geduld en voor zowel jou als Veerle geldt…. tot de maan en terug en dan nog drie keer 
om de aarde.
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Curriculum Vitae
Marion van der Kolk grew up in the village Ittersum close to the city of Zwolle. After 
graduating from the Thomas à Kempis Scholengemeenschap ( Atheneum B)  in Zwolle, 
she studied Medicine at the University of Groningen. She graduated “Cum Laude” from 
medical school.   
After her internship at Medisch Spectrum Twente in Enschede, she became resident at 
the department of surgery at Medical Center Leeuwarden ( Dr. P.L. de Vogel). She started 
her surgical residency at Maximà Medical Center in Veldhoven ( Dr. C.M.A. Bruyninckx) 
and continued her surgical residency at Radboud University Medical Center ( Prof.dr. R.J.A. 
Goris). After becoming a surgeon she continued her training as a fellow in gastro-intes-
tinal surgery at the department of surgery at the Radboudumc. Her interest in intensive 
care medicine and peri-operative care arose in Leeuwarden and after her fellowship she 
became a CHIVO ( Chirurg-in-vervolg-opleiding) in Intensive Care Medicine at the depart-
ment of Intensive Care at Maastricht University Medical Center ( Prof.dr. G. Ramsay) and 
Amsterdam Medical Center (Prof.dr. J. Kesecioglu). She obtained her European Exam in 
Intensive Care Medicine in Rome in 2000. 
In 2001 she was appointed as a staff surgeon at the department of surgery and as a 
staff intensivist at the department of intensive care at the Radboudumc. She has been 
a member of the board of the Dutch Society of Intensive Care medicine ( NVIC) and  a 
member of the Gemeenschappelijke Intensivisten Commissie (GIC). She was a founder 
and a board member of the organization and instructor in Fundamentals in Critical Care 
Support Nederland (FCCS). 
Member of the working group National Guideline CBO: Esophagealcarcinoma 2002-2004 
and working group National Guideline CBO: Organization and structure Intensive Care 
2002-2005. She was appointed chair of the committee Intensive Care and peri-opera-
tive care of the Dutch Society of Surgeons (NVvH ) 2004-2012. Member Patient Safety 
Agency Programme (VWS) to develop a national guideline for early  “recognition of the 
vitally threatened patient” and member of the team that developed and implemented the 
Early Warning Score and Medical Emergency Team at the Radboudumc together with the 
essential ALERT training. 
Since 2012 she works as a colorectal and pancreas surgeon at the department of 
gastro-intestinal and oncologic surgery of the Radboudumc and has many functions 
associated with quality and safety. In December 2017 she was appointed by the Board 
of the Radboudumc as Chair and Clinical leader of the project: Care Pathways. Their mis-
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sion is to redevelop and innovate Care Pathways  into patient-centered care pathways 
within the Radboudumc and its Network.
Marion lives with her partner Robert Kraaijenzank, their daughter Veerle ( 2005) and their 
Labrador Retriever Luna ( 2016) in Doorwerth.
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